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Development of the nervous system requires precise regulation of proliferation to prevent 
neurological diseases such as microcephaly or cancer. Particularly, postnatal neurogenesis in the 
cerebellum gives rise to the largest population of neurons in the brain, cerebellar granule neurons 
(CGNs). Thus, cerebellar neurogenesis must be tightly regulated to prevent growth failure which 
could give rise to cerebellar hypoplasia or hyperproliferation, which can lead to the formation of 
tumors like medulloblastoma. While the mechanisms driving proliferation in the cerebellar granule 
neuron progenitors (CGNPs) is widely known to be mostly dependent on Sonic Hedgehog 
signaling (SHH), little is known about the mechanisms that oppose growth and promote 
differentiation. Furthermore, whether CGNP-derived medulloblastomas require similar 
mechanisms to promote growth remains unclear. 
To address this, in Chapter 2 we used a genetic knockout of both isoforms of glycogen 
synthase kinase (GSK-3), the main brake on WNT signaling in the brain, to determine the effect 
of WNT pathway activation in the cerebellum. We demonstrated that activation of the WNT 
signaling pathway through deletion of Gsk-3α and Gsk-3β in Math1+ cerebellar progenitors led to 
massive cerebellar hypoplasia by promoting cell cycle arrest but not cell death, which was driven 
by increased CDKN1A. Co-deletion of the main effector of the WNT signaling pathway, Ctnnb, 
was able to rescue proliferation in Gsk-3-deficient CGNPs. Moreover, we found that deletion of 
Gsk-3 was sufficient to block tumor growth in SHH-driven medulloblastomas in mice. 
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Pharmacological inhibition of GSK-3 in vitro was sufficient to block CGNP and medulloblastoma 
tumor cell growth. Together, our research suggests that endogenous GSK-3 is necessary to prevent 
WNT signaling in the cerebellum and medulloblastoma to promote SHH-driven proliferation. 
In Chapter 3, we used single-cell transcriptomics analysis to probe the response of 
medulloblastoma tumor cells to a SHH pathway inhibitor, vismodegib. Administration of 
vismodegib produced a heterogenous response in SHH-driven tumor cells, leading to recurrence. 
We identified distinct cell types in untreated tumors, including stromal cells and tumor-derived 
cells in a spectrum of proliferative and differentiated states, through Drop-Seq. Vismodegib 
reduced a subset of proliferative tumor cells and enriched cells in a differentiated state. However, 
a subset of proliferative tumor cells, which expressed stem cell markers or persistent SHH-pathway 
activation remained after vismodegib treatment. Our findings demonstrate diversity within tumors 
that can confer inherent resistance to targeted inhibitor therapies. 
In Chapter 4, we dissected the role of the exon junction complex core component 
MAGOH in cerebellar development and medulloblastoma. Temporally controlled, conditional 
deletion of Magoh during cerebellar growth induced DNA damage and apoptosis within 48 hours, 
leading to massive depopulation of highly neurogenic regions, especially the external granule layer 
of the cerebellum. We found that deletion of trp53 was sufficient to block the DNA damage 
response in Magoh-deleted cells but was unable to inhibit Caspase-dependent cell death. 
Moreover, we explored the necessity of MAGOH in maintaining medulloblastoma tumor growth 
by conditionally deleting Magoh after tumor formation. As in CGNPs, Magoh loss was sufficient 
to induce DNA damage and cell death in tumor cells. Our studies show that MAGOH is necessary 
to promote survival in cerebellar progenitors and medulloblastoma tumor cells. Taken together, 
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CHAPTER 1: INTRODUCTION 
Cerebellar development depends on SHH signaling 
Cerebellar development occurs postnatally, in the first two weeks of life in mice and the 
first year of life in humans (Carletti and Rossi, 2007; Ten Donkelaar and Lammens, 2009; Marzban 
et al., 2015). The cerebellum is home to multiple cell types, of which inhibitory GABA-ergic 
Purkinje neurons are the sole output, and excitatory glutamergic cerebellar granule neurons 
(CGNs) are the most numerous cell type (Morales and Hatten, 2006; White and Sillitoe, 2013). 
Cerebellar development is characterized by the rapid expansion of cerebellar granule neuron 
progenitors (CGNPs), which give rise to CGNs. The cerebellum forms from the dorsal plate of the 
neural tube as part of the metencephalon and comprises cells from at least two germinal zones 
(Goldowitz and Hamre, 1998). The ventricular zone (VZ) around the fourth ventricle gives rise to 
Purkinje neurons, interneurons, and glial cells, while the rhombic lip gives rise to CGNs (Morales 
and Hatten, 2006). 
In the mouse, Purkinje neurons from the VZ exit the cell cycle and differentiate in the 
cerebellum around embryonic day 10.5 (E10.5). Beginning at E12.5, neural progenitors migrate 
from the rhombic lip into the cerebellum to form the external granule layer (EGL) (Machold and 
Fishell, 2005; Wang et al., 2005; Morales and Hatten, 2006). CGNP proliferation is largely driven 
by SHH secreted by nearby Purkinje neurons (Dahmane and Ruiz, 1999; Wechsler-Reya and Scott, 
1999; Lewis et al., 2004). SHH binds to the transmembrane receptor Patched (PTCH), which 
normally antagonizes SHH signaling by inhibiting Smoothened (Smo) (Wechsler-Reya and Scott, 
1999; Lewis et al., 2004). Release of Smo inhibition promotes the transcription of genes necessary 
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for CGNP proliferation, such as Gli1/2 (Dahmane and Ruiz i Altaba, 1999; Dahmane et al., 2001). 
CGNPs also express mouse atonal homolog (Math1; aka Atoh1), a basic-helix-loop-helix (bHLH) 
transcription factor necessary for cerebellar neurogenesis (Ben-Arie et al., 1997; Lumpkin et al., 
2003; Wang et al., 2005; Chizhikov et al., 2006). After proliferation, CGNPs begin to migrate 
along radial glial (Bergmann glia) processes across the molecular and Purkinje cell layers, 
eventually depleting the EGL, where they then differentiate into mature granule neurons in the 
internal granule layer (IGL) by P15 (Martinez et al., 2013). This migratory phenotype might be 
regulated by the interaction of neuregulin (NRG), expressed by granule neurons, and Erb-B2 
Receptor Tyrosine Kinase 4 (ERBB4), expressed by Bergmann glia (Rio et al., 1997). Cerebellar 
growth is largely thought to be complete by P21 in mice. 
Altered development results in abnormal structure, size, shape, and/or position of the 
cerebellum, defined as cerebellar malformations (Haldipur and Millen, 2019). Disruptions in a 
variety of signaling pathways can lead to cerebellar hypoplasia, the most commonly recognized 
cerebellar malformation. Cerebellar hypoplasia presents with an atypically small cerebellum, 
which may or may not exhibit foliation. Human cerebellar hypoplasia can be caused by congenital 
syndromes such as Walker-Warburg syndrome or Chiari malformations; metabolic disorders such 
as Williams syndrome; or other neurodegenerative disorders such as ataxia telangiectasia or 
transmission of the Zika virus in utero (Basson and Wingate, 2013; Parrini et al., 2016; Bertini et 
al., 2018; Chimelli and Avvad-Portari, 2018; Lerman-Sagie et al., 2018). Children with cerebellar 
hypoplasia present with symptoms such as weakened muscle tone, atypical walking and balance, 
seizures, intellectual disability, headaches, dizziness, tinnitus, and/or developmental delays 
(Bosemani and Poretti, 2016). 
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Molecular pathways underlying cerebellar hypoplasia are poorly understood and highly 
variable. Granule cells are frequently absent in cases of cerebellar hypoplasia and although 
Purkinje neurons are present, they show abnormal morphology such as swollen dendrites (Sarnat 
and Alcalá, 1980). Global deletion of Wnt1 and targeted deletion of Ctnnb in Wnt1-expressing 
cells both resulted in a loss of the midbrain and cerebellum (McMahon and Bradley, 1990; Thomas 
and Capecchi, 1990; (McMahon and Bradley, 1990; Thomas and Capecchi, 1990; Brault et al., 
2001). Subsequent studies also demonstrated hypoplastic phenotypes in the cerebellum with the 
deletion of Ctnnb in cells expressing the neuronal stem cell marker, Nestin (Schuller and Rowitch, 
2007). These early studies set the stage to define a role for WNT signaling during cerebellar 
development, although currently poorly understood. 
Medulloblastoma is a disorder of cerebellar development 
Similarly, medulloblastoma can result from a dysregulation of cerebellar granule cell 
proliferation. Medulloblastoma was originally classed in 1925 as a brain tumor of the posterior 
fossa. Harvey Cushing and Percival Bailey pioneered the classification of posterior fossa tumors, 
distinguishing tumors in similar locations by their putative cell types and histological 
characteristics. However, surgical resection of medulloblastomas proved difficult, given their 
localization near the midline, fourth ventricle, brainstem, and cerebellum, and survival was a mere 
30% (Rutka and Hoffman, 1996; Millard and De Braganca, 2016). Tumors were originally 
grouped according to pathological observation of resected tissue, which defined four distinct types: 
medulloblastoma with excessive nodularity (MBEN), classic, large cell anaplastic, and 
nodular/desmoplastic medulloblastoma (Pollack et al., 2019). However, pathological variation was 
insufficient to properly target medulloblastoma in patients, as results were often heterogeneous 
and poorly linked with prognosis. 
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Survival rates drastically improved in the 1950s with Edith Paterson’s seminal work 
detailing craniospinal radiation as a treatment for medulloblastoma (Paterson and Farr, 1953). 
With radiation therapy and the eventual addition of chemotherapeutics such as vincristine, a 
microtubule inhibitor, overall survival rates have increased to 80%. Nevertheless, radiation and 
chemotherapy are aggressive treatments and commonly cause severe side effects  
In the last ten years, multiple labs have made a concerted effort to characterize 
medulloblastoma according to molecular markers, copy number variation, and clinical features in 
the hopes of identifying novel therapeutic targets. By 2011, multiple researchers reached a 
consensus reviewed to classify medulloblastoma into four distinct molecular subgroups based on 
transcriptomic analysis conducted on formalin fixed paraffin embedded (FFPE) human brain 
tumor samples (Northcott et al., 2011; Northcott et al., 2012a). Activating mutations in 
developmental signaling pathways characterized the SHH and WNT subgroups coined in 2012. 
Two other two subgroups established at the time were named Group 3 and Group 4 for lack of 
distinguishable biologically significant markers. 
SHH subgroup comprises up to 30% of all medulloblastomas and is commonly marked by 
loss of function mutations in PTCH (43% of patients) or the SHH signaling repressor, suppressor 
of fused (SUFU) (10% of patients), or activating mutations in Smo (9% of patients) (Northcott et 
al., 2019). Recurrent tumors, while rare, tend to harbor additional mutations in tp53 or 
phosphoinositide-3 kinase (PI3K). TP53 is a known tumor suppressor and the most frequently 
mutated gene in all cancers (Joerger and Fersht, 2016; Duffy et al., 2017; Barnoud et al., 2019). 
Recent studies have further subdivided SHH medulloblastoma into four distinct classes (SHHα, 
SHHβ, SHHγ, SHHδ) based on methylation status, age at diagnosis, and gene expression analysis 
(Cavalli et al., 2017). For example, SHHα is characterized as frequently harboring p53 mutations 
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and MYCN/GLI2 amplifications, while SHHβ is associated with presentation in infants, frequent 
metastases, and poor outcome. Survival within the SHH subgroup remains heterogeneous, with an 
overall survival rate of approximately 60-75% (Northcott et al., 2011; Cavalli et al., 2017; 
Schwalbe et al., 2017). 
WNT subgroup medulloblastoma is typified by homogenous activation of the WNT 
signaling pathway and comprises around 10-15% of all medulloblastomas. Common genes 
expressed at high levels in WNT subgroup medulloblastomas include Ctnnb, Wif1, Lef1, and 
Axin2. Recently, WNT subgroup medulloblastomas have been further subdivided into two 
subgroups partly based by age of diagnosis, with WNTα frequently having monosomy 6 in young 
children and WNTβ being diagnosed in adults (Cavalli et al., 2017). WNT subgroup presents with 
the most favorable prognosis (98% 5-year event free survival) (Northcott et al., 2011; Cavalli et 
al., 2017; Schwalbe et al., 2017). 
Although activation of WNT and SHH signaling pathways represent two of the molecular 
subgroups identified in medulloblastoma, mutations in WNT and SHH proteins are mutually 
exclusive and may represent tumors from distinct cellular origins. Studies genetically modelling 
medulloblastoma in mice have identified distinct drivers that produce tumors in mice that look 
histopathologically similar to human medulloblastomas. For example, activation of a 
constitutively active form of Smo in Math1+ CGNPs produce tumors that resemble human SHH-
subgroup medulloblastoma. Activation of a constitutively active Ctnnb in glial stem cells produced 
tumors similar to human WNT-subgroup medulloblastoma. On the other hand, constitutively 
activating Ctnnb in Math1+ CGNPs caused mild cerebellar hypoplasia, abnormal foliation, and 
decreased CGNP proliferation (Schuller and Rowitch, 2007). These preliminary studies suggest 
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that SHH and WNT may play opposing roles in cerebellar development and medulloblastoma 
according to cell of origin. 
WNT signaling regulates proliferation and differentiation in diverse cell types 
Although first discovered and purified in 1980 as a key enzyme in glycogen metabolism, 
glycogen synthase kinase-3 (GSK-3) is now recognized as an important kinase for the regulation 
of multiple cellular functions such as proliferation, differentiation, and apoptosis (Tejeda-Muñoz 
and Robles-Flores, 2015). GSK-3 is encoded by two distinct genes that produce proteins with 98% 
homology in the central 30 kDa kinase domain (Plyte et al., 1992). Although the GSK-3 isoforms 
differ in the N- and C-terminals, both GSK-3α and GSK-3β can redundantly regulate WNT 
signaling in differing cell types (Force and Woodgett, 2009). 
Canonically, GSK-3 functions to regulate the WNT signaling pathway by phosphorylating 
the main WNT signaling effector, β-Catenin (CTNNB), to signal it for degradation. 
Phosphorylation of CTNNB at Ser45, Thr41, Ser37, and Ser33 by GSK-3 primes CTNNB for 
proteosomal degradation (Hagen and Vidal-Puig, 2002). When Wnt ligand is present, however, it 
interacts with Frizzled (FZD), lipoprotein-receptor related proteins (LRP), and disheveled (DVL). 
DVL then sequesters GSK-3 in a complex with adenomatous polyposis coli (APC) and Axin to 
prevent the destruction of CTNNB. CTNNB can then translocate into the nucleus and bind to 
transcription factors such as lymphoid enhancer binding factor 1 (LEF1) and T-cell transcription 
factor (TCF) to promote transcription. 
Importantly, GSK-3 has been shown to play a major role during neurogenesis. 
Dorsal/ventral patterning in the brain and spinal cord relies on concentration-dependent gradients 
of key signaling pathways including Sonic Hedgehog (SHH), WNT, and Notch. In the spinal cord, 
WNT signaling is present in the ventral region, while SHH signaling is present dorsally (Yu et al., 
2008). WNT signaling in the spinal cord is able to regulate cell fate specification in part by 
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activating a transcriptional repressor in the SHH signaling pathway, Gli3 (Yu et al., 2008). 
However, the role of WNT signaling in cerebellar growth is currently unclear. 
Single-cell sequencing deconvolutes cellular diversity in complex tissues 
Although modern neuroscience has embraced the concept of cellular diversity within the 
central nervous system, it was the work of Santiago Ramón y Cajal in the late nineteenth century 
which began to unravel the complexity of the brain. His revolutionary work carefully outlined 
morphologically and functionally distinct cells within the brain, establishing principles that would 
later be proved with technological advancements (Garcia-Lopez et al., 2010). Recently, the advent 
of single-cell RNA-sequencing (scRNA-Seq) has provided researchers with a new approach to 
better understand cellular heterogeneity in complex tissues like the brain (Macosko et al., 2015; 
Rosenberg et al., 2018). The ability to generate transcriptomic profiles from individual cells has 
shed some light on tissue complexity, brain development, and tumor heterogeneity (Puram et al., 
2017; Saunders et al., 2018; Loo et al., 2019; Vladoiu et al., 2019). 
Tumor heterogeneity has been posited as a potential mechanism of resistance for cancer, 
in which tumor cells inherently use different signaling mechanisms and are thus able to evade 
targeted therapies. Although bulk transcriptomic analysis can subdivide tumors into molecular 
subgroups, scRNA-seq in tumors like gliomas has shown that cells within specific molecular 
subgroups can show transcriptomic profiles from multiple molecular subtypes (Patel et al., 2014; 
Tirosh et al., 2016). Additionally, some tumor cells show more stem cell-like properties, providing 
evidence for the theory that cancer stem cells may play a role in repopulating recurrent tumors 
(Patel et al., 2014; Tirosh et al., 2016; van Dijk et al., 2018). scRNA-seq may also be used to probe 
differences in microenvironment, infer tumor cell lineage, and compare and contrast similar 
tumors (Venteicher et al., 2017). 
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While scRNA-seq experiments have largely been exploratory in nature, scRNA-seq can be 
used for more targeted experiments. Transgenic mice have provided researchers with a powerful 
tool to study the effects of a single oncogenic stressor in vivo. Coupling scRNA-seq with mouse 
tumor models allows for more flexibility. For example, it is now possible to study how a single 
targeted therapy can provoke heterogenous responses in tumor cells in a mouse model. These 
studies may provide new insights into cellular diversity, potential cell of origin, and mechanisms 
of resistance within tumors. 
Microcephaly genes may provide new targets for medulloblastoma treatment 
Understanding the mechanisms underlying cellular growth during normal brain 
development may provide new therapeutic targets for neurodevelopmental diseases caused by 
dysregulation of neural progenitor amplification. In the cerebellum, neurogenesis mostly occurs 
postnatally, in which CGNPs proliferate rapidly to give rise to CGNs. We have previously shown 
that loss of function mutations in genes such as Aspm, which have been associated with autosomal 
recessive microcephaly (Naveed et al., 2018; Okamoto et al., 2018), are required for cerebellar 
growth (Williams et al., 2015). Cancers like medulloblastoma retain some molecular and genetic 
properties of their cells of origin (Dirks, 2008; Dirks et al., 2014; Vladoiu et al., 2019). Therefore, 
microcephaly-related genes like Aspm and Atr may also be necessary for growth in tumors such as 
medulloblastomas (Williams et al., 2015; Lang et al., 2016; Lang and Gershon, 2018). 
Recent genetic screens have posited a role for RNA-processing in cellular proliferation 
during brain development. Specifically, loss of function mutations in Magoh, a core component of 
the exon junction complex (EJC), in mice resulted in microcephaly caused by disruptions in cell 
division, which induced premature differentiation and apoptosis (Silver et al., 2010; Silver et al., 
2013; Pilaz et al., 2016). Loss of other components of the EJC, such as RBM8A (aka Y14) have 
also been shown to cause microcephaly in mice (Mao et al., 2015; Zou et al., 2015; McMahon et 
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al., 2016). Therefore, regulation of mRNA by the EJC may be necessary to promote cell cycle 
progression and cell specification during normal development (Inaki et al., 2011; Silver et al., 
2013; Fukumura et al., 2016; Pilaz et al., 2016; Baralle and Giudice, 2017). 
Alternative mRNA splicing and regulation of nonsense-mediated decay (NMD) by the EJC 
may also be necessary for cancer cell survival (Eswaran et al., 2013). Expression of EJC 
component members have been reported across multiple cancer types, such as hepatocellular 
carcinoma, gliomas, lung cancer, and breast cancer (Degot et al., 2004; Baguet et al., 2007; 
Lindeboom et al., 2016; Lin et al., 2018; Lin et al., 2019). However, expression of the EJC has 
been linked to different phenotypes and outcomes across tumors (Lindeboom et al., 2016), 
indicating that regulation of growth through the EJC may be cell-type specific. For example, high 
MAGOH expression in breast cancer has been linked to favorable prognoses (Stricker et al., 2017), 
while high expression of another core component of the EJC, eIF4A3, has been associated with 
poor prognoses in multiple cancers (Lin et al., 2018). Therefore, understanding how the EJC 
regulates cerebellar growth and whether EJC components like MAGOH are necessary for 
cerebellar development and medulloblastoma tumor growth may provide new insights into 




CHAPTER 2:  
GSK-3 IS NECESSARY TO SUPPRESS WNT/CDKN1A SIGNALING DURING 
CEREBELLAR DEVELOPMENT AND MEDULLOBLASTOMA GROWTH1 
Introduction 
Proliferation must be precisely controlled during brain development. Insufficient 
proliferation causes microcephaly while excessive proliferation causes tumorigenesis (Ten 
Donkelaar and Lammens, 2009; Bosemani and Poretti, 2016; Lerman-Sagie et al., 2018; Haldipur 
and Millen, 2019). Cerebellar neurogenesis occurs in the first two weeks of postnatal life in mice 
and the first year of life in humans (Ten Donkelaar and Lammens, 2009; Marzban et al., 2015). 
During this proliferative period, CGNPs in the external granule layer of the cerebellum proliferate 
rapidly in response to SHH secreted by nearby Purkinje neurons to give rise to the largest 
population of neurons in the central nervous system (Wechsler-Reya and Scott, 1999). SHH has 
long been known as the main driver of CGNP proliferation during early postnatal development. 
Moreover, increased cerebellar proliferation can lead to medulloblastoma, the most common 
malignant pediatric brain tumor (Dahmane et al., 2001; Yang et al., 2009; Dey et al., 2012). 
Transcriptomic analysis of patient-derived medulloblastomas have identified four main molecular 
subgroups (Northcott et al., 2011). SHH activation and WNT activation recapitulate 
medulloblastomas from distinctly different pre-malignant cells that derive from different regions 
of the rhombic lip (Schüller et al., 2008; Gibson et al., 2010; Vladoiu et al., 2019).   
 
1 The work described in this chapter has been published at Development: 
Ocasio JK, Bates RDP, Rapp CD, and Gershon TR. 2019. GSK-3 modulates SHH-driven proliferation in postnatal 
cerebellar neurogenesis and medulloblastoma. Development. 146(20). pii: dev177550. doi: 10.1242/dev.177550. 
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Studies performed in the last ten years have implicated WNT signaling as a potential 
negative regulator of cerebellar growth (Schuller and Rowitch, 2007; Lorenz et al., 2011; Moreno 
et al., 2014). WNT signaling is a known driver of proliferation in multiple cell types, such as 
intestinal stem cells (Harada et al., 1999; Giles et al., 2003) and progenitors in the CNS (Spittaels 
et al., 2002; Kim et al., 2009; Morgan-Smith et al., 2014). Notably, a series of studies have 
identified GSK-3 as a necessary brake on proliferation in forebrain progenitors. Uncommitted 
neural progenitors express Nestin throughout the brain during prenatal development and in select 
postnatal neurogenic regions (Mignone et al., 2004; Bernal and Arranz, 2018). Deletion of both 
isoforms of Gsk-3 in Nestin+ progenitors led to a massive increase in Sox2+ stem cells, a folded 
neocortex, and a decrease in both intermediate and fully differentiated neurons. This increase in 
proliferative early progenitors was linked to an increase in WNT signaling, as demonstrated by 
increased CTNNB and Axin2. Interestingly, the authors also demonstrated an increase in SHH 
signaling markers after genetic deletion of Gsk-3, including an increase in the transcription factors 
Gli1 and Gli2 and the SHH receptor, Patched (Ptch). Deletion of Gsk-3 also led to an increase in 
c-Myc, which is commonly activated in various cancer types (Kim et al., 2009; Morgan-Smith et 
al., 2014).  
However, studies over the years have not been able to conclusively determine the role of 
WNT signaling during cerebellar development. Deletion of Wnt1 prevents growth of the midbrain 
and rhombomere 1, which eventually gives rise to the cerebellum (McMahon and Bradley, 1990; 
Thomas and Capecchi, 1990). Additionally, deletion of Ctnnb targeted to Nestin-Cre caused 
cerebellar hypoplasia by P0, which was incompatible with life (Schuller and Rowitch, 2007). 
Subsequent studies have demonstrated that WNT/CTNNB signaling is present in the embryonic 
rhombic lip during prenatal development and is then restricted to Bergmann glial cells during 
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postnatal development (Selvadurai and Mason, 2011). Deletion of the CTNNB destruction 
complex member, APC, in committed Math1+ cerebellar progenitors resulted in a mild hypoplastic 
phenotype in the cerebellum. APC-deleted cerebella lacked CGNs in the rostral regions of the 
cerebellum and demonstrated ectopic expression of CGNs in the molecular layer of the cerebellum 
(Lorenz et al., 2011). Constitutive activation of CTNNB in Math1+ cells also resulted in a 
hypoplastic cerebellum, with a significantly smaller cerebellar area, fewer CGNPs during 
proliferation, and fewer CGNs. Understanding the role of WNT signaling during SHH-driven 
cerebellar growth may lead to better understanding of cerebellar development and new targeted 
therapies for medulloblastomas. 
Since GSK-3 is an integral member of the CTNNB destruction complex and is responsible 
for phosphorylating CTNNB to signal the protein for degradation, we wanted to explore whether 
GSK-3-mediated repression of WNT signaling was necessary to modulate SHH-driven cerebellar 
growth. We examined the role of GSK-3 in CGNPs and medulloblastoma by conditionally deleting 
Gsk-3β in Math1+ cells in Gsk-3α null mice. We found that conditional deletion of Gsk-3 during 
cerebellar development led to severe cerebellar hypoplasia hallmarked by decreased proliferation 
and increased WNT/CDKN1A. Deletion of Ctnnb in Math1+ progenitors led to a transient increase 
in CGNP proliferation. Co-deletion of Ctnnb in Gsk-3-deleted mice rescued proliferation defects. 
As in cerebellar development, deletion of Gsk-3 in medulloblastoma-prone mice expressing a 
constitutively active form of the SHH receptor Smo, SmoM2, blocked growth. These findings 
demonstrate a physiological role for GSK-3 during cerebellar development and medulloblastoma 





Gsk-3DKO mice exhibit severe cerebellar hypoplasia 
To explore the function of GSK-3 in CGNPs, we targeted deletion of both isoforms of Gsk-
3 to MATH1+ CGNPs by breeding Gsk-3α-/- and Math1-Cre/Gsk-3βloxP/loxP mice. CGNPs are the 
predominant cell type expressing MATH1 in the cerebellum. Math1-Cre induces recombination 
at loxP sites in CGNPs from E12.5 from the anterior to posterior regions of the cerebellar cortex 
in a rostro-caudal progression (Machold and Fishell, 2005; Wang et al., 2005). Mice with either 
Gsk-3α (Gsk-3α-/-) or Gsk-3β (Math1-Cre/Gsk-3βloxP/loxP) deleted exhibited no phenotypic changes. 
However, breeding these genotypes to generate Math1-Cre/Gsk-3α-/-/Gsk-3βloxP/loxP (Gsk-3DKO) 
produced mice with severe cerebellar growth failure (Fig. 2.1A, P21), demonstrating that GSK-3 
is required for normal cerebellar growth and that either isoform of Gsk-3, Gsk-3α or Gsk-3β is 
sufficient to maintain growth. 
Gsk-3DKO mice were born with the expected Mendelian frequency and were viable 
neonatally. However, by P12, mice exhibited severe tremors, were unable to be weaned by P20-
22 and did not survive beyond P25. At birth, Gsk-3DKO mice exhibited normal cerebellar 
architecture, with a clearly defined external granule layer populated by CGNPs (Fig. 2.1A, P0). 
By P3, Gsk-3DKO cerebella lacked foliation and the EGL was markedly thinned, indicating a lack 
of progenitor expansion between P1-3 (Fig. 2.1A, P2-3). Additionally, the internal granule layer 
(IGL) where the differentiated progeny of CGNPs, cerebellar granule neurons (CGNs), reside was 
markedly reduced by P7 (Fig. 2.1A, P7). These findings demonstrate the failure of Gsk-3DKO 
CGNPs to generate an appropriately large population of neurons. 
Loss of Gsk-3 impairs proliferation early in postnatal development but does not induce apoptosis 
We investigated whether the loss of CGNPs and CGNs was caused by increased cell death. 
We stained cerebella from Gsk-3DKO mice and control littermates with either Gsk-3α or Gsk-3β 
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deleted or Gsk-3α/β intact with cleaved Caspase-3 (cC3) as a marker for apoptotic cell death. We 
have previously found that deletion of the DNA repair gene, Atr (Math1-Cre/AtrloxP/loxP; AtrcKO), 
induces extensive cC3-mediated cell death in CGNPs (Lang et al., 2016), which we used as a 
positive control for cC3 detection. We did not detect an increase in cC3+ cells in Gsk-3DKO mice at 
P2, before the onset of hypoplasia, or at P3 (Fig. 2.1B, C). To determine if CGNPs or CGNs were 
undergoing Caspase-independent death, we also performed Terminal deoxynucleotidyl transferase 
dUTP Nick End Labeling (TUNEL) staining at each time point and found no indication of 
increased cell death in Gsk-3DKO cerebella (data not shown). 
We next examined whether Gsk-3 deletion altered proliferation. While we found no 
changes in apoptosis as labeled by cC3, we found decreased proliferation and a trend toward 
increased differentiation in P2 and P3 Gsk-3DKO cerebella as labeled by PCNA and CDKN1B (p27) 
respectively (Fig. 2.1D, E). This pattern of staining indicated an increase in cell cycle exit. Staining 
for the cell cycle progression marker phosphorylated RB (p-RB) demonstrated marked decreased 
in p-RB-expressing CGNPs in Gsk-3DKO mice at P2 and P3, supporting the possibility of increased 
cell cycle exit (Fig. 2.1F, G). 
We directly compared cell cycle exit in Gsk-3DKO mice and control littermates by pulse-
labeling cells with thymidine analogs, BrdU and EdU. We administered BrdU intraperitoneally 
(I.P.) at P1 or P2 before administering EdU I.P. 24 hours later, and harvested samples 2 hours after 
EdU administration. We fixed brains, embedded in paraffin, and sectioned in the sagittal plane. 
We identified CGNPs by their localization in the EGL and defined the cell cycle exit fraction as 
the cells that were labeled by BrdU but were not dual-labelled by EdU. We also determined the 
number of proliferating cells at the age of collection as the percent of cells expressing EdU in the 
EGL. Both the percent of BrdU+ and EdU+ cells were significantly decreased at P2 and P3, 
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confirming reduced CGNP proliferation at P2 and P3 (Fig. 2.2A, B). Moreover, the cell cycle exit 
fraction was significantly increased in Gsk-3DKO CGNPs (Fig. 2.2C), indicating that the CGNP 
that were proliferating in these mice showed reduced self-renewal relative to CGNPs in control 
littermates.   
Molecular signatures of Gsk-3 deletion include WNT and CDKN1A signaling 
To identify the transcriptomic changes induced by Gsk-3α/β deletion, we performed 
expression microarray analysis. We compared whole cerebella dissected from Gsk-3DKO and 
control littermates at P2, before the onset of severe hypoplasia in Gsk-3DKO mice. We compared 
Gsk-3DKO cerebella to cerebella from Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP mice, which retain a 
single Gsk-3α allele but have no Gsk-3β alleles in CGNPs, and No Cre/Gsk-3α+/-/Gsk-3βloxP/+ mice, 
which retain a single Gsk-3α allele and retain two Gsk-3β alleles in CGNPs. We identified 68 genes 
that were differentially expressed in Gsk-3DKO cerebella, with 14 genes significantly down-
regulated and 54 genes significantly up-regulated as determined by a fold change > |2| and an FDR 
p-value < 0.05 (Fig. 2.3A; Table 2.1). In the genes that were down-regulated, we identified Gsk-
3, consistent with genetic disruption, as well as neuronal markers, Chrna3, Chrnb4, and Cadps2, 
consistent with the decreased neuronal population in Gsk-3DKO mice. 
We performed Gene Set Enrichment Analysis (GSEA) on our dataset to determine whether 
the set of genes defined by the microarray showed a significant different in known signaling 
pathways. GSEA identified an enrichment in the WNT signaling pathway (ES = 0.5224 FDR q-
value = 0.037) and the p53 signaling pathway (ES = 0.7996, FDR q-value = 0.034)  in Gsk-3DKO 
mice, with an up-regulation in WNT markers such as Tcf7, Lef1, Wif1, and Wnt10a and p53 
markers Cdkn1a, Gadd45a and Pmaip1 (Fig. 2.3B, C). Immunofluorescence confirmed increased 
LEF1+ and CDKN1A+ CGNPs in Gsk-3DKO cerebella (Fig. 2.3D). TC7 expression labeled 
Bergmann glia processes during normal development, as identified by their location outside of the 
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EGL, morphology, and expression of FABP7 (Fig. A.1). In Gsk-3DKO cerebella, however, labeled  The 
cellular distributions of LEF1, CDKN1A and TCF7 show that disrupting GSK-3 in CGNPs caused 
both cell autonomous and non-cell autonomous WNT activation, and cell autonomous, CGNP-
specific induction of CDKN1A. To resolve the roles of WNT activation, p53, and CDKN1A in the 
pathogenesis of the Gsk-3DKO phenotype, we performed a series of co-deletion experiments. 
CTNNB activation drives hypoplasia in Gsk-3 deleted cerebella 
GSK-3 negatively regulates the WNT signaling pathway by phosphorylating CTNNB to 
signal proteasomal degradation (Hagen and Vidal-Puig, 2002). To determine if CTNNB is required 
for cerebellar growth, we conditionally deleted Ctnnb in Math1+ CGNPs by crossing breeding 
Math1-Cre and CtnnbloxP/loxP mice to produce Math1-Cre/CtnnbloxP/loxP (CtnnbcKO) mice. CtnnbcKO 
mice were born at the expected Mendelian frequency, were viable, and exhibited no phenotypic 
changes as compared to control littermates with only one copy of Ctnnb deleted. However, at the 
peak of cerebellar proliferation at P7, CtnnbcKO cerebella exhibited foci of hyperproliferation, 
marked by increased EGL thickness. CGNPs in the thickened regions of EGL were PCNA+ and p-
RB+ (Fig. 2.4A). This hyperproliferation did not lead to tumor formation, and by P15, all CGNPs 
in CtnnbcKO mice had exited the cell cycle and migrated to the IGL, as in Ctnnb-intact controls 
(Fig. 2.4A, P15). These findings are consistent with a physiologic role for CTNNB in CGNPs that 
can be compensated by additional, redundant mechanisms that limit CGNP proliferation. 
To determine the function of CTNNB in Gsk-3-deleted cerebella, we conditionally deleted 
Ctnnb in Gsk-3DKO mice by crossing CtnnbloxP/loxP mice with Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP 
to produce Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP/CtnnbloxP/loxP (Gsk-3/CtnnbTKO) mice. In contrast 
to Gsk-3DKO mice, Gsk-3/CtnnbTKO mice were markedly less symptomatic. Gsk-3/CtnnbTKO mice 
were viable and although they demonstrated tremors, were able to be weaned. Gsk-3/CtnnbTKO 
mice survived for at least 40 days, our study endpoint, demonstrating significantly longer lifespans 
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than Gsk-3DKO mice (Fig. 2.4B). Gsk-3/CtnnbTKO mice also experienced significantly less falls over 
a 120 second span as compared to Gsk-3DKO mice (Fig. 2.4C). Consistent with the improved 
phenotype, Gsk-3/CtnnbTKO cerebella exhibited a defined foliated, EGL at P3 that persisted 
through the peak of proliferation at P7 (Fig. 2.4D, P3, P7). Gsk-3/CtnnbTKO CGNPs were PCNA+ 
and p-RB+ at P7, indicating a rescue of the proliferation deficit observed in Gsk-3DKO mice (Fig. 
2.4E). The percent of p-RB+ cells quantified in the Gsk-3/CtnnbTKO mice was not significantly 
different from age-matched controls (Fig. 2.4F). 
Although proliferation was rescued with Ctnnb co-deletion, migration was not rescued. We 
observed ectopic regions of CGNs and overall disrupted cerebellar organization in adult Gsk-
3/CtnnbTKO mice, indicating a deficit in CGNP migration across the Purkinje cell layer into the 
IGL (Fig.2.4D, adult). Migration defects in Gsk-3/CtnnbTKO were present by P7, as demonstrated 
by increased thickness in the EGL and a thinned IGL, despite the presence of other cell types such 
as Purkinje neurons and Bergmann glia, as labeled by Calbindin and FABP7 staining respectively 
(Fig. 2.4F). Although both Purkinje neurons and Bergmann glia showed some morphological 
abnormalities, such as smaller dendritic arbors in Purkinje neurons and more sparse Bergmann 
glial processes, they were largely intact in Gsk-3/CtnnbTKO cerebella and appeared more organized 
than in Gsk-3DKO cerebella (Fig. A.1). These findings indicate a cell-autonomous deficit in 
migration induced by Gsk-3 deletion that was unable to be rescued by Ctnnb co-deletion. 
Trp53 or Cdkn1a co-deletion are unable to rescue hypoplasia induced by loss of Gsk-3 
P53 can induce CDKN1A expression in response to cellular stress (He et al., 2005; 
Macleod et al., 2007; Benson et al., 2014; Karimian et al., 2016). To determine if the growth failure 
of Gsk-3DKO mice requires signaling through p53, we tested whether co-deletion of Trp53 could 
rescue the proliferation defects in Gsk-3DKO CGNPs. We co-deleted Trp53, Gsk-3α and Gsk-3β by 
crossing mice with a conditional allele of Trp53 (Trp53loxP/loxP) with Gsk-3DKO mice to generate 
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the genotype Math1-Cre/Gsk-3α-/-/Gsk-3βloxP/loxP/Trp53loxP/loxP (Gsk-3/p53TKO) (Marino et al., 
2000). Gsk-3/p53TKO mice exhibited severe cerebellar hypoplasia similar to Gsk-3DKO mice and 
did not survive beyond P20-22. Gsk-3/p53TKO, like Gsk-3DKO mice, did not show apoptotic rates 
as labeled by cC3 staining, but demonstrated decreased PCNA+ and p-RB+ and increased 
CDKN1B+ and CDKN1A+ CGNPs throughout the EGL (Fig. 2.5A). These studies demonstrate 
that p53-mediated transcription is not required for the induction of CDKN1A, nor for the 
premature cell cycle exit and growth failure in Gsk-3DKO CGNPs. 
To determine if CDKN1A mediates the growth failure in Gsk-3DKO mice, we next co-
deleted Cdkn1a and Gsk-3α/β. Global Cdkn1a deletion in mice produces no phenotypic changes 
during development but progenitors exhibit impaired G1 checkpoint control (Deng et al., 1995). 
Therefore, we bred Cdkn1a-/- and Gsk-3DKO mouse lines to generate Math1-Cre/Gsk-3α-/-/Gsk-
3βloxP/loxP/Cdkn1a-/- (Gsk-3/Cdkn1aTKO) mice. Similar to Gsk-3/p53TKO mice, Gsk-3/Cdkn1aTKO 
exhibited severe cerebellar hypoplasia (Fig. 2.5B) with ataxia and early mortality similar to Gsk-
3DKO mice. Gsk-3/Cdkn1aTKO mice showed no significant differences in PCNA or p-RB as 
compared to Gsk-3DKO mice. 
The lack of rescue with Cdkn1a co-deletion demonstrates that the growth failure induced 
by Gsk-3 does not require the induction of CDKN1A. While CDKN1A might be sufficient to block 
CGNP proliferation, the effect of Gsk-3 loss in cerebellar progenitors appear to be predominantly 
mediated by activation of CTNNB, which suppresses growth. Taken together, these rescue studies 
show that SHH-driven CGNP proliferation requires GSK-3 to suppress CTNNB-mediated WNT 
signaling, while CGNP migration requires GSK-3 for a yet uncharacterized mechanism. Consistent 
with this interpretation, cortical neurons migration is controlled by GSK-3-mediated, WNT-
independent processes (Morgan-Smith et al., 2014). 
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Pharmacological inhibition of GSK-3 blocks CGNP proliferation 
To determine if a physiological reduction in SHH-driven proliferation could be achieved 
by pharmacologically reducing GSK-3 activity in CGNPs, we pharmacologically inhibited GSK-
3 in cultured CGNPs. We cultured freshly dissociated CGNPs from wild-type mice for 24 hours 
in media with or without SHH, or with SHH plus increasing doses of the GSK-3 inhibitor, CHIR-
98014 (CHIR98). After culturing CGNPs for 24 hours, we lysed cells and quantified 
phosphorylated CTNNB (p-CTNNB) as a measure of GSK-3 inhibition and p-RB as a measure of 
proliferation using western blot (Fig. 2.6A). We found that increasing doses of CHIR98 were able 
to suppress proliferation even in the presence of the mitogenic signal, SHH, as demonstrated by 
decreased p-RB and an increased CDKN1A in cultured CGNPs (Fig. 2.6B). CHIR98 was also able 
to decrease p-CTNNB expression at every dose as compared to the SHH control, demonstrating a 
physiologic role for CTNNB phosphorylation in CGNPs. 
In a parallel experiment, CGNPs were treated with EdU 1 hour before fixing with 4% 
paraformaledyde for immunofluorescence analysis. GSK-3 inhibition with 1 µM CHIR98 
decreased p-RB, EdU incorporation, and expression of the mitotic marker, phosphorylated Histone 
H3 (p-HH3) (Fig. 2.6C, D), demonstrating fewer cells in S-phase and M-phase. Treatment of 
CGNPs with the GSK-3 inhibitors LY2090314 (LY209), AZD1080, or LiCl did not decrease p-
RB or p-HH3 levels or reduce EdU incorporation as effectively as CHIR98 at similar 
concentrations (Fig. A.2). These results show that modulation of SHH-driven proliferation by 
GSK-3 is seen outside of the context of genetic deletion and can be achieved within the dynamic 
range of physiological GSK-3 activity. 
Deletion of Gsk-3 in medulloblastoma-prone mice blocks tumor growth 
To determine if GSK-3 is similarly required for SHH-driven tumor growth as in cerebellar 
development, we examined the effect of Gsk-3α/β co-deletion in CGNP-derived tumors. Mice with 
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the constitutively active SHH receptor, Smoothened (SmoM2) targeted to Math1+ CGNPs (Math1-
Cre/SmoM2loxP/+; M-Smo) develop medulloblastoma with 100% frequency by P12 (Schüller et al., 
2008). We crossed Math1-Cre, Gsk-3DKO and SmoM2 mouse lines mice to generate the genotype 
Math1-Cre/Gsk-3α-/-/Gsk-3βloxP/loxP/SmoM2loxP/+ (M-Smo/Gsk-3DKO). Although M-Smo/Gsk-3DKO 
mice could not survive beyond weaning at P20-22, like the Gsk-3DKO mice, we were able to analyze 
tumor growth during cerebellar development. We compared M-Smo, M-Smo/Gsk-3DKO cerebella 
to littermate controls with the genotypes Math1-Cre/Gsk-3α-/-/Gsk-3βloxP/+/SmoM2loxP/+ (M-
Smo/Gsk-3α KOβHET) or Math1-Cre/Gsk-3α-/+/Gsk-3βloxP/loxP/SmoM2loxP/+ (M-Smo/Gsk-3α HETβKO). 
Pathological analysis of brain sections showed that tumor growth in M-Smo/Gsk-3DKO mice 
was markedly reduced as compared to tumor mice with one allele of Gsk-3 intact (M-Smo/Gsk-3α 
KOβHET or M-Smo/Gsk-3α HETβKO) (Fig. 2.7A). Primary tumor area normalized to total cerebellar 
area was significantly decreased in Gsk-3-deleted tumors when compared to Gsk-3-intact tumors 
(Fig. 2.7B). PCNA staining at P12 and P15 demonstrated small foci of proliferating cells in the 
otherwise hypoplastic M-Smo/Gsk-3DKO cerebella (Fig. 2.7C). Co-staining with CDKN1B 
demonstrated pockets of differentiating cells in Gsk-3DKO tumors that were absent in Gsk-3-intact 
tumors (Fig. 2.7C). 
Immunofluorescent staining of GSK-3 and PCNA and p-RB show that proliferating cells 
in the M-Smo/Gsk-3DKO tumors are Gsk-3-deficient (Fig. 2.7D). Moreover, we found foci of 
CDKN1A-expressing cells M-Smo/Gsk-3DKO tumors, which was undetectable in Gsk-3-intact 
tumors (Fig. 2.7D). Quantification of the percent of positive cells in the tumor revealed a 
significant decrease in p-RB expression and a significant increase in CDKN1A expression in M-
Smo/Gsk-3DKO tumors (Fig. 2.7E). We were unable to detect a significant increase in cC3+ cells in 
M-Smo/Gsk-3DKO tumors as compared to controls (Fig. A.3). These data indicate that Gsk-3 
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deletion blocked tumor growth by restricting cell cycle progression, rather than by increasing cell 
death. We also noted induction of CDKN1A in M-Smo/Gsk-3DKO tumors, indicating that the GSK-
3/CTNNB/CDKN1A axis that we noted in CGNPs remains intact in SHH-driven 
medulloblastoma. 
Pharmacological inhibition of Gsk-3 blocks tumor growth in vitro 
The growth restriction in tumors deficient for Gsk-3 indicated a potential physiologic role 
for GSK-3 in SHH-driven tumors. To determine if pharmacological inhibition could exert a 
similarly growth suppressive effect, we used an in vitro culture assay to examine the function of 
GSK-3 in promoting medulloblastoma growth. Briefly, we harvested primary M-Smo tumors from 
P15 mice, dissociated the tumor cells and plated them in serum-free media. We then cultured the 
dissociated tumors with or without GSK-3 inhibitor CHIR98. After 24 hours, we collected cells 
for western blot or flow cytometry. Given the intrinsic increase in SHH signaling in M-Smo tumors, 
we cultured tumor cells in the absence of SHH. The presence of exogenous SHH in cultured M-
Smo tumor cells did not produce a discernable effect in tumor cell growth. 
Incubation of M-Smo tumor cells with 1 µM CHIR98 produced a decrease in p-RB and p-
CTNNB, and an increase in CDKN1A protein levels (Fig. 2.7F, G). We also noted a decrease in 
the inhibitory phosphorylation of GSK-3β, in an apparent homeostatic response to GSK-3 
inhibition. The decrease in p-RB in M-Smo tumor cells treated CHIR98 was dose dependent and 
correlated with decrease in Cyclin D2 (CCND2) expression as determined by flow cytometry 
analysis (Fig. 7H, I, Fig. A.4). These data show that SHH-driven medulloblastoma cells are 
sensitive to changes in GSK-3 activity that are within the range of modulation that can be achieved 




In this study, we explored the function of GSK-3 in cerebellar development and 
medulloblastoma growth through genetic, molecular, and pharmacological studies. We showed 
that GSK-3 is required to promote SHH-driven proliferation in the developing cerebellum and in 
medulloblastoma. Conditional deletion of both isoforms of Gsk-3 during cerebellar development 
was sufficient to block cerebellar growth by inhibiting cell cycle progression and promoting cell 
cycle exit, without inducing cell death. Pharmacologic inhibition of GSK-3 produced similar 
growth suppression. Our transcriptomic and molecular studies identified WNT and CDKN1A 
activation as a consequence of Gsk-3 loss. Co-deletion experiments demonstrated that up-
regulation of CDKN1A was independent of p53-mediated transcription and that CDKN1A was 
not required for the Gsk-3DKO phenotype. Rescue studies with co-deletion of Ctnnb demonstrate 
that growth suppression and abnormal migration are aspects of the Gsk-3DKO phenotype that can 
be dissociated, as Ctnnb co-deletion in Gsk-3/CtnnbTKO mice allowed Gsk-3-deleted CGNPs to 
proliferate but not to migrate normally.  
Previous studies have presented growth-promoting and growth-suppressive effects of 
GSK-3-mediated WNT signaling in both CGNPs (Knoepfler and Kenney, 2006; Penas et al., 2015) 
and in other cell types in the brain (Kim et al., 2009; Morgan-Smith et al., 2014). In CGNPs, the 
negative regulation of MYCN by GSK-3 suggested a growth suppressive effect (Knoepfler and 
Kenney, 2006), while the destabilization of WEE1 by GSK-3 suggested a role in promoting cell 
cycle progression (Penas et al., 2015). Our Gsk-3DKO studies make clear that GSK-3 is required for 
proliferation, and our Gsk-3/CtnnbTKO studies show that the regulation of the WNT pathway by 
GSK-3 is sufficient to mediate this effect. 
GSK-3-mediated growth suppression in CGNPs opposes the growth-promoting effects of 
WNT activation in progenitors of the CNS (Spittaels et al., 2002; Kim et al., 2009; Morgan-Smith 
23 
 
et al., 2014) and the gut (Harada et al., 1999; Giles et al., 2003). The contrasting response to WNT 
signaling we observe in CGNPs may be due to their specific reliance of SHH signaling. In the 
developing neural tube and in colon cancer cells WNT signaling induces the repressive SHH 
transcription factor, GLI3 (Alvarez-Medina et al., 2008; Song et al., 2015). In contrast, WNT 
activation in epidermal cells and cortical progenitors induces GLI1, which activates SHH-
dependent transcription (Kim et al., 2009; Wang et al., 2018). Our finding that WNT signaling 
opposes SHH-driven proliferation is consistent with an antagonistic interaction between these 
developmental signaling pathways. 
Our findings build on previous studies in which constitutive WNT signaling, induced by a 
mutant allele of Ctnnb, impaired cerebellar and medulloblastoma growth (Pöschl et al., 2013). We 
demonstrate a physiologic necessity for WNT during normal cerebellar growth by activating WNT 
signaling through a loss of function mutation, rather than engineering a gain of function. Deletion 
of Ctnnb induced hyperproliferation in CGNPs, further supporting the idea that GSK-3/WNT 
signaling is necessary for the normal regulation of cerebellar development. Importantly, GSK-3 is 
a kinase that can be manipulated by small molecule inhibitors. Our data suggest a potential 
deleterious impact of exposure to GSK-3 inhibitors during cerebellar development, as well as the 
potential of GSK-3 inhibitors to advance the treatment of SHH-driven tumors. 
It is important to note that our data support the potential of GSK-3 inhibition specifically 
in the SHH-driven subset of medulloblastoma. If GSK-3 activity shows the same bivalence in 
medulloblastoma that is seen in development, other medulloblastoma subtypes may be promoted, 
rather than suppressed by GSK-3 inhibition. This is supported by recent studies demonstrating 
distinct cells of origin for medulloblastoma subgroups (Gibson et al., 2010; Cavalli et al., 2017; 
Vladoiu et al., 2019). The potential effects of GSK-3 inhibition in Group 3 and Group 4 
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medulloblastomas are unknown and GSK-3 inhibition in WNT subgroup tumors might be 
expected to increase proliferation. Within the SHH subgroup however, WNT activation through 
GSK-3 inhibition may provide a new, targeted approach to therapy. 
 
Methods 
A detailed list of all reagents and materials used can be found in Table 2.2. 
Mouse models 
All animal handling and protocols were carried out in accordance with established NIH 
practices established by the Guide for the Care and Use of Laboratory Animals and approved under 
the University of North Carolina (UNC) Institutional Animal Care and Use Committee. All mice 
were maintained on a 12 hr:12 hr. light:dark cycle and given food and water ad libitum. Adult mice 
were group housed with 2 to 5 mice per cage. 
Gsk-3α-/- and Gsk-3βloxP/loxP mice were generously shared by Dr. William Snider. Gsk-3α-/- 
harboring an exon 2 deletion and Gsk-3βloxP/loxP mice with exon 2 flanked by loxP sites have been 
previously described (MacAulay et al., 2007; Patel et al., 2008). Gsk-3α-/- and Gsk-3βloxP/loxP mice 
were bred with the Math1-Cre mouse line (Matei et al., 2005), generously shared by Dr. David 
Rowitch and Dr. Robert Wechsler-Reya, to produce Gsk-3DKO mice (Math1-Cre/Gsk-3α-/-/Gsk-
3βloxP/loxP). Littermate Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP and Math1-Cre/Gsk-3α-/-/Gsk-3βloxP/wt 
(M-Cre/Gsk-3) mice were used as controls. 
Ctnnb conditional (CtnnbloxP/loxP ) mice were generously shared by Dr. Eva Anton. These 
mice harbor loxP sites flanking exons 2 – 6 of Ctnnb as previously described (Brault et al., 2001). 
CtnnbloxP/loxP were bred with Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP to generate Math1-Cre/Gsk-3α-/-
/Gsk-3βloxP/loxP/CtnnbloxP/loxP (Gsk-3/CtnnbTKO). Littermates heterozygous for Gsk-3 or Ctnnb were 
used as controls. Trp53loxP/loxP mice were purchased from the Jackson Laboratory (Marino et al., 
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2000) and crossed with Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP mice to generate Math1-Cre/Gsk-3α+/-
/Gsk-3βloxP/loxP/trp53loxP/loxP (Gsk-3/p53TKO) mice. Littermates heterozygous for Gsk-3 or p53 were 
used as controls. Cdkn1a-/- mice were purchased from Jackson Laboratories (Deng et al., 1995). 
These mice were bred with Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP to generate Math1-Cre/Gsk-3α-/-
/Gsk-3βloxP/loxP/Cdkn1a-/- (Gsk-3/Cdkn1aTKO) progeny. Littermates heterozygous for Gsk-3 or 
Cdkn1a were used as controls.  
Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP were crossed with SmoM2loxP/loxP mice purchased from 
Jackson Laboratories (Mao et al., 2006) to produce Math1-Cre/Gsk-3α+/-/Gsk-3βloxP/loxP/ 
SmoM2loxP/wt (M-Smo/Gsk-3αHET/Gsk-3βKO), Math1-Cre/Gsk-3α-/-/Gsk-3βloxP/wt/SmoM2loxP/wt (M-
Smo/Gsk-3αKO/Gsk-3βHET), and Math1-Cre/Gsk-3α-/-/Gsk-3βloxP/loxP/SmoM2loxP/wt (M-Smo/Gsk-
3DKO) mice. SmoM2loxP/loxP mice were also crossed with Math1-Cre mice to produce Math1-
Cre/SmoM2 (M-Smo) progeny. All mice were maintained on a C57BL/6 background. 
Cell culture 
CGNPs were isolated by size selection and explanted as previously described (Kenney et 
al., 2003; Lang et al., 2016). Briefly, cerebella were dissected from P5 pups, dissociated with 
papain using the Papain Dissociation System (Worthington Biochemical Corporation) and selected 
on a density gradient of ovomucoid inhibitor, then allowed to adhere to coated culture wells at 
37oC with 5% CO2 in DMEM/F12 with 25 mmol/L KCl, supplemented with heat inactivated FBS 
(HI-FBS) and N2. After 4 hours, media was replaced with identical serum-free media. Cells were 
maintained in 0.5 mg/mL SHH (#464SH, R&D Systems) or vehicle (0.1% BSA in 1x PBS). 
Where indicated, the specified dose of GSK-3 inhibitor (CHIR-980914, #S2745/ 
LY2090314, #S7063, Selleckchem) was added to cultures after the first 4 hours and cells were 
harvested 24 hours after drug treatment. In vitro proliferation was assessed by EdU incorporation 
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after a 1 hour exposure to 20 µmol/L EdU. EdU was visualized using the Click-iTTM EdU Alexa 
Fluor Imaging Kits (#C10337, ThermoFisher Scientific) according to manufacturer’s protocol. 
Cell counts were performed using Olympus CellSens software. Tumor cultures from 
medulloblastomas freshly harvested from Math1-Cre/SmoM2 mice were prepared according to the 
CGNP culture protocol above, with SHH supplementation omitted. 
Immunostaining cerebellar sections and quantification 
Mouse brains were processed and immunostained as previously described (Crowther et al., 
2016; Lang et al., 2016) using antibodies listed in Table 2.2. EdU was visualized using the Click-
iTTM EdU Alexa Fluor Imaging Kits (ThermoFisher Scientific, #C10337) according to 
manufacturer’s protocol. Immunostained sections were counterstained with 200 ng/mL 4’6-diami-
dino-2-phenylindole (DAPI/ #D1306, Thermo Fisher Scientific) in 1x PBS for 20 minutes. Stained 
slides were digitally acquired using an Aperio ScanScope XT (Aperio). 
To quantify proliferating cell nuclear antigen (PCNA), CDKN1B/p27, phosphorylated 
Retinoblastoma (p-RB), CDKN1A/p21, cleaved Caspase-3, BrdU or EdU-positive cells, the EGL 
region was manually annotated on each section, which was then subjected to automated cell 
counting using Tissue Studio (Definiens) for fluorescent slides. Quantification of cultured cells 
was performed by randomly imaging 3 sections of each well and performing cell counts with 
binary images using the particle analyzer in ImageJ/Fiji. P values were determined by two-tailed 
Student’s t-tests with R version 3.6.0. 
Cell cycle exit analysis 
5-bromo-2-deoxyuridine (BrdU) and 5-ethnynyl-2’-deoxyuridine (EdU) experiments, 
mice were subjected to intraperitoneal (IP) injection of BrdU (#B23151, ThermoFisher 
Scientific;100 mg/kg in 25 µl of HBSS). After 24 hours, mice were IP injected with EdU 
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(#A10044, Life Technologies; 40 mg/kg in 25 µl of HBSS) and dissected 2 hours later. Brains 
were fixed in 4% PFA in 1X PBS for 48 hours at 4oC before being processed for histology. 
Differential expression analysis 
RNA was purified from whole P2 cerebella according to manufacturer’s protocol (RNeasy 
Mini Kit, #74104, QIAGEN). RNA quality and quantity were assessed by spectrophotometry and 
capillary gel electrophoresis. We quantified transcripts using the Affymetrix Mouse Gene 2.1 ST 
24-Arrays. Differential gene expression analysis was performed by 2-way ANOVA, using the 
Partek Genomics Suite standard workflow for expression analysis. 
Pathway analysis 
Gene sets collected from microarray analysis were subjected to Gene Set Enrichment 
Analysis (GSEA) using freely available software from the Broad Institute (Mootha et al., 2003; 
Subramaniana et al., 2005). The Molecular Signatures Database (MSigDB) were used to provide 
annotated gene sets for comparative analysis and p-values were estimated by 1000 permutations. 
Western blot analysis 
Cultured cells and whole cerebella were lysed by homogenization in RIPA buffer 
containing protease inhibitor cocktail (PIC), sodium fluoride (NaF), and sodium orthovanadate 
(Na3VO4). Protein concentrations were quantified using the bicinchoninic acid (BCA) method and 
equal concentrations of protein were resolved on SDS-polyacrylamide gels followed by transfer 
onto polyvinylidene difluoride membranes. Immunologic analysis was performed on the SNAP 
i.d. 2.0 Protein Detection System (Millipore) as per manufacturer's protocol with antibodies listed 
in Table 2.2. Western blots were developed using the enhanced chemiluminescent SuperSignal 
West Femto Maximum Sensitivity Substrate, digitized using the C-DiGit blot scanner (LI-COR 
Biosciences) and quantified using Image Studio Lite software (LI-COR Biosciences). 
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Flow cytometry analysis 
M-Smo/Gsk-3DKO mice and control, tumor-bearing littermates were anesthetized with 
isoflurane and euthanized by decapitation for flow cytometry analysis. Tumor tissue was dissected 
and dissociated using the Papain Dissociation System as described above. Cells were resuspended 
in HBSS supplemented with 6g/L glucose and fixed with the Fix & Perm Cell Fixation & Cell 
Permeabilization Kit (ThermoFisher Scientific). Cells were stained for FxCycle Violet and p-RB 
using the antibodies listed in Table 2.2. Samples were run on the Becton Dickinson LSR Fortressa 





Figure 2.1. Gsk-3 deletion in CGNPs causes cerebellar hypoplasia early in development without 
inducing apoptosis. (A) Representative H&E-stained sagittal cerebellar sections of Gsk-3DKO cerebella 
compared to Gsk-3 intact littermate controls. Black arrowheads identify the EGL. Red arrows identify the 
IGL. (B) Representative sagittal cerebellar sections of Gsk-3DKO mice and Gsk-3 intact controls stained for 
cleaved Caspase-3 (cC3). AtrcKO cerebella were used as positive controls for apoptosis. Black arrowheads 
highlight positive cells. (C) Quantification of cC3+ cells in the EGL at P2 and P3 performed using replicates 
of the genotypes presented in 2.1B (n=6 per genotype at P2; n=5 per genotype at P3). (D) Immunostaining 
for PCNA and CDKN1B in Gsk-3 deleted and littermate control cerebella at P2 and P3. (E) Quantification 
of the PCNA+ and CDKN1A+ cells in the EGL at P2 or P3 using replicates of the genotypes presented in 
1D (n=3 per genotype). (F) Immunostaining for phosphorylated RB (p-RB) in Gsk-3DKO and littermate 
control cerebella. (G) Quantification of the p-RB+ cells in the EGL using replicates of the genotypes 
presented in 2.1F (n=3 per genotype). The regions of the higher magnification images are outlined by 
rectangles on the low magnification images. Scale bars measure 1 mm for low magnification images and 
500 μm for higher magnification images in (A), and 500 μm for low magnification images and 50 μm for 
higher magnification images in (B, D, F). Error bars indicate SEM. Significance for quantification is 





Figure 2.2. GSK-3 is required for CGNP proliferation and cell cycle progression. (A) Representative 
Gsk-3 intact and Gsk-3DKO cerebella pulse-labeled by BrdU and EdU at the indicated age. (B) Quantification 
of EdU+ cells in the EGL of Gsk-3DKO or littermate control cerebella from replicate mice as in 2A (P2 
control: n=8; P2 Gsk-3DKO: n=4; P3 control: n=5; P3 Gsk-3DKO: n=7). (C) Quantification of cell cycle exit 
fraction as determined by the proportion of BrdU cells not co-expressing EdU divided by the total BrdU+ 
population in Gsk-3-deleted CGNPs as compared to littermate controls from replicate mice as in 2A and 
2B. Error bars indicate SEM. Statistical significance is denoted by *p<0.05, **p<0.01, ***p<0.001 as 
determined by student’s t-test (B, C). The regions of the higher magnification images are outlined by 
rectangles on the low magnification images. Scale bars measure 500 μm for low magnification images and 






Figure 2.3. GSK-3 inhibition blocks proliferation in vitro. (A) Representative western blot images show 
p-RB, p-CTNNB, and CDKN1A protein levels in response to increasing concentrations of the GSK-3 
inhibitor CHIR98. (B) Quantification of western blot data as in 3A, with luminescence normalized to actin 
and expressed as fold change relative to SHH control (n=3 per condition). Statistical significance denoted 
by *p<0.05, **p<0.01, ***p<0.001 as determined by ANOVA with Tukey HSD post-hoc test. (C) 
Representative DAPI-stained and immunofluorescence images of cultured CGNPs treated as indicated and 
pulse-labeled with EdU 1 hour before fixation. Cells were stained for p-RB, EdU, and p-HH3. (D) 
Quantification of p-RB, EdU, and p-HH3 from replicate cultures (n=12 per condition) as in 3C, expressed 
as fold change relative to SHH control. Scale bars measure 50 μm. Error bars indicate SEM. Statistical 





Figure 2.4. Transcriptional analysis reveals upregulation of WNT/CDKN1A signaling in Gsk-3DKO 
mice. (A) Volcano plot of log2(FC) vs. -log10(p-value) with color threshold (green dots) set at |log2(FC)| > 
2 and FDR < 0.05 (lines). Significant genes are labeled and outlined in black dashed circles. Legend 
indicating dot color-coding in the bottom right corner (n=5 per genotype). (B) Dot plots show representative 
genes that were upregulated in Gsk-3 mutants, including WNT markers Lef1 and Tcf7, and Cdkn1a, as 
compared to M-Cre/Gsk-3α+/- and No-Cre/Gsk-3 controls. (C) GSEA analysis demonstrates upregulation 
of WNT and p53 signaling pathways in Gsk-3 deleted cerebella as compared to M-Cre/Gsk-3α+/- controls. 
(D) Immunostaining of select gene markers TCF7, LEF1, and CDKN1A identified from the microarray in 
Gsk-3DKO mice and littermate controls. The regions of the higher magnification images are outlined by 
rectangles on the low magnification images. Scale bars measure 500 μm for low magnification images and 




Figure 2.5. CTNNB modulates CGNP proliferation downstream of GSK-3. (A) Comparison of 
CtnnbcKO mice and littermate controls, in representative cerebellar sections stained with H&E at P7 and 
P15, and for PCNA/CDKN1B and p-RB at P7. (B) Survival curve demonstrating cumulative survival of 
Gsk-3/CtnnbTKO mice as compared to Gsk-3DKO mice (n=6 per genotype). Statistical significance is denoted 
by *p<0.05, **p<0.01, ***p<0.001 as determined by the Kaplan-Meier method and log rank test. (C) 
Comparison of Gsk-3DKO and Gsk-3/CtnnbTKO mice by number of falls per 120s (n=3 per genotype). (D) 
Comparison of Gsk-3DKO and Gsk-3/CtnnbTKO cerebella, in representative H&E stained slides at the 
indicated ages. (E) Comparison of Gsk-3DKO and Gsk-3/CtnnbTKO in PCNA/CDKN1B, p-RB, or CDKN1A 
stained cerebellar sections. (F) Quantification of p-RB+ cells in the EGL of Gsk-3/CtnnbTKO mice (n=4) and 
Gsk-3-intact littermate controls (n=3), from replicate mice as in 5E. (G) Comparison of Gsk-3/CtnnbTKO 
mice and littermate controls in representative Calbindin and FABP7-stained sections the regions of the 
higher magnification images are outlined by rectangles on the low magnification images. Scale bars 
measure 700 μm for low magnification images and 50 μm for higher magnification images in (A, D, F). 
Error bars indicate SEM. Statistical significance is denoted by *p<0.05, **p<0.01, ***p<0.001 as 




Figure 2.6. Reduced proliferation in Gsk-3-mutants is independent of p53 and CDKN1A. (A) 
Comparison of control, Gsk-3DKO and Gsk-3/p53TKO cerebella, in representative H&E, PCNA/CDKN1B, p-
RB, and CDKN1A stained cerebellar sections (B) Comparison of control and Gsk-3/Cdkn1aTKO cerebella 
in representative H&E, CDKN1A, or p-RB-stained sections. The regions of the higher magnification 
images are outlined by rectangles on the low magnification images. Scale bars measure 500 μm for low 
magnification images and 50 μm for higher magnification images in (A) or 700 μm for low magnification 





Figure 2.7. GSK-3 is required for Shh-driven medulloblastoma tumor growth. (A) Comparison of 
cerebellar regions in M-Smo/Gsk-3DKO mice and Gsk-3 intact Smo-mutant in representative H&E-stained 
cerebellar sections at P12 and. Primary tumor area outlined with a black dashed line. (B) Comparison of 
tumor area in Gsk-3-deleted and control tumors, using replicates of the genotypes in 7A, normalized to total 
cerebellar area at P12 (n=4 for P12 control; n=3 per genotype) (C) Comparison of PCNA and CDKN1B 
immunostaining in Gsk-3-deleted and control tumors, using replicates of the genotypes in 7A. (D) 
Comparison of PCNA, GSK-3 and CDKN1B immunostaining in Gsk-3-deleted and control tumors, using 
replicates of the genotypes in 7A. (E) Quantification of p-RB+ and CDKN1A+ cells comparing Gsk-3-
deleted and control tumors (P12 control: n=4; P12 Gsk-3DKO: n=3; P15 control: n=5; P15 Gsk-3DKO: n=3). 
(F) Representative western blot images of p-RB, p-CTNNB, CDKN1A, p-GSK-3β, and actin protein levels 
in cultured M-Smo tumor cells treated with or without 1 μM of the GSK-3 inhibitor CHIR-98014. (G) 
Quantification of western blot data from replicates as in 7F, normalized to actin and expressed as fold 
change relative to control tumor cells (n=4 per condition). (H) Histograms of p-RB+ and p-RB- tumor cells 
treated in vitro with vehicle, 1 μM, or 2 μM of CHIR98. (I) Quantification of p-RB+ cells in biological 
replicates from 7H (n=4 per condition). Error bars indicate SEM. Significance is denoted by *p<0.05, 
**p<0.01, ***p<0.001 as determined by student’s t-test. Brain outlined in blue and primary tumor area 
outlined in red (C, D). The regions of the higher magnification images are outlined by rectangles on the 
low magnification images. Scale bars measure 2 mm for low magnification images and 50 μm for higher 





Gene FDR Fold Change 
Chrnb4 4.62E-07 -3.56487 
Mfap4 5.34E-08 -2.77489 
Chrna3 4.04E-07 -2.54283 
Gsk3a 2.76E-10 -2.53513 
Rnf148 9.31E-06 -2.39022 
Nhlh1 1.64E-06 -2.27388 
Cadps2 1.25E-06 -2.21815 
Pisd-ps3 0.026387 -2.15748 
A930017K11Rik 2.42E-05 -2.15248 
Gm10002 0.031835 -2.12494 
Gm10002 0.031835 -2.12494 
Slc22a6 0.010923 -2.07768 
Esd 0.023577 -2.06687 
Gm16169 8.85E-05 -2.00995 
6430573F11Rik 8.99E-08 2.00458 
LOC100503213 0.034094 2.01892 
Bmp4 0.01273 2.06115 
Gna14 3.35E-08 2.08821 
Gm11744 2.32E-05 2.09393 
Cbln4 0.021051 2.12643 
Hoxb9 0.003801 2.12871 
Nkd1 2.14E-05 2.15054 
Mettl7a2 1.65E-06 2.21692 
Lrrc26 0.000573 2.22882 
Lrrc55 2.25E-05 2.24894 
Igk 0.01754 2.26064 
Adamts19 5.60E-07 2.29237 
Cdkn1a 7.58E-09 2.32177 
Dock5 6.89E-08 2.32746 
Glra1 0.002186 2.33206 
Gadd45g 3.03E-06 2.34539 
Axin2 1.23E-09 2.36502 
Dlx3 7.96E-09 2.3702 
Gpr50 0.002571 2.49813 
Syk 2.43E-05 2.49831 
2700046A07Rik 7.68E-07 2.53502 
Wnt10a 2.42E-05 2.53589 
Tcf7 1.17E-08 2.54261 
Spo11 4.61E-06 2.65145 
Gadd45a 8.94E-05 2.67878 
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Mylk 1.71E-05 2.6964 
Mafb 6.74E-05 2.73824 
Gm9926 3.98E-05 2.82476 
Emilin3 3.17E-06 2.87132 
Rasl11b 1.35E-06 2.87278 
Zfp503 2.29E-06 2.89595 
C030034L19Rik 3.49E-07 3.00969 
Sp5 3.47E-07 3.15039 
Fzd10 1.74E-05 3.25743 
Sostdc1 2.08E-05 3.3585 
Ascl4 4.28E-08 3.48996 
Il6ra 1.13E-05 3.52424 
Lef1 1.51E-08 3.5281 
Onecut1 8.25E-06 3.59348 
D630039A03Rik 8.58E-08 3.65652 
Gabra6 5.96E-07 3.72096 
Ism1 1.31E-06 3.81828 
Myo1e 1.58E-08 3.98353 
Lgr6 9.71E-08 5.12478 
Esyt3 6.02E-08 5.60377 
Fst 1.51E-10 5.60408 
Adam18 3.27E-06 5.75826 
Notum 6.56E-11 6.26911 
Cryba2 3.34E-07 7.95998 
Mybpc1 1.17E-09 8.1496 
Pmaip1 6.77E-09 9.39472 
Igk 1.10E-05 11.0986 
Wif1 1.91E-11 13.0107 
   
 
Table 2.1. List of differentially expressed genes in Gsk-3DKO mice as compared to M-Cre/Gskα+/- 
controls. A list of the differentially expressed genes in Gsk-3DKO cerebella as compared to Cre+ controls, 









Reagent Concentration Source Identifier 
Animal Studies 
C57BL/6 mice N/A The Jackson 
Laboratory 
Stock #000664 
Math1-Cre mice N/A The Jackson 
Laboratory 
Stock #011104 
Gsk-3α-/- mice N/A Donated by Dr. 
William Snider’s lab 
N/A 
Gsk-3βloxP/loxP mice N/A The Jackson 
Laboratory 
Stock #029592 
SmoM2-eYFPloxP/loxP mice N/A The Jackson 
Laboratory 
Stock #005130 
Trp53loxP/loxP mice N/A The Jackson 
Laboratory 
Stock #008462 
CtnnbloxP/loxP mice N/A The Jackson 
Laboratory 
Stock #004152 
Cdkn1a-/- mice N/A The Jackson 
Laboratory 
Stock #016565 




5-bromo-2-deoxyuridine (BrdU) 100 mg/kg in 




5-ethnynyl-2’-deoxyuridine (EdU) 40 mg/kg in 25 
µl of HBSS 
Life Technologies Catalog #A10044 
PCR 




Cre Forward Primer: GCG GTC 
TGG CAG TAA AAA CTA TC 
200 µM Invitrogen JAX #oIMR1084 
Cre Reverse Primer: GTG AAA 
CAG CAT TGC TGT CAC TT 
200 µM Invitrogen JAX #oIMR1085 
Gsk-3α Forward Primer: CCC CCA 
CCA AGT GAT TTC ACT GCT A 
200 µM Invitrogen N/A 
Gsk-3α Reverse Primer: AAC ATG 
AAA TTC CGG GCT CCA ACT 
CTA T 
200 µM Invitrogen N/A 
Gsk-3β Forward Primer: GCC ATC 
AAG AAA GTT CTA CAG GA 
200 µM Invitrogen JAX #32390 
Gsk-3β Reverse Primer: GCT GAA 
GTC CAG AGC AAG TCT 
200 µM Invitrogen JAX #32391 
Trp53 Forward Primer: GGT TAA 
ACC CAG CTT GAC CA 
200 µM Invitrogen JAX #oIMR8543 
Trp53 Reverse Primer: GGA GGC 
AGA GAC AGT TGG AG 
200 µM Invitrogen JAX #oIMR8544 
Ctnnb Forward Primer: AAG GTA 
GAG TGA TGA AAG TTG TT 
200 µM Invitrogen JAX #oIMR1512 
Ctnnb Reverse Primer: CAC CAT 
GTC CTC TGT CTA TTC 
200 µM Invitrogen JAX #oIMR1513 
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Cdkn1a 1 Primer: GTT GTC CTC 
GCC CTC ATC TA 
200 µM Invitrogen JAX #12427 
Cdkn1a 2 Primer: GCC TAT GTT 
GGG AAA CCA GA 
200 µM Invitrogen JAX #12428 
Cdkn1a 3 Primer: CTG TCC ATC 
TGC ACG AGA CTA 
200 µM Invitrogen JAX #12429 
SmoM2-eYFP Forward primer:  
AAG TTC ATC TGC ACC ACC G 
400 µM Invitrogen JAX #oIMR0872 
SmoM2-eYFP Reverse primer: TCC 
TTG AAG AAG ATG GTG CG 
400 µM Invitrogen JAX #oIMR1416 
Apex Taq DNA Polymerase Master 
Mix 
1X Genessee Scientific Catalog #42-138 
Platinum Blue PCR SuperMix 1X Invitrogen Catalog # 12580015 
Dissociation 







Heat inactivated FBS 100% for 
dissociation 
10% in media 
Gibco Catalog #10437028 
Hank’s Balanced Salt Solution 1X Gibco Catalog #14175-095 
D-(+)-Glucose 6g/L (33 mM) Millipore Sigma Catalog #G7021 
Cell Culture 
Poly-L-Lysine 1X Sigma-Aldrich Catalog #P4832 
DMEM/F12 1X Gibco Catalog #11330-032 
N2 Supplement 1:10000 in 
media 
BD Biosciences Catalog #35-100 
Penicillin-Streptomycin 1:10000 in 
media 
Sigma-Aldrich Catalog #P4333 
Potassium Chloride (KCl) 2.5 µM Mallinckrodt Catalog #6858 
Sonic hedgehog (SHH) 0.5 mg/mL R&D Systems Catalog #464SH 
Paraformaldehyde (PFA) 4% fixative 
0.1% in sheath 
fluid 
Sigma-Aldrich Catalog #P6148 
Immunofluorescence and Western Blot 
Antigen Retrieval 1:100 Vector Laboratories Catalog #H-3300 
Phosphate Buffered Saline (PBS) 1X Corning Inc. Supplier #46-013-CM 
Tween 20 0.3% in PBS Sigma-Aldrich Catalog #P9416 
Donkey serum 2% in 0.3% 
PBST 
Millipore Sigma Catalog #D9663 
Tris Buffered Saline with Tween 
(TBST) 
1X Cell Signaling 
Technology 
Catalog #9997 
Bovine Serum Albumin (BSA) 1% in 0.1% or 
0.3% PBST 
Fisher Scientific Catalog #BP9700-100 








4-20% Mini-PROTEAN® TGXTM 
Precast Protein Gels 
N/A Bio Rad Catalog #4561094 
DAPI 1:2500 for IF Invitrogen Catalog #D1306 
cleaved Caspase-3 (Asp175) 1:200 for IHC Cell Signaling 
Technology 
Catalog #9661 
GSK-3α/β (D75D3) 1:100 for IF Cell Signaling 
Technology 
Catalog #5676 
PCNA 1:2000 for IF Abcam Catalog #ab92552 
CDKN1B/p27 1:1000 Cell Signaling 
Technology 
Catalog #3686 
phospho-RB (Ser807/811) 1:3000 for IF 




phospho-Histone H3 (Ser10) (6G3) 1:100 for IHC Cell Signaling 
Technology 
Catalog #9706 
LEF1 1:200 for IF Sigma Catalog #HPA002087 
TCF1 (C63D9) 1:100 for IF Cell Signaling 
Technology 
Catalog #2203 
CDKN1A/p21 1:500 for WB 
1:2000 for IHC 
Abcam Catalog #ab109199 
phospho-CTNNB (Ser33/37/Thr41) 1:500 for WB Cell Signaling 
Technology 
Catalog #9561 
CTNNB 1:500 for WB Cell Signaling 
Technology 
Catalog #8480 
phospho-GSK-3β (Ser9) (D85E12) 1:500 for WB Cell Signaling 
Technology 
Catalog #5558 
Cyclin D2 (D52F9) 1:500 for WB Cell Signaling 
Technology 
Catalog #3741 
β-Actin (8H10D10) 1:5000 for WB Cell Signaling 
Technology 
Catalog #3700 
Goat anti-rabbit Alexa Fluor 488 1:400 for IF ThermoFisher 
Scientific 
Catalog #A-11034 
Goat anti-mouse Alexa Fluor 555 1:400 for IF ThermoFisher 
Scientific 
Catalog #A-21424 
Novolink Polymer Per 
manufacturer’s 
instructions 
Leica Biosystems Catalog #RE7200-CE 





Vector Laboratories Catalog #MP-7401 





Vector Laboratories Catalog #MP-7402 














Click-iT™ EdU Cell Proliferation 










Table 2.2: List of reagents and materials used in Chapter 2 with concentrations, vendor name, and 
catalog number listed where applicable. 









CHIR-98014 As indicated Selleckchem Catalog #S2745 
LY2090314 As indicated Selleckchem Catalog #S7063 
AZD1080 As indicated Selleckchem Catalog #S7145 
Lithium Chloride (LiCl) As indicated Sigma Aldrich Catalog #203637 
Flow Cytometry 








Heat inactivated FBS 5% in FACS 
wash buffer 
Gibco Catalog #10437028 
Sodium azide (NaN3) 0.1% in FACS 
wash buffer 
Fisher Scientific Catalog #S2271-25 
FxCycle Violet 1:100 ThermoFisher 
Scientific 
Catalog #F10347 







SINGLE-CELL TRANSCRIPTOMICS REVEALS CELLULAR HETEROGENEITY IN 
SHH-DRIVEN MEDULLOBLASTOMAS WITH DIFFERENTIAL RESPONSES TO 
VISMODEGIB2 
Introduction 
Medulloblastoma is one of the most common malignant pediatric brain tumors, comprising 
up to 20% of all childhood brain tumors (Dahmane et al., 2001; Yang et al., 2009; Dey et al., 
2012). Bulk transcriptomic analysis of medulloblastomas have stratified tumors into four 
molecular subgroups: WNT, SHH, Group 3, and Group 4 (Northcott et al., 2011; Northcott et al., 
2012a; Northcott et al., 2012b). SHH subgroup tumors, which comprise up to 30% of all 
medulloblastomas, are typified by activating mutations in the SHH signaling pathway, a 
developmental signaling pathway required for the proliferation of cerebellar granule neuron 
progenitors (CGNPs) during normal cerebellar development (Dahmane and Ruiz i Altaba, 1999; 
Wechsler-Reya and Scott, 1999; Lewis et al., 2004). Activating SHH pathway mutations in CGNPs 
in genetically engineered mice can produce medulloblastomas, suggesting CGNPs are the cell of 
origin for SHH-driven medulloblastomas (Yang et al., 2008; Dey et al., 2012). Medulloblastomas 
typically respond to conventional treatments such as radiation therapy and chemotherapy. 
However, even within subgroups outcomes are heterogenous and targeted therapies have not been 
as effective for medulloblastoma as other cancers, such as chronic myelogenous leukemia and 
 
2 The work described in this chapter has been accepted for publication by Nature Communications: 
Ocasio JK, Babcock B, Malawsky D, Weir SJ, Loo L, Simon JM, Zylka MJ, Hwang D, Dismuke T, Sokolsky M, 
Rosen EP, Vibhakar R, Taylor MD, Colaneri A, Wilhelmsen K, and Gershon TR. 2019. Single-cell RNA-seq shows 
cellular heterogeneity and lineage expansion in a mouse model of SHH-driven medulloblastoma support resistance 
to SHH inhibitor therapy. Accepted for publication at Nature Communications. 
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basal cell carcinoma (Druker et al., 1996; Thomas et al., 2002; Lupi, 2007; Westin and Kurzrock, 
2012; Sekulic et al., 2012). 
Cellular diversity within tumors may explain the limited efficacy of targeted therapies for 
cancers. Single cell transcriptomic analysis can provide detailed information on cellular diversity 
within tumors and may provide insights into the diversity of targeted treatment failure (Tirosh et 
al., 2016; Puram et al., 2017; Venteicher et al., 2017; Filbin et al., 2018; Karaayvaz et al., 2018). 
Recent studies analyzing single cells from glioblastomas, a highly aggressive brain tumor, have 
shown that tumors contain subpopulations with diverse receptor tyrosine kinase (RTK) mutations, 
suggesting that single RTK inhibitors would be insufficient to inhibit all tumor cells (Patel et al., 
2014). To examine how intra-tumor heterogeneity contributes to therapeutic failure in SHH-driven 
medulloblastomas, we used high-throughput single cell transcriptomic analysis to compare cellular 
diversity in tumor-bearing mice before and after SHH inhibitor therapy. 
Small-molecule inhibitors of SHH signaling have been investigated as potential therapies 
for SHH-driven cancers (Rubin and de Sauvage, 2006). Vismodegib, an FDA-approved inhibitor 
of the transmembrane protein Smoothened (SMO), disrupts SHH signaling and has been shown to 
be effective for basal cell carcinoma (Sekulic et al., 2012; Axelson et al., 2013). However, while 
vismodegib induces initial growth inhibition in SHH-driven medulloblastoma, tumors are 
ultimately resistant to therapy (Yauch et al., 2009; Robinson et al., 2015; Samkari et al., 2015). 
We bred transgenic mice with a mutant, constitutively active form of Smo to study the early effects 
vismodegib on cellular diversity in SHH-driven tumors and to determine if this diversity may 





Vismodegib initially slows medulloblastoma growth in M-Smo mice 
We generated SHH-driven medulloblastomas in mice by breeding the transgenic SmoM2 
mouse line, which harbors a mutant, constitutively active allele of Smo, preceded by a loxP-STOP-
loxP sequence, with Math1-Cre mice, which express Cre recombinase in CGNPs driven under the 
Math1 promoter (Machold and Fishell, 2005; Matei et al., 2005; Mao et al., 2006). The resulting 
Math1-Cre/SmoM2 (M-Smo) progeny develop medulloblastoma with 100% frequency by 
postnatal day 12 (P12). We administered either vismodegib or vehicle to medulloblastoma-bearing 
P12 M-Smo mice, daily from P12-P15, and then every other day until symptomatic progression. 
Acute exposure to vismodegib induced transient tumor regression, characterized by reduced 
expression of phosphorylated RB, a marker of cell cycle progression (Fig. 3.1A, B’). However, 
long-term treatment with vismodegib resulted in recurrence (Fig. 3.1B, B’) and did not produce a 
statistically significant increase in survival (Fig. 3.1C). 
To measure pharmacodynamic responses longitudinally, we administered vismodegib to a 
similar medulloblastoma-prone mouse model, hGFAP-Cre/SmoM2/Gli-luc (G-Smo/Gli-luc). G-
Smo/Gli-luc mice develop histologically identical tumors as M-Smo mice, with a synthetic, SHH-
sensitive luciferase reporter construct. We performed luciferase imaging after vismodegib or 
vehicle administration in G-Smo/Gli-luc for 3 days (Fig. 3.1D). Luciferase imaging showed that 
the first dose of vismodegib decreased total tumor SHH activation but that by the 3rd day of 
treatment tumors were no longer responsive (Fig. 3.1E, E’). Prior studies have posited that tumor 
stem cells, defined by Sox2 expression, may contribute to treatment failure with vismodegib 
(Vanner et al., 2014). To explore how diverse cell identities may contribute to early resistance to 
vismodegib treatment, we subjected M-Smo tumors to high-throughput single cell transcriptomic 
analysis and compared tumors in the early stages of vismodegib therapy to vehicle-treated controls. 
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Drop-seq analysis defines discrete subsets of stromal and tumor cells 
We treated two groups of 5 P12 M-Smo tumor mice with a daily dose of either vismodegib 
or vehicle for three days, then harvested tumors from all ten mice at P15. Tumors were dissociated 
and run using the Drop-seq protocol V3.1, wherein individual cells where co-captured with primer-
coated beads in a microfluidics chamber, allowing for cell- specific bar coding of mRNA to be 
amplified for cDNA library construction (Macosko et al., 2015). After sequencing, transcript 
identities were determined by the 3’ UTR sequence and matched to cell identities determined from 
the bead-specific barcodes. We restricted the analysis to cells with > 500 detected genes, and 
removed outlier cells as described in Methods to address the common problems of gene drop out, 
unintentional cell-cell multiplexing and premature cell lysis (Loo et al., 2019; Vladoiu et al., 2019). 
To assess cellular diversity, we first analyzed the cells collected from vehicle-treated 
tumors. We conducted a principal component analysis (PCA) of the ~1,500 genes that showed the 
highest cell-cell expression variation, defined by the magnitude of mean expression and dispersion 
from the mean. We retained the first 11 principal components (PCs) for further analysis and 
rejected one PC, PC10, which highlighted batch effect variables as described in prior studies 
(Saunders et al., 2018). Louvain clustering on the PCs divided the cells into 15 distinct clusters. 
We applied t-Distributed Stochastic Neighbor Embedding (t-SNE) to the PCs synchronously with 
Louvain clustering to project each cell into a 2-dimensional graph in which cells were colored 
according to their cluster identities (Fig. 3.2A). We compared the expression of each gene by cells 
within each cluster against all cells outside of the selected cluster to generate cluster-specific 
differential expression profiles (Table 3.1). We identified specific markers within these profiles to 
infer the biological identity of cells within each cluster. 
These methods identified 6 clusters that localized to discrete regions of the t-SNE 
projection, without close neighbors. Analysis of the gene expression patterns identified these 
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clusters as endothelial cells, vascular fibroblasts, microglia, neurons, oligodendrocytes, and 
astrocytes (Fig. 3.2B, Table 3.1). These cell types are expected to be present in the stroma within 
or adjacent to the tumors. The other 9 clusters identified formed a cohesive, multi-cluster complex, 
suggesting a spectrum of cells in transition between different states. 
To develop an ordered classification within the multi-cluster complex, we applied 
hierarchical cluster analysis (HCA) to the centroids of the PCA-defined cluster. The resulting 
dendrogram separated the 6 clusters of cells with stromal characteristics from the rest of the 
population (Fig. 3.2C). The other 9 clusters subdivided into 2 subsets, one of which split again 
before individual clusters emerged, highlighting 3 key branch points (Fig. 3.2C). We designated 
these branch points as Nodes AVehicle, BVehicle, and CVehicle (AV-CV). We next assessed whether cells 
from vehicle-treated tumors resembled cells during normal cerebellar development. 
SHH-driven medulloblastomas contain cells in a range of differentiation states that resemble 
CGNP development 
To determine if the cells in each cluster and node resembled cells during normal cerebellar 
development, we compared our tumor set to wild-type cerebella collected during the peak of 
postnatal neurogenesis. We subjected 5 WT cerebella from P7 mice to single-cell analysis through 
Drop-Seq. Analysis of 7,090 cells from WT cerebella produced 14 clusters, with cluster-specific 
differential expression profiles and recognizable patterns of gene expression (Fig. 3.3A; Table 
3.2). As in the vehicle-treated tumors, we identified 6 clusters as stromal cell types, including 
endothelial cells, vascular fibroblasts, microglia, Purkinje neurons, oligodendrocytes, and 
astrocytes. 
Two subsets of cells formed separate multi-cluster groupings. Expression of the 
proliferation marker, Mki67, and the neuronal differentiation marker, Meg3, indicated a 
developmental progression from progenitors to neurons across both of these multi-cluster groups. 
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One multi-cluster population expressed Pax3 and Pax2, identifying it as cerebellar interneuron 
progenitors and their differentiated neuronal progeny (Rosenberg et al., 2018). Within this 
cerebellar interneuron group, we noted sequential expression of the transcription factors Ascl1, 
Sox2, Pax3, and Pax2, paralleling the progression from proliferation to differentiation (Fig. 3.3B). 
The other multi-cluster grouping showed gene expression patterns resembling CGNPs in a similar 
gradient of differentiation states, from proliferative cells expressing the SHH pathway 
transcription factor Gli1, to cells in successive states of granule neuron differentiation marked by 
sequential expression of markers Ccnd2, Barhl1, Ctntn2, Rbfox3, and Grin2b (Fig. 3.3C). 
Differentiated neurons were subclassified using glutamatergic marker Slc17a6 (aka vGlut2), 
GABAergic marker Gad1 (aka Gad67), Purkinje neuron marker Calb1 and the CGN marker Calb2 
(Fig. A.5). 
We next used the k-nearest neighbor (kNN) algorithm to project the P15 vehicle-treated 
M-Smo cells into the P7 WT t-SNE (Fig. 3.3D). This method determined the best fit of the M-Smo 
cells into the cell types represented in the WT dataset. The k-NN projection correctly matched the 
stromal cells from the M-Smo tumors into the same cell types in the WT cerebella, validating the 
approach. The cells of Nodes AV, BV, and CV predominantly localized to the multi-cluster CGNP 
group and mapped in a progression from proliferative to successively more differentiated regions 
(Fig. 3.3C, D). This projection showed that the cells of Nodes AV-CV most closely resemble 
CGNPs, paralleling the CGNP developmental trajectory. 
M-Smo tumor cells exhibit two discrete fate trajectories 
To further understand the cell fate progressions within M-Smo tumors, we used 
independent component analysis (ICA). We selected the population of cells within Nodes AV – 
CV, which corresponded to the CGNP-like tumor cells, and selected genes that met variability 
criteria within this specific sub-population. We found that generating 4 ICs (IC 1V – 4V) produced 
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robust components that identified non-overlapping sets of cells at each component’s extremes 
(Table 3.3). Analysis of the 50 most heavily-weighted genes associated each IC with a specific 
cellular process: IC 1V with DNA replication, IC 2V with neuronal differentiation, IC 3V negatively 
with both mitosis and differentiation, highlighting G1 cells re-entering the cell cycle, and IC 4V 
with mitosis (Table 3.3; Fig. A.6A). We used these ICs as dimensions to map the medulloblastoma 
cells into a new, IC-based t-SNE projection. As in the PC-based projection, Nodes AV – CV 
localized to discrete and adjacent regions, indicating that the cell types identified by the PCA of 
all cells and the ICA on the CGNP-like tumor cells showed close correspondence (Fig. 3.4A). 
The ICA-based t-SNE projection suggested two discrete patterns of transition. IC 2V 
defined a gradient of neuronal differentiation across Node CV, while the other 3 ICs defined a set 
of transitional states that combined to form a circular trajectory (Fig. 3.4B; Fig. A.6A). Sequential 
expression of cyclins Ccnd1, Ccne2, Ccna2, and Ccnb2 in adjacent regions demonstrated a 
progression through the cell cycle, marking G1, S, G2, and M phases respectively (Fig. 3.4C). 
Comparison of our dataset to larger cell cycle phase-specific gene lists identified by prior single-
cell transcriptomic studies confirmed this cell cycle progression (Fig. A.6B-G) (Macosko et al., 
2015). Node BV denoted the transition between the circular path of cycling cells and the linear path 
of differentiating cells. Based on these observations, we infer that ICA sorts medulloblastoma cells 
into various stages of two fundamental processes, the cycling and self-renewal of proliferative 
cells, and the terminal differentiation of cells exiting the cell cycle (Fig. 3.4D). 
Differential gene expression markers selected from each node also mirrored a spectrum of 
developmental states of medulloblastoma cells. We found sequential expression of the 
proliferation markers Mki67, Pcna, Ccnd1, and Ccnd2, the SHH pathway marker Gli1, CGNP 
markers Atoh1 (Math1) and Barhl1, late CGNP marker Cntn2 (Tag1), and the neuronal markers 
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Rbfox3 (NeuN) and Meg3 across Nodes AV – CV (Fig. A.7). Consistent with the differentiation 
trajectory determined by ICA, the cells of Nodes AV – CV could be parsed into 3 cohesive sets, 
from undifferentiated and proliferative cells to early neuronal differentiation to non-proliferative 
with advanced neural differentiation, terminating in mature neurons (Fig. 3.4E). 
Lineage tracing identifies tumor cell differentiation along a glial trajectory 
The SmoM2 transgene contains a 3’ YFP sequence that we used to trace tumor cell lineage 
(Mao et al., 2006). Cre-mediated excision of the stop codon is required for the expression of 
SmoM2 in M-Smo mice and is limited to the descendants of cells expressing Math1-Cre. 
Expression of Yfp thus identified cells descended from Math1-Cre expressing cells. We found Yfp+ 
cells scattered throughout Nodes AV – CV, indicating that these CGNP-like tumor cells descended 
from the Math1 lineage (Fig. 3.5A). The sensitivity of detecting individual markers within cells 
may be low because high-throughput single-cell transcriptomics with Drop-Seq captures only 10-
20% of mRNAs in each cell. Therefore, the true rate of Yfp+ cells is likely higher than the rate 
detected and most, if not all, of the cells in Nodes AV – CV may be derived from Math1-Cre-
expressing predecessors. However, we also detected Yfp expressing cells in the astrocytic and 
oligodendrocytic clusters, inconsistent with the Math1 lineage. Quantification of the Yfp+ cells 
showed that 8.04 ± 2.84% (Mean ± SEM) expressed the astroycytic marker Gfap and 7.59 ± 1.16% 
expressed the oligodendroglial marker Sox10. The co-expression of Yfp with glial markers 
indicates that Math1-Cre tumor cells may give rise to progeny with glial phenotypes. 
The expression of Yfp within non-CGNP-like cells in M-Smo tumors indicates that SHH 
hyperactivation caused a lineage expansion. Lineage tracing studies in WT cerebella demonstrated 
Math1 expression only in cells with neural commitment (Machold and Fishell, 2005; Wang et al., 
2005). However, these studies did not test for the possibility of rare deviations from the typical 
trajectory of Math1+ cells. Moreover, Math1-Cre is a synthetic transgene and the domain of Cre 
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expression in Math1-Cre mice may not exactly correspond with native Math1 expression. To 
experimentally determine the descendants of Math1-Cre cells during development, we generated 
Math1-Cre/Pham mice, which express the fluorescent reporter DENDRA2 through Cre-mediated 
activation (Pham et al., 2012). We used flow cytometry to quantify the co-expression of 
DENDRA2 and GFAP in cells. 
We detected robust GFAP expression in 9.53 ± 0.73 % (Mean ± SEM) of the DENDRA2- 
population and in 0.04 ± 0.01% of the DENDRA2+ population (Fig. 3.5B, B’). Expression of 
GFAP in the DENDRA2- population serves as a positive control and is consistent with Bergmann 
glia and astrocytes present during normal cerebellar development. The fraction of GFAP 
expressing cells in the DENDRA2+ population was >200-fold lower than either the DENDRA2- 
population or the Yfp+ population in tumors, demonstrating that GFAP+ descendants of Math1-Cre 
expressing cells are exceedingly rare during cerebellar development. Moreover, we generated M-
Smo mice with the Pham fluorescent reporter to trace the Math1 lineage in medulloblastomas. In 
contrast, we detected significantly more GFAP expressing cells in the DENDRA2+ population of 
M-Smo/Pham tumors (8.73 ± 1.74%), while the expression of GFAP in the DENDRA2- population 
was not significantly changed (4.95 ± 1.54%) as determined by student’s t-test (Fig. 3.5B, B’). 
When considered with our data on the astrocytic phenotype in Yfp+ cells in tumors, these data show 
that SmoM2-driven tumorigenesis expanded the Math1-Cre lineage. 
Our data are consistent with prior studies demonstrating that SHH hyperactivation in vitro 
can expand the Math1 lineage, as CGNPs cultured with SHH and BMP4 give rise to astrocytes 
(Okano-Uchida et al., 2004). The observed expansion of cell fates driven by SmoM2 activation in 
Math1-Cre+ cells was selective to astrocytic and oligodendrocytic clusters, as 2-way ANOVA of 
the stromal populations showed significantly lower rates of Yfp+ cells in endothelial, vascular 
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fibroblast, and microglial clusters (p<0.001 for each comparison). Thus, medulloblastoma cells 
are able to assume a range of fates that is broader than the expected neuronal fate of Math1-
expressing progenitors but is limited to cells within the neuroectodermal lineage. 
Tumors contain a diverse set of cells expressing stem cell markers 
We next examined whether Math1-Cre descendants could give rise to multipotent stem-
like cells in light of our data suggesting cell fate expansion in M-Smo tumors. Prior studies have 
shown that SHH medulloblastomas driven by radiation and heterozygous deletion of the 
transmembrane receptor, Ptch, express stem-like Sox2+ cells. Sox2+ cells from Ptch+/-/Sox2-eGFP 
mice recapitulated tumors upon transplantation, exhibited self-renewal, and showed the ability to 
give rise to progeny with diverse cell fates (Vanner et al., 2014). Bulk transcriptomic analysis of 
eGFP+ tumor cells from these mice showed up-regulation of specific stem cell markers, including 
Sox2, Gfap, Olig1, Olig2, Blbp7 (Fabp7), and Pdgfra (Vanner et al., 2014). 
We were able to detected Sox2+ cells within our M-Smo single-cell transcriptomic dataset. 
Gene expression profiles of Sox2+ cells compared to all other cells resembled the previously 
reported transcriptomic profile of Sox2-eGFP+ cells (Table 3.4; hypergeometric test, p=3.2x10-124) 
(Vanner et al., 2014). However, Sox2+ expression was dispersed throughout different regions of 
the t-SNE, including astrocytic and oligodendrocytic clusters and the CGNP-like cells of Nodes 
AV – CV and occasionally overlapped with Yfp expression (Fig. 3.5A). Different subsets of Sox2+ 
cells expressed different combinations of the markers identified by Vanner et al. (Fig. 3.5C). 
However, not all Sox2+ cells were tumor-derived, as glial cells in normal P7 cerebella also 
expressed Sox2 (Fig. 3.3B). Together, these findings show that the Sox2+ population is comprised 
of diverse cell types that include both normal glia and tumor-derived cells with either glial-like or 
neural progenitor-like characteristics. 
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We next subjected the Sox2+ cells from the vehicle-treated M-Smo tumors to ICA and 
Louvain clustering to classify the diversity of Sox2-expressing cells. The resulting t-SNE 
projection divided the Sox2+ population into 3 clusters: a Sox10+ oligodendrocytic cluster, an 
Aqp4+ astrocytic cluster, and a CGNP-like cluster containing cells from Nodes AV – CV (Fig. 
3.5D). Analysis of gene expression profiles identified 2 discrete groups within the astrocytic and 
oligodendrocytic clusters (Table 3.5). A subset of the oligodendrocytic cluster expressed markers 
of early oligodendrocyte precursors (OPCs) such as Pdgfra, while the other cluster expressed 
markers of more mature oligodendrocytes, such as Mbp and Mog (Fig. 3.5E). Within the astrocytic 
cluster, we differentiated the groups by the presence or absence of the early astrocyte precursor 
(AP) markers Olig1 (Fig. 3.5F). We detected expression of the Yfp transcript within the OPC-like 
and AP-like cells, indicating that tumor-derived glial cells maintained less differentiated states 
(Fig. 3.5E, F). Together, our data show that Sox2+ cells derived from M-Smo tumors can exhibit 
both glial and stem-cell like properties. 
Inhibiting SHH signaling at SMO promotes differentiation 
To determine the effect of SHH inhibition on cellular heterogeneity and tumor cell fate, we 
compared single-cell gene expression data from vismodegib- and vehicle-treated tumors, including 
>30,000 cells harvested from a total of 10 tumors. We identified PCs using the same workflow as 
the vehicle-only and WT analyses and used these PCs for t-SNE visualization and Louvain 
clustering. Cells within the t-SNE localized to several single-cluster groups and one large multi-
cluster group. The single-cluster groups could be identified as endothelial cells, vascular 
fibroblasts, microglia, oligodendrocytes, astrocytes, and neurons by expression of specific markers 
(Fig. 3.6A). Hierarchical cluster analysis on the 11 clusters comprising the multi-cluster group 
defined 4 distinct nodes, designated Nodes ATogether – DTogether (Nodes AT – DT; Fig. 3.6B). Nodes 
AT – CT resembled cells from Nodes AV – CV, while cells in Node DV expressed late differentiation 
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markers (Fig. 3.6C). A small proportion of the Node CV cells from vehicle-treated tumors 
populated Node DT. However, 85% of Node DT derived from vismodegib-treated tumors (p=0.007; 
two-sample T-test), indicating that vismodegib induced a more differentiated state (Fig. 3.6D). 
Cells throughout Node DT expressed Yfp, confirming the tumor lineage of these differentiated cells 
(Fig. 3.6E). 
We mapped the vehicle- and vismodegib-treated tumor cells according to their best fit on 
the P7 WT cerebellum t-SNE as in Fig. 3.3D. Glial, endothelial, vascular fibroblast, and microglial 
cells from vehicle- and vismodegib-treated tumors matched corresponding cell types in normal 
cerebella (Fig. 3.6F). The CGNP-like cells from vismodegib-treated tumors mapped to more 
differentiated regions of the WT CGNPs compared to vehicle-treated tumors (Fig. 3.6E). ICA 
performed on tumor cells from Nodes AT – DT also showed increased differentiation, with more 
vismodegib-treated cells at the extreme of the differentiation-weighted IC (Fig. 3.6G; Table 3.6). 
Developmental mapping and ICA both confirm a shift in the CGNP-like tumor cells toward more 
differentiated states. 
Uneven depletion of proliferative tumor subtypes indicates variation in vismodegib sensitivity 
To determine how vismodegib altered each cell type, we compared the populations of each 
node and cluster in vehicle- and vismodegib-treated tumors. We normalized the number of cells in 
each node and cluster to the total number of cells from each individual mouse. We then compared 
the distribution of cells across nodes and clusters from vehicle- and vismodegib-treated mice (Fig. 
3.6H, Fig. A.8A). These comparisons demonstrated depletion of proliferative populations (Nodes 
AT + BT) and enrichment of non-proliferative populations (Nodes CT + DT) with vismodegib 
treatment (p<0.001). Enrichment of differentiated cell types was relative to the total number of 
cells, rather than absolute. 
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Prior studies have shown that differentiated progeny of stem cells from medulloblastomas 
tend to undergo apoptosis after a period of days (Vanner et al., 2014). Consistent with this finding, 
we have previously shown that blocking apoptosis through the deletion of Bax in 
medulloblastoma-prone mice induced large accumulations of neurons after cytotoxic stimuli such 
as radiation (Garcia et al., 2013). However, we did not observe accumulation of neurons in M-Smo 
tumors after 2 weeks of vismodegib treatment (Fig. A.8B). While we did not observe significant 
increases in cC3-mediated cell death after vismodegib treatment (Fig. A.8C), the lack of 
accumulated neurons supports the proposal that vismodegib-induced differentiation is followed by 
latent cell death. 
Depletion of proliferating cells by vismodegib was not uniform. Vismodegib treatment 
produced a statistically significant 2-fold decrease in Node BT (p<0.001), while Node AT showed 
a 30% decrease that was not statistically significant (Fig. 3.6I). Vismodegib also significantly 
depleted Yfp+ cells in Node BT, significantly enriched Yfp+ cells in Node DT, and produced no 
statistically significant changes in Yfp+ fractions of Node AT or the astrocytic or oligodendrocytic 
clusters (Fig. 3.6I). The different effects of vismodegib on the node populations identify the 
proliferating cells of Node BT as vismodegib-sensitive, and the proliferating cells of Node AT, 
along with the Yfp+ glial cells, as relatively vismodegib-resistant. 
SHH pathway activation persists in vismodegib-resistant medulloblastoma cells 
We found that SHH activation persisted in cells that remained proliferative in Node AT in 
vismodegib-treated tumors, marked by continued expression of SHH pathway markers Gli1, 
Ptch1, Hhip, and Sfrp1 (Fig. 3.7A, G, top graph; Fig. A.9). These results are consistent with the 
continued expression of Gli-luc signal after 3 days of vismodegib treatment, indicating that in a 
subset of cells, vismodegib failed to suppress SHH-driven transcription (Fig. 3.1E, E’). We 
hypothesized that this failure could potentially arise from a pharmacodynamic mechanism in 
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which the drug is present but unable to block the pathway, or from a pharmacokinetic mechanism, 
in which the unaffected cells are not exposed to the drug, due to local variation in drug penetration. 
To test the distribution of vismodegib within the brain, we visualized drug distribution by 
mass spectrometry imaging (MSI) accomplished by infrared matrix-assisted laser desorption 
electrospray ionization (IR-MALDESI) (Robichaud et al., 2014; Bokhart et al., 2015). Brains were 
harvest from vehicle- and vismodegib-treated mice, rapidly frozen, and sectioned in the sagittal 
plane. We then scanned across the frozen sections progressively with the IR-infrared laser and the 
ionized species arising from each successively scanned region were detected by mass spectrometry 
to generate concentration maps for each ion across the entire section. We were able to map 
vismodegib and compare vismodegib concentrations to endogenous metabolites. We found 
relatively high concentrations of cholesterol throughout the brain and low concentrations in all 
regions of the tumor (Fig. 3.7B). In contrast, vismodegib was evenly distributed across the brain 
and tumor, without local variation (Fig. 3.7B). The even distribution of vismodegib argues against 
a pharmacokinetic variation in drug penetration that could account for differential cell responses 
to vismodegib. 
HES1 and MYOD1 mark subsets of tumor cells with differential responses to vismodegib 
To determine the mechanism underlying diverse pharmacodynamic responses to 
vismodegib within different cell types, we compared gene expression profiles of untreated cells in 
the vismodegib-sensitive and vismodegib-resistant clusters. The cluster most strongly affected by 
vismodegib treatment appeared to be cluster 0 in Node BT, so we performed differential gene 
analysis comparing cluster 0 in vehicle-treated tumors to all other cells in vehicle-treated tumors 
(Table 3.7). We focused on identifying transcription factors that were differentially expressed, and 
noted specific expression of the Notch pathway transcription factor Hes1. Hes1 was predominantly 
expressed in cluster 0 in Node BT in control tumors, but was also dispersed in clusters within Node 
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AT and in the astrocytic and oligodendrocytic clusters (Fig. 3.7C). Hes1+ cells predominantly 
expressed Gli1 in vehicle-treated tumors, indicating SHH pathway activation. Vismodegib 
decreased Hes1 expression in Nodes AT and BT, while glial clusters remained Hes1+ (Fig. 3.7C). 
We confirmed HES1 protein expression in tumor sections by immunohistochemistry. 
HES1+ cells were distributed throughout the vehicle-treated tumors and frequently co-localized 
with phosphorylated RB (pRB), indicating the proliferative potential of these cells (Fig. 3.7D). 
Vismodegib reduced pRB expression and HES1 expression in tumors, and markedly reduced pRB 
in the HES1 population (Fig. 3.7G, middle graph). Long term treatment with vismodegib continued 
to ablate HES1+ and pRB+/HES1+ cells in tumors (Fig. A.10A, A’). These data show that 
proliferative HES1+ tumor cells were widely distributed and disproportionately inhibited by 
vismodegib. 
To define the mechanisms underlying vismodegib-resistance, we compared the set of genes 
up-regulated in the proliferative vismodegib-treated cells of Node AT to the vehicle-treated cells 
of Node BT (Table 3.8). We identified the transcription factor MyoD1, which localized primarily 
to Node AT in control tumors, with some cells dispersed throughout Node BT (Fig. 3.7E). Like 
Hes1+ cells, MyoD1+ cells were predominantly expressed in Gli1+ Nodes AT and BT in control 
tumors (Fig. 3.7E). Unlike Hes1+ cells, MyoD1+ cells were still present in Nodes AT and BT after 
vismodegib treatment and these cells continued to express Gli1 (Fig. 3.7A, E). 
Immunohistochemical analysis of MYOD1 protein expression demonstrated MYOD1+ cells 
throughout the tumors (Fig. 3.7F, G). MYOD1 expression frequently co-localized with pRB, 
confirming the proliferative state predicted by transcriptomic data (Fig. 3.7F, G, bottom graph). 
Flow cytometric analysis showed MYOD1+ cells in each phase of the cell cycle, with a 
preponderance of cells in S phase, while MYOD1- cells largely accumulated in G1 (Fig 7H). 
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Vismodegib minimally reduced the fraction of MYOD1+ cells, and did not reduce pRB expression 
in the MYOD1 population or alter cell cycle phase distribution (Fig. 3.7E-H). Long term 
vismodegib treatment did not further reduce MYOD1 expression nor p-RB+ expression in the 
MYOD1 population (Fig. A.10C, C’). These data show that HES1 and MYOD1 mark subsets of 
proliferating tumor cells with markedly different sensitivities to vismodegib. 
We next analyzed bulk transcriptomic data from human medulloblastomas to determine if 
HES1 and MYOD1 are frequently expressed. We found heterogeneous expression of both genes in 
published data from patient-derived tumor samples (Fig. 3.7I, J; Fig. A.11). We noted variation in 
mean expression across medulloblastoma subtypes, and wide variability within each subtype. 
These data show that human tumors contain HES1+ and MYOD1+ cells, and that expression of 
these genes is heterogeneous in human tumors, as in mouse tumors.   
Potential factors regulating vismodegib resistant tumor cells 
The polycomb repressive complex 2 (PRC2) has previously been associated with tumor 
growth in many cancers (Chan and Morey, 2019; Harutyunyan et al., 2019; Singh et al., 2019). 
We noted that Ezh2, a component of the PRC2, was significantly up-regulated in the proliferative, 
vismodegib-treated cells of Node AT as compared to the vehicle-treated Node BT, suggesting a 
potential role for the PRC2 in vismodegib resistance, like MyoD1 (Fig. 3.8A). However, Ezh2 
expression was not specific to Node AT but was expressed throughout diverse cells at variable 
levels (Fig. 3.8A). Other components of the PRC2, Suz12 and Eed, were similarly broadly 
expressed throughout the tumor cells (Fig. 3.8A). In contrast, the set of cells expressing all 3 core 
PRC2 components, Ezh2, Suz12, and Eed, was more limited to the regions of Nodes AT and BT 
that persisted in vismodegib-treated tumors (Fig. 3.8A). This correspondence suggests that the 
PRC2 may play a role in maintaining proliferation in the vismodegib-resistant subset of CGNP-
like tumor cells. 
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Given the persistence of Gli1 expression in MyoD1-expressing cells, we considered 
whether differential expression of the intracellular SHH pathway regulator Sufu may mediate 
vismodegib resistance in M-Smo tumors. Prior studies have shown that vismodegib resistant SHH-
driven medulloblastomas can have SUFU mutations (Robinson et al., 2015). We plotted Gli1 
expression as a function of Sufu expression, and for comparison plotted the SHH target Ptch1 as a 
function of Gli1 expression. To prevent biasing the data from cells with stochastic drop out of 
Gli1, Ptch1, or Sufu, we used the Markov affinity-based graph imputation of cells (MAGIC) 
algorithm to impute expression values in cells with 0 detected transcripts of each gene (van Dijk 
et al., 2018). 
Ptch1 expression positively correlated with Gli1 in both vehicle-treated and vismodegib-
treated tumors (r= 0.971, p<1x10-15 and r= 0.925, p<1x10-15, respectively; Fig. 3.8B). In contrast, 
Sufu showed a statistically significant positive correlation with Gli1 in vehicle-treated tumors (r= 
0.406, p<1x10-15), but a statistically significant negative correlation in vismodegib-treated tumors 
(r= -0.566, p<1x10-15; Fig. 3.8C). Moreover, we stratified the vehicle-treated and vismodegib-
treated cells by node denotation, and excluded Node DT since this node comprised mostly of highly 
differentiated cells and was heavily skewed toward vismodegib-treated cells. While Ptch1 and 
Gli1 expression positively correlated across nodes, nodes showed differential responses to Sufu 
expression (Fig. A.12A). Although Node BT and CT demonstrated a negative correlation between 
Gli1 and Sufu expression, Node AT appeared to positively correlate Gli1 and Sufu expression (Fig. 
A.12B), suggesting a potential mechanism of resistance within these cells. Our findings suggest 
that vismodegib sensitizes medulloblastoma cells to SUFU-mediated SHH pathway inhibition, 
causing cells with higher SUFU to differentiate while cells with lower SUFU remain proliferative. 
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Sox2+ cells respond heterogeneously to vismodegib 
We detected Sox2+ cells within our single-cell transcriptomic data with variable sensitivity 
to vismodegib. We divided the Sox2+ population into an Fabp7+ glial population and an Fabp7- 
CGNP-like population to analyze the heterogeneity of responses to vismodegib. We performed 
ICA on the Sox2+ populations of vehicle- and vismodegib-treated tumors and found that a 
significant population of the CGNP-like, Sox2+ cells in vehicle-treated tumors were Hes1+ and 
Fabp7- (41.1 ± 2.5%). Vismodegib significantly depleted this population (5.1 ± 2.9%; FC=0.1245; 
p=1.5x10-5; Fig. 3.8D). In contrast, the oligodendrocytic, OPC-like, astrocytic, and AP-like glial 
subsets of Sox2+ cells were relatively unaffected by vismodegib treatment (Fig. 3.8E). We 
identified subsets of cells that were relatively depleted or enriched by vismodegib treatment by 
stratifying Sox2+ cells by Yfp expression and by previously published markers identified by Vanner 
et al. Thus, within the Sox2+ population, as the broader tumor population, specific subsets of cells 
were relatively sensitive or resistant to vismodegib and tumor-derived cells with stem cell-like 
transcriptomes persisted after vismodegib treatment. 
 
Discussion 
We found that SHH-driven medulloblastomas harbored heterogeneous cell populations, 
including CGNP-like cells with varying differentiation states, and tumor-derived cells with glial-
like gene expression patterns outside of the expected Math1 neural lineage. The heterogeneity we 
observed in M-Smo tumors resembled the diversity identified by single-cell transcriptomic analysis 
in other malignant brain tumors (Tirosh et al., 2016; Filbin et al., 2018). Tumor-derived 
medulloblastoma cells gave rise to both CGNP-like cells and oligodendrocytic-like and astrocytic-
like cells, with variations in differentiation states. We found that CGNP-like tumor-derived cells 
showed heterogeneous responses to vismodegib, with proliferating HES1+ cells marking the 
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vismodegib-sensitive population, and proliferating MYOD1+ and EZH2+/SUZ12+/EED+ cells 
marking the vismodegib-resistant population. Vismodegib sensitized cells to the inhibitory 
regulation of SUFU, but SHH pathway activation was still present in MYOD1+ cells, indicating 
resistance to pathway inhibition. Similarly, Sox2+ cells showed a heterogeneous response to SHH 
inhibition, with Fabp7-/Hes1+/Sox2+ cells depleted by vismodegib and OPC-like, AP-like, and 
Fabp7-/MyoD1+/Sox2+ populations persisting after treatment. The diversity of vismodegib-
resistant cell types identifies several populations of cells that may drive recurrence and treatment 
failure. 
Our findings of distinct populations within the Sox2+ cells, including vismodegib-resistant 
Sox2+ stem-like cells, mirrors previously published studies demonstrating that Sox2+ cells can 
recapitulate tumors after vismodegib treatment (Vanner et al., 2014). Additionally, we identified 
populations of cells expressing MYOD1, which expressed pRB after vismodegib treatment, 
indicating continued proliferative potential after treatment. Thus, cellular diversity in untreated 
tumors indicates inherent cellular populations that no longer depend on the initiating oncogenic 
mutation and may repopulate tumors after a long period of selective pressure. 
Hes1 expression in CGNP-like tumor cells in Nodes AT and BT may indicate active 
NOTCH signaling or alternate induction of Hes1 through aberrant SHH signaling. Hes1 is a known 
transcription factor in the NOTCH signaling pathway and specific signaling through NOTCH2 has 
been shown in both CGNP development and in medulloblastoma (Solecki et al., 2001; Fan et al., 
2004). Prior studies have also shown direct activation of Hes1 through SHH signaling pathway 
components, SMO and GLI2, which can bind to the Hes1 promoter (Ingram et al., 2008; Wall et 
al., 2009). Our studies suggest Hes1 expression may be directly mediated through SHH 
hyperactivation, since Hes1+ cells were markedly enriched with SmoM2 activation in tumors as 
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compared to P7 WT cerebella. The depletion of Hes1+ cells in response to SHH pathway inhibition 
through vismodegib also support a direct mechanism of SmoM2-mediated SHH hyperactivation 
and Hes1 expression in tumor cells. Inhibition of the NOTCH pathway would thus be predicted to 
have limited potential to block growth in SHH-driven tumors. 
Consistent with prior reports of MyoD1 expression in rare cells within the CGNP 
population and in proliferative tumor cells in SHH-driven medulloblastomas, we found MYOD1 
expression in all four human medulloblastoma subtypes and in our SmoM2-driven tumors (Dey et 
al., 2013). Interestingly, MyoD1 haploinsufficiency increased SHH-driven tumorigenesis in 
SmoA1 and SmoA2 mouse models, suggesting a tumor suppressive role (Dey et al., 2013). 
However, MYOD1-expressing cells in M-Smo tumors are proliferative, and may have mechanisms 
that overcome a putative tumor-suppressive effect to drive recurrence. The potential relationship 
between MyoD1+ CGNP-like cells and Sox2+ stem-like cells requires further study. The potential 
for Sox2+ cells to give rise to MyoD1+ cells could indicate a hierarchical relationship, while the 
potential for MyoD1+ cells to give rise to Sox2+ cells could indicate that pluripotency is not limited 
to hierarchy. Additionally, the finding of Yfp+ cells in glial populations indicated that SmoM2-
mediated oncogenesis could transform Math1+ progenitors into pluripotent neural stem cells. 
Whether this induced pluripotency could regenerate tumor cells, remains unanswered. Lineage 
studies would inform which subsets of cells should be targeted to block recurrence. 
Our finding of persistent SHH pathway activation in MyoD1+ cells after vismodegib 
treatment demonstrates SMO-independent SHH activation. Vismodegib-mediated inhibition of 
Gli1 in Hes1+ cells indicates that SmoM2 is vismodegib-sensitive. We found MyoD1-expressing 
cells and vismodegib distributed throughout the tumor, supporting a pharmacodynamic variation 
in responses in diverse cell types throughout the tumor that leads to vismodegib resistance. We 
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propose that the observed variation may be mediated by endogenous SUFU, which has been 
correlated with vismodegib resistance in patients with medulloblastoma and basal cell carcinoma 
(Robinson et al., 2015; Sharpe et al., 2015). Vismodegib may sensitize tumor cells to SUFU-
mediated inhibition by reducing stimulation through SMO and SmoM2, based on the inverse 
correlation between Sufu and Gli1 expression. Inhibition of SMO and SmoM2 through vismodegib 
promoted cells with more SUFU to reduce Gli1 expression and differentiation, while cells with 
less SUFU continue SHH-driven proliferation. We speculate that PRC2-mediated inhibition may 
reduce Sufu expression or otherwise prevent differentiation in the Myod1+ population. Targeted 
inhibition or deletion of PRC2 components may clarify this mechanism, and if confirmatory, may 
provide a mechanism for blocking vismodegib resistance. Together, our studies identify diverse 
cell populations within SHH-driven medulloblastomas that are sensitive or resistant to SHH 
inhibition through vismodegib and may inform new targets to prevent recurrent tumors. 
 
Methods 
A detailed list of reagents and materials used can be found in Table 3.10. 
Mouse models 
C57BL/6 mice, SmoM2-eYFPloxP/loxP mice and PhamloxP/loxP mice were purchased from the 
Jackson Laboratory (Mao et al., 2006; Pham et al., 2012). Math1-Cre mice, which express Cre 
recombinase under control of a cloned Math1 promoter sequence (Machold and Fishell, 2005), 
were generously shared by Dr. Robert Wechsler-Reya. Gli-luc mice, which express luciferase 
under the GLI promoter, were generously shared by Dr. Oren Becher and Dr. Eric Holland. Mouse 
genotyping was performed using the primers indicated in Table 3.10. All mice were of the species 





M-Smo littermates were injected intraperitoneally (I.P.) with 50 μl of 75 mg/kg vismodegib 
dissolved in one part of N-Methyl-2-Pyrrolidone (NMP) and 9 parts of polyethylene glycol (PEG) 
or a vehicle control of 1:10 NMP:PEG. Equal numbers of female and male mice were randomly 
assigned to vehicle or vismodegib treated groups as we did not detect sex differences. Mice were 
injected once daily for 3 days from P12 to P14 and collected at P15 for Drop-Seq, IHC, and/or 
FACS. For survival studies, mice were administered 50 μl of vehicle or 100 mg/kg vismodegib in 
NMP:PEG (1:10) once daily from P12 to P14 and then every other day. For long-term vismodegib 
studies, M-Smo mice underwent a similar protocol and were administered 50 µl of vehicle or 75 
mg/kg vismodegib in NMP:PEG (1:10) once daily from P12 to P14 and then every other day and 
collected at P25. Mice were monitored daily for changes in body weight and symptoms such as 
ataxia, tremor, and seizures. Animals were euthanized and brains collected if body weight dropped 
more than 20% over 24 hours and/or they developed severe neurological symptoms according to 
approved protocols. 
Whole cerebellum and tumor dissociation for Drop-Seq and flow cytometry 
Mice were anesthetized with isoflurane and euthanized by decapitation. Brains were cut in 
half sagittally and drop-fixed in 4% paraformaldehyde (PFA) for IHC, and half cerebellum or 
tumor collected for Drop-Seq. Alternatively, half of the tumor was collected for flow cytometry. 
Cells were dissociated using the Papain Dissociation System (Worthington Biochemical) as 
previously described (Lang et al., 2016). Briefly, tumors or cerebella were dissected from 
isoflurane-anesthetized C57BL/6 or M-Smo mice and incubated in papain at 37oC for15 min. The 
tissue was then triturated, and the cells were spun down, resuspended, and a density gradient was 
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formed with ovomucoid inhibitor. Lastly, cells were resuspended in Hank’s Balanced Salt Solution 
(HBSS) with 6g/L glucose and diluted to approximately 100 cells/ul for Drop-seq. 
Alternatively, cells were resuspended in HBSS with 6g/L glucose, fixed and permeabilized 
for FACS using the Fix & Perm Cell Fixation & Cell Permeabilization Kit (ThermoFisher 
Scientific). Cells were stained for FxCycle Violet, phospho-RB, and MyoD1. Samples were run 
on the Becton Dickinson LSR Fortressa and data was analyzed with FlowJo V10. 
Immunofluorescence imaging 
Brains were fixed in 4% PFA for at least 48 hours. Tissue was processed and embedded in 
paraffin at the UNC Center for Gastrointestinal Biology and Disease Histology core. Sections were 
deparaffinized and antigen retrieval was performed using a low pH citric acid-based buffer. 
Staining was performed with assistance from the Translational Pathology Laboratories. Slides 
were scanned using the Leica Biosystems Aperio ImageScope software (12.3.3). 
IR-MALDESI 
Spatial distribution of vismodegib drug levels was studied by IR-MALDESI (Robichaud 
et al., 2014; Bokhart et al., 2015). Sagittal sections (10μm) of mouse brain samples were prepared 
in a cryotome, thaw-mounted on glass microscope slides, and maintained at -10°C on the sample 
stage of the IR-MALDESI source chamber prior to analysis. The stage translated the sample step-
wise across the focused beam of an IR laser (l=2.94μm, IR-Opolette 2371; Opotek, Carlsbad, CA, 
USA), which desorbed sample material from adjacent 100μm diameter sampling locations. An 
electrospray (50/50 mixture of methanol/water (v/v) with 0.2% formic acid) ionized the desorbed 
neutral molecules, and resulting ions were sampled into a high resolving power Thermo Fisher 
Scientific Q Exactive Plus (Bremen, Germany) mass spectrometer for synchronized analysis. The 
mass spectrometer was operated in positive ion mode from m/z 200 to 800, with resolving power 
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of 140,000FWHM at m/z 200. With high mass measurement accuracy (MMA) within 5 ppm 
maintained using protonated and sodiated adducts of diisooctyl phthalate as two internal lock 
masses at m/z 391.28428 and 413.26623, vismodegib was identified by its protonated molecular 
ion [M+H+]+ at m/z 421.01695. To generate images from mass spectrometry data, raw data from 
each voxel was converted to the mzXML format using MSConvert software (Kessner et al., 2008). 
These mzXML files were interrogated using MSiReader, a free software developed for processing 
MSI data (Robichaud et al., 2013). 
Single Cell Encapsulated with Barcoded Microparticle Droplet-Sequencing (Drop-Seq) 
library preparation and sequencing 
Drop-Seq libraries were prepared as previously described (Drop-seq protocol V3.1) 
(Macosko et al., 2015), with full details available online (http://mccarrolllab.com/dropseq/). Cell 
and bead concentrations were both set to between 95 and 110/uL. WT cerebellum cells were co-
encapsulated with barcoded beads using FlowJEM brand PDMS devices. Flow rates on the PDMS 
device for cells and beads were set to 3800 µL/hr, flow rate for oil was maintained at 15,000 µL/hr, 
resulting in a 4.5% bead occupancy rate in a 0.7 nL droplet. Medulloblastoma cells were co-
encapsulated using a Dolomite brand glass device. All cells were processed within one hour of 
tissue dissociation. Flow rates on the glass device were set to 2,400 and 12,000 µL/hr for 
cells/beads and oil, respectively, with a 1-2.5% bead occupancy rate. Droplet breakage and library 
preparation steps followed those of Macosko et al. (Macosko et al., 2015), with specific 
modifications: 
• Following each PCR, an additional Ampure XP cleanup was performed at a 1x ratio, for a 
total of one 0.3x purification followed by a 1x purification to reduce residual PCR primer 
in the bioanalyzer electropherogram. 
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• Beads were stored at 4°C after exonuclease step for up to two months prior to generating 
cDNA. 
Following the completion of each set of experiments, a library pool consisting of the 
tagmented cDNA from 2,000 beads/run was prepared and sequenced to low depth (~2.5M 
reads/2K beads). This data was used to assess library efficiency, including total read losses to 
PolyA regions, nonsense barcodes and adapter sequences as well as the quality and number of the 
transcriptomes captured. Passable runs contained 40-60% of reads associated with the top 80-100 
barcodes found in 2,000 beads. For those runs that passed our quality assessment we re-sequenced 
newly prepared libraries from the stored beads. The bulk cDNA libraries were prepared using the 
same ratio of 2,000 beads/PCR. 
Drop-Seq data processing and analysis 
Raw sequence data was processed in a Linux environment using Drop-seq Tools V1.13. 
(https://github.com/broadinstitute/Drop-seq/releases) to generate a digital expression (DGE) 
matrix. Step-by-step protocols may be found in the original documentation. DGE matrices were 
used to generate Seurat objects in R (https://satijalab.org/seurat/). We followed a default Seurat 
workflow with the following modifications: 
• Determining the appropriate number of Principal Components (PCs) to use was done by a 
z-scoring method, in which we first calculated the contribution of each PC to the total 
variance (percent of total variance). We selected PCs with percent of total variance greater 
than 2 SDs away from the mean. 
• To compare between different datasets we employed a k-Nearest Neighbors (KNN) 




Drop-Seq data processing 
Input data 
Input data is raw sequence in Fastq format, demultiplexed by sample identity. We convert 
Fastq to BAM/SAM format and merge samples that were sequenced across multiple lanes. 
Alignment 
The Drop-Seq Alignment pipeline (Macosko et al., 2015) is run following default settings, 
with the STAR aligner (Dobin et al., 2013). STAR version 2.5.4a was used to align against either 
an mm10, or an mm10 & hg19 mixed reference. For medulloblastoma Drop-Seq runs, cells were 
multiplexed with a spike-in of cultured HEK 293 cells to serve as an internal control. First, data 
was aligned against a mixed-species reference consisting of both hg19 and mm10 reference 
genomes, with chromosome and gene IDs annotated to contain a species-specific string. Cell 
barcodes were selected based on their human/mouse transcriptomic content, and only barcodes 
with 90%+ mouse transcript were chosen for further analysis. 
Cells identified as mouse in origin were then aligned a second time, using a reference 
genome consisting of mm10, plus two synthetic chromosomes consisting of the Cre recombinase 
and SmoM2/EYFP fusion transcript transgenes. Detail on the transgenes can be found above under 
the “Mouse models” section. Wild-type cerebella were processed with no species-mixed spike-in 
and were only aligned once against the mm10 transgenic reference. 
Drop-Seq data analysis 
Data analysis overview 






Data analysis was performed in an R environment using the Seurat toolkit (Butler et al., 
2018). Following Seurat standard recommendations, data was first filtered for quality. Genes were 
required to be detected in as many as 30 cells to qualify as a “true” transcript to prevent misaligned 
reads appearing as rare transcripts in the data and was adjusted according to the depth of sequence 
of each sample. 
Low quality cells were defined as genes with below 500 genes. Cells with high 
mitochondrial transcript levels were suspected to be undergoing apoptotic stress and so barcodes 
containing >4-5 standard deviations above the median level of mitochondrial transcript were 
likewise rejected. Finally, cells with greater than average levels of UMIs or genes were considered 
to be potential doublets, and > 4-5 standard deviations above the median nUMI or nGene was used 
to exclude these from further analysis. 
Clustering and t-SNE visualization 
Highly variable gene selection 
Genes were selected for differential expression across the sample using Seurat’s highly 
variable gene selection tool, “FindVariableGenes”. Mean expression and variance was calculated 
across the sample, and mean expression plotted against dispersion (variance/mean). Genes were 
sorted into equal-width bins and z-scored. We applied low and high mean expression cutoffs of 
0.125 and 3 (x-cutoff) and minimum z-score of 0.5. 
Principal Components Analysis 
Principal Components Analysis (PCA) was used to reduce the dimensionality of the gene 
expression matrix. A Singular Value Decomposition (SVD) PCA was performed on the subset of 
highly variable genes. To identify an appropriate number of Principal Components (PCs), we 
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employed a z-scoring method. We run a complete PCA reduction, and z-score the contribution of 
each PC to the total variance. PCs with z > 2 were considered significant and used further in 
analysis. The SVD PCA returns right singular values, representing the embeddings of each cell in 
PC space, and left singular values, representing the loadings (weights) of each gene in the PC 
space. Cell embeddings (right singular values) were weighted by the variance of each PC. 
Clustering and t-SNE 
A reduction to two dimensions was applied to the PCA matrix (a matrix of cells by their 
PC embeddings, hereafter referred to as PC-space) in order to place cells in a 2d plot for easy 
visualization (https://github.com/jkrijthe/Rtsne) (Laurens van der Maaten and Geoffrey E., 2008). 
In parallel, but independent to the t-SNE, Louvain-Jaccard clustering was performed on the PC-
space. This “bottom-up” clustering method employs a stochastic Shared-Nearest-Neighbor (SNN) 
approach, in which cells are grouped according to their neighbors in PC space. The nearness of 
two cells is weighted by the Jaccard index, or the degree of sharing between the lists of each cell’s 
nearest neighbors. The algorithm builds small groups of cells and attempts to iteratively merge 
them into clusters, until the modularity is maximized. We found that a resolution of 0.8 was most 
appropriate for building biologically meaningful clusters. 
Cell type identification 
Following PCA and t-SNE we visually inspect clusters for expression of indicated markers. 
We determined differentially expressed genes using the Seurat implementation of the likelihood-
ratio test for single cell gene expression (McDavid et al., 2013). Marker genes were plotted using 
an expression cutoff to facilitate the visualization of both high- and low-expression genes on a 
single plot. Cutoffs are applied so that only cells with expression > cutoff received the color 
corresponding to that gene. These cutoffs (gene expression thresholds) are found in Table 3.9. In 
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feature plots of multiple genes, for individual cells expressing multiple markers, each gene was 
over-plotted in the order presented in figure legends. To provide open access to our data through 
a convenient graphical user interface, we have set up an interactive data viewer accessible through 
the Gershon Lab web site (gershon-lab.med.unc.edu/single-cell).  
Doublet removal 
Doublets consist of transcriptomes from 2 distinct cells co-captured on the same barcoded 
bead. Many doublets are removed during the initial filtering steps. However, we found clusters (or 
parts of clusters) that were identified by differential gene expression to be doublets. The 
characteristic signature of these groups in our data is the significant differential expression of many 
genes with a low fold-change and high percent of cells expressing the gene in each group. These 
doublets are considered a technical effect and removed from further analysis of the sample. 
Hierarchical clustering analysis 
To classify clusters according to their similarities, we applied Seurat’s “BuildClusterTree” 
function running on default parameters. This applies a hierarchical clustering algorithm to the 
cluster centroids in PC-space. Clusters closely apposed in the resulting dendrogram are referred to 
in the text as Nodes, owing to the fact that they are composed of clusters co-localized below a 
branch point, or node. 
Placement into WT PC-space 
To place medulloblastoma cell types in the context of developmental biology, we 
performed PCA and cluster analysis on single-cell gene expression data from wild type (WT) 
cerebella harvested at P7, at the peak of postnatal cerebellar neurogenesis (Carletti and Rossi, 
2007). The PCA matrices for cells and genes were both extracted from the WT data. Here the right 
singular values of the PCA represent a weighting (called Gene Loading) of each gene in WT PC-
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space. The left singular values (called Cell Embeddings) can be approximated for a given cell by 
multiplying the right singular values (gene weights) by a vector of the cells’ gene expression. The 
sum of this product returns the left singular value. We apply this method to approximate the PC-
space embeddings for a cell from outside of the original PCA, here a medulloblastoma cell into 
WT PC-space. 
Approximation of t-SNE coordinates 
For visualization purposes we place each medulloblastoma (MB) cell into the WT t-SNE 
coordinate system using k-Nearest Neighbors (kNN). For each medulloblastoma cell, we identify 
the five most similar WT cells (K=5). Considering these WT cells to be the 5 nearest neighbors, 
we average the t-SNE coordinates of these 5 WT cells to generate a t-SNE position for the 
projected MB cell. Plotting the projected cells overlaid on the WT cells demonstrates visually 
which WT and tumors cells were most similar and places the medulloblastoma cells in the 
biological context of a P7 cerebellum. 
Independent Components Analysis: 
To further understand the underlying biology of the medulloblastomas, we removed the 
stromal cells and performed an Independent Components Analysis (ICA). ICA was run on an input 
matrix of variable genes x cells expression data. To predict the number of significant IC 
dimensions we perform a PCA on the same data, predict the number of significant PC dimensions 
as previously described, and proceed with an equivalent number of ICs. A t-SNE reduction of the 
ICs places cells into a 2-dimensional space for visualization. 
Gene-Gene Correlation 
In Drop-Seq, as well as other single-cell transcriptomic methods, much of the expression 
data suffers from under sampling, a phenomenon often referred to as gene drop-out. To recover 
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gene correlations we employed the MAGIC denoising method (van Dijk et al., 2018). MAGIC 
shares information across similar cells to impute missing values by diffusing gene expression 
across the neighbors. We found 12 neighbors to be the appropriate number which recovered 






Figure 3.1. Vismodegib treatment induces initial tumor response in M-Smo mice followed by rapid 
recurrence. (A) Medulloblastoma in sagittal hindbrain sections stained for pRB, from representative P15 
M-Smo mice, treated with 3 daily doses of vehicle or vismodegib. (B) Medulloblastoma after 2 weeks of 
vismodegib treatment, prepared as in (A) with quantification of %pRB+ cells from vehicle-treated, 
vismodegib-treated after 3 days, and vismodegib-treated after 2 weeks in (B’). (C) Kaplan Meier curve 
comparing survival of M-Smo mice treated with vismodegib or vehicle. (D) Schematic showing the timing 
of luciferase imaging of vismodegib administration. (E) Luciferase signal driven by Gli-luc at indicated 
times, with luminescence fold change graphed in (E’). Horizontal bars represent the mean and error bars 
represent SEM. Each dot represents an individual animal. p values determined by 2-sided student’s t-test. 




Figure 3.2. Single cell transcriptomic identifies discrete types of cells in M-Smo tumors. (A) t-SNE 
projection of cells from 5 vehicle-treated tumors, with cells placed according to Euclidean distance from 
each other in 11-dimensional PCA. The color code indicates clusters. (B) Feature plot of indicated markers 
on the t-SNE projection in (A). (C) Nodes AV-CV, plotted on the t-SNE projection in (A). Dendrogram 




Figure 3.3. The tumor cells predominantly map to CGNPs when projected on the WT P7 cerebellum. 
(A) t-SNE projection of cells from 5 P7 WT cerebella, based on PCA as in (Fig. 3.2A), color-coded for the 
expression of indicated markers. (B) Feature plot of indicated markers on the t-SNE projection in (A). (C) 
Feature plot of indicated CGNP markers on the t-SNE projection in (A). (D) Cells from the 5 vehicle-treated 
tumors, mapped using the k-NN algorithm onto the WT P7 cerebella t-SNE projection in (A), with Nodes 




Figure 3.4. ICA on CGNP-like tumor cells demonstrates the latent factors of self-renewal and 
differentiation. (A) t-SNE projection of CGNP-like cells from vehicle treated tumors directed by ICA, 
with Nodes AV-CV color-coded. (B) t-SNE projection of ICA with differentiation IC2V plotted, color-coded 
from high (yellow) to low (dark blue). (C) Feature plot of indicated Cyclins on ICA t-SNE in (A). Arrows 
indicate progression along Cyclin expression patterns, which correspond with the cell cycle. (D) 
Pseudotime trajectories inferred by the IC gradients and Cyclin expression, plotted on ICA t-SNE in (A). 
(E) Dot Plot showing expression of developmental markers across Nodes AV-CV. Average expression 




Figure 3.5. Tumors show lineage expansion and stem cell marker expression. (A) Feature plot of Sox2 
and Yfp on the t-SNE projection of Fig. 3.2A. (B) Flow cytometry data of M-Cre/Pham cerebella and M-
Cre/SmoM2/Pham (M-Smo/Pham) tumors showing GFAP and DENDRA2 fluorescence intensity with (B’) 
quantification of %GFAP+ cells in the DENDRA2+ lineage. (C) Bar plot showing the proportions of Sox2+ 
cells expressing indicated markers in each of the 5 vehicle-treated tumors. Error bars are SEM. (D) t-SNE 
projection of Sox2+ cells from the 5 vehicle-treated tumors, directed by ICA, with feature plots of Sox10, 
Aqp4 and Nodes AV-CV. (E) Oligodendrocytic clusters of the t-SNE projection in (D), with feature plots of 
Pdgfra, Mbp1, Plp1, Mog, and Yfp. (F) Astrocytic clusters of the t-SNE projection in (D), with feature plots 
of Olig1 and Yfp. Statistical significance of genes indicated in (B’) were determined by 2-tailed student’s 




Figure 3.6. Vismodegib advances differentiation while depleting specific subsets of proliferative 
tumor cells. (A) t-SNE projection of cells from 5 vehicle-treated and 5 vismodegib-treated tumors, directed 
by PCA as in Fig. 3.2A, plotted either with cells from both conditions shown together or in separate images, 
color-coded for the expression of indicated markers. (B) Dendrogram depicts the HCA. (C) Dot Plot 
showing expression of developmental markers across Nodes AV-CV. (D) Nodes AT-DT, plotted on the t-
SNE projections in (A). (E) Feature plot of Yfp on the t-SNE projections of (A). (F) Cells from the 5 vehicle-
treated or 5 vismodegib-treated tumors, mapped using the k-NN algorithm onto the WT P7 cerebella t-SNE 
projection in Fig. 3.3A, with Nodes AT-DT and identified cell types color-coded. (G) ICA-directed t-SNE 
projection of CGNP-like cells from vehicle-treated and or vismodegib-treated tumors, with the 
differentiation IC color-coded. (H)  Fractional population of indicated groups from vehicle-treated and 
vismodegib-treated mice, normalized to the total number of cells per mouse. Each dot represents the fraction 
of cells from a specific replicate in each Node. Horizontal lines indicate the means, and error bars indicate 
SEM. (I) Fractional population changes in Yfp+ cells induced by vismodegib, formatted as in (H). p values 




Figure 3.7. HES1 and MYOD1 mark vismodegib-responsive and vismodegib-resistant subsets of 
medulloblastoma cells. (A) t-SNE projections as in Fig. 3.6A, with Gli1+ cells indicated. (B) MALDESI 
images of cholesterol and vismodegib distribution in sagittal brain sections including both tumor and 
normal brain. (C) t-SNE projections as in (A), with Hes1+ cells indicated. (D) Sagittal brain sections treated 
as indicated as in Fig. 3.1A, stained for HES1 and pRB by IHC and then quantified. (E) t-SNE projections 
as in (A), with Myod1+ cells indicated. (F) Sagittal brain sections treated as indicated, stained for MYOD1 
and pRB by IHC and then quantified, formatted as in (D). Scale bars = 2 mm, except in insets where scale 
bars = 100 µm. (G) Quantification of data from (C-F). (H) Analysis of MYOD1, pRB and cell cycle phase 
by flow cytometry. Graphs formatted as in (G). (I,J) Expression microarray data on HES1 and MYOD1 
expression in human medulloblastoma samples, as presented in Northcott et al. (Northcott et al., 2011). 
Horizontal bars represent the mean and error bars indicate SEM. Each dot represents an individual mouse. 




Figure 3.8. Factors that maintain proliferative and stem-like phenotypes after vismodegib. (A) 
Correlation plot after imputation of data, showing expression of Gli1 on the X-axis and Ptch1 on the Y-
axis, in vehicle- and vismodegib-treated tumors graphed separately. Each dot represents an individual cell. 
(B) Correlation plot after imputation of data, showing expression of Sufu on the X-axis and Gli1 on the Y-
axis, in vehicle and vismodegib-treated tumors graphed separately as in (A). (C) t-SNE projection of Sox2+ 
cells from vehicle-treated and vismodegib-treated tumors, directed by ICA with expression of Fabp7 and 
Hes1 color coded. (D) t-SNE projection of Sox2+ cells from the 5 vehicle-treated and 5 vismodegib-treated 
tumors, directed by ICA, with expression of Nes, Vim, and Yfp indicated. (E) Bar plots comparing the 
proportions of Sox2+ cells expressing indicated markers in each of the 5 vehicle-treated or vismodegib-




Cluster Gene FDR log2(FC) %Cluster %Others 
0 2810417H13Rik 0 1.316068 0.836 0.306 
0 Top2a 0 1.173177 0.881 0.341 
0 Esco2 0 1.088688 0.522 0.132 
0 Rrm2 0 0.985892 0.494 0.148 
0 Pbk 0 0.959796 0.538 0.162 
1 Ube2c 0 2.072918 0.908 0.176 
1 Cenpf 0 1.846262 0.936 0.278 
1 Cenpa 0 1.757118 0.88 0.16 
1 Cdc20 0 1.731163 0.795 0.109 
1 Prc1 0 1.634666 0.817 0.175 
2 Hes1 0 1.261043 0.432 0.107 
2 Tubb5 0 -0.73098 0.819 0.928 
2 Stmn2 0 -1.61873 0.208 0.602 
2 Neurod1 0 -1.86221 0.203 0.58 
2 Tuba1a 0 -0.77284 0.852 0.94 
3 Top2a 5.3E-184 -1.1085 0.255 0.452 
3 Mki67 5.7E-155 -1.02468 0.224 0.419 
3 Prc1 3.8E-143 -1.04044 0.078 0.282 
3 Smc4 1.9E-140 -0.68255 0.487 0.578 
3 Arl6ip1 8.1E-140 -0.77501 0.429 0.567 
4 Neurod1 1E-216 -1.5216 0.256 0.564 
4 Pcna 2.4E-182 0.751477 0.583 0.332 
4 Lig1 4.1E-177 0.798601 0.592 0.32 
4 Mcm6 2.6E-176 0.815715 0.504 0.249 
4 Tuba1a 1.5E-170 -0.62696 0.861 0.937 
5 Tubb3 0 1.22049 0.866 0.43 
5 Pde1c 0 1.112396 0.684 0.353 
5 Cntn2 0 1.082691 0.674 0.218 
5 Miat 0 1.021771 0.838 0.479 
5 Nnat 0 0.971628 0.84 0.695 
6 Celf4 0 1.681048 0.82 0.267 
6 Neurod1 0 1.600624 0.968 0.486 
6 Meg3 0 1.526734 0.406 0.062 
6 Mapt 0 1.506963 0.635 0.171 
6 Gpm6a 0 1.47765 0.834 0.364 
7 Cntn2 0 1.570952 0.891 0.22 
7 Neurod1 0 1.446811 0.987 0.501 
7 Tubb3 0 1.295784 0.941 0.442 
7 Gap43 0 1.170999 0.954 0.574 
7 Stmn2 0 1.049003 0.966 0.524 
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8 Cenpa 4.1E-210 1.116561 0.778 0.228 
8 Cenpe 1E-139 0.99569 0.718 0.266 
8 Ccnb2 1.1E-130 1.021999 0.574 0.169 
8 Hsp90b1 2.3E-114 0.709507 0.891 0.683 
8 Tpx2 2.6E-112 0.785592 0.682 0.263 
9 Olig1 0 2.902829 0.937 0.059 
9 Serpine2 0 2.715137 0.844 0.038 
9 Cspg5 0 2.683292 0.693 0.013 
9 3110035E14Rik 0 2.3893 0.713 0.007 
9 Cacng4 0 2.361371 0.808 0.085 
10 Apoe 0 4.814817 0.983 0.241 
10 Ctsd 0 4.346427 0.971 0.166 
10 C1qb 0 4.200489 0.977 0.009 
10 Lyz2 0 4.183327 0.943 0.009 
10 C1qc 0 3.891818 0.954 0.006 
11 Fabp7 0 4.487123 0.992 0.117 
11 Slc1a3 0 3.661779 0.992 0.147 
11 Dbi 0 2.747635 1 0.459 
11 Apoe 0 3.60396 1 0.243 
11 Aqp4 8.7E-305 3.971161 0.967 0.019 
12 Apod 0 5.195875 0.824 0.037 
12 Ptn 0 3.212768 0.983 0.438 
12 Col3a1 3.1E-286 4.141856 0.941 0.01 
12 Col4a1 1.2E-277 3.35861 0.966 0.066 
12 Igf2 7.5E-262 3.755193 0.815 0.03 
13 Meg3 1.2E-177 3.380973 0.961 0.09 
13 Snap25 4.9E-144 2.244034 0.864 0.278 
13 Syt4 1E-133 2.69085 0.699 0.016 
13 Chgb 1.1E-125 2.391751 0.845 0.237 
13 Gabra6 7.4E-120 2.243927 0.563 0.002 
14 Bsg 3.5E-160 2.728841 0.904 0.422 
14 Fth1 4.6E-147 2.505561 1 0.707 
14 Itm2a 1.4E-136 3.278525 0.942 0.043 
14 Ctla2a 7.2E-123 4.032005 0.904 0.004 
14 Igfbp7 1.1E-117 4.010019 1 0.016 
      
 
Table 3.1. Cluster-specific differential expression profiles from vehicle-treated tumors. A partial list 
of the top 5 differentially expressed genes from each cluster of the vehicle-treated tumors. Genes for each 
cluster are listed with FDR-adjusted p-value, log2(Fold Change), the percent of cells expressing the 





Cluster Gene FDR log2(FC) %Cluster %Others 
0 2810417H13Rik 0 1.30668484 0.838 0.308 
0 Top2a 0 1.179765802 0.886 0.342 
0 Esco2 0 1.087460776 0.525 0.133 
0 Rrm2 0 0.969782719 0.493 0.149 
0 Pbk 0 0.964207338 0.543 0.162 
1 Pcna 3.7476E-293 0.867280045 0.646 0.316 
1 Lig1 5.981E-270 0.868113677 0.649 0.304 
1 Mcm6 4E-268 0.886715542 0.564 0.234 
1 Hells 7.0199E-263 0.940881409 0.496 0.171 
1 Ung 2.7399E-251 0.848326835 0.321 0.059 
2 Ube2c 0 2.077394928 0.91 0.175 
2 Cenpf 0 1.845794758 0.937 0.278 
2 Cenpa 0 1.759793074 0.88 0.16 
2 Cdc20 0 1.735096474 0.796 0.109 
2 Prc1 0 1.631979143 0.815 0.175 
3 Hes1 0 1.26392952 0.433 0.107 
3 Tubb5 0 -0.737587596 0.818 0.928 
3 Stmn2 0 -1.616189432 0.207 0.603 
3 Neurod1 0 -1.857252384 0.203 0.58 
3 Tuba1a 0 -0.766515807 0.851 0.94 
4 Top2a 8.5605E-194 -1.320278839 0.194 0.455 
4 CRE_RECOMBINASE 9.4224E-175 0.668830695 0.906 0.751 
4 Mki67 2.6731E-133 -1.065347818 0.192 0.418 
4 Smc4 3.1844E-127 -0.786387506 0.428 0.583 
4 Prc1 7.3663E-123 -1.032445324 0.061 0.28 
5 Tubb3 0 1.161993281 0.853 0.433 
5 Igfbpl1 0 0.882645815 0.889 0.621 
5 Stmn2 0 0.764137199 0.897 0.516 
5 Ckb 0 0.711171111 0.95 0.792 
5 Miat 0 0.974764068 0.818 0.482 
6 Celf4 0 1.670783338 0.821 0.27 
6 Neurod1 0 1.581942962 0.967 0.49 
6 Meg3 0 1.545660771 0.42 0.063 
6 Mapt 0 1.506170676 0.643 0.174 
6 Arpp21 0 1.492349535 0.48 0.076 
7 Cntn2 0 1.597898918 0.889 0.213 
7 Neurod1 0 1.460194366 0.986 0.496 
7 Tubb3 0 1.339017309 0.939 0.437 
7 Gap43 0 1.175882847 0.955 0.571 
7 Nhlh2 0 1.096764378 0.836 0.39 
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8 Cenpa 1.2317E-197 1.138911783 0.784 0.23 
8 Cenpe 5.0684E-132 1.010472014 0.724 0.268 
8 Ccnb2 1.8441E-123 1.033226316 0.579 0.171 
8 Cdc20 4.3008E-111 0.887002429 0.582 0.18 
8 Hsp90b1 1.1858E-110 0.725220431 0.894 0.683 
9 Olig1 0 2.903177018 0.937 0.059 
9 Serpine2 0 2.715342148 0.844 0.038 
9 Cspg5 0 2.683401309 0.693 0.013 
9 3110035E14Rik 0 2.389352667 0.713 0.007 
9 Cacng4 0 2.361277033 0.808 0.085 
10 Apoe 0 4.754507745 0.984 0.241 
10 Ctsd 0 4.288821601 0.957 0.167 
10 C1qb 0 4.143669221 0.946 0.009 
10 Lyz2 0 4.126398341 0.924 0.009 
10 C1qc 0 3.83865028 0.946 0.007 
11 Fabp7 0 4.487435605 0.992 0.117 
11 Slc1a3 0 3.662214228 0.992 0.146 
11 Dbi 0 2.747454896 1 0.459 
11 Apoe 0 3.599922742 1 0.244 
11 Aqp4 7.5425E-305 3.971284743 0.967 0.019 
12 Apod 0 5.196128317 0.824 0.037 
12 Ptn 0 3.213414212 0.983 0.437 
12 Col3a1 1.3008E-286 4.141714635 0.941 0.01 
12 Col4a1 9.7311E-278 3.358682168 0.966 0.066 
12 Igf2 1.049E-261 3.754831938 0.815 0.03 
13 Meg3 1.3424E-183 3.370066536 0.954 0.089 
13 Snap25 2.1056E-145 2.225637245 0.861 0.278 
13 Syt4 4.0888E-134 2.656734449 0.676 0.016 
13 Chgb 3.4208E-127 2.3744119 0.833 0.237 
13 Gabra6 1.986E-121 2.213667594 0.546 0.002 
14 Bsg 2.9063E-160 2.729192797 0.904 0.422 
14 Fth1 7.3039E-147 2.504407897 1 0.708 
14 Itm2a 9.7739E-137 3.278467338 0.942 0.043 
14 Ctla2a 6.7739E-123 4.03203715 0.904 0.004 
14 Igfbp7 1.0498E-117 4.010266913 1 0.016 
      
 
Table 3.2. Cluster-specific differential expression profiles from P7 WT cerebella. A partial list of the 
top 5 differentially expressed genes from each cluster of the P7 wild-type cerebella. Genes for each cluster 
are listed with FDR-adjusted p-value, log2(Fold Change), the percent of cells expressing the transcript 




IC1 IC2 IC3 IC4 
Gene Loading Gene Loading Gene Loading Gene Loading 
Mki67 -11971.4 1700025G 
04Rik 
-2444.54 Tubb3 -9617.15 Cenpa -5473.99 
Top2a -11879.5 Clspn -2477.2 Stmn2 -8694.39 Ccnb2 -5031.5 
Tpx2 -11053.1 Mki67 -2493.07 Neurod1 -8288.09 Pttg1 -4988.21 
Nusap1 -10911.5 Birc5 -2557.19 Tuba1a -8286.86 Cdc20 -4782.24 
Prc1 -10881.2 Hmgn5 -2624.09 Gap43 -6915.4 Ube2c -4753.86 
Birc5 -10843.5 Ezh2 -2646.17 Tex14 -6755.01 Eef1a1 -4399.75 
Cdk1 -10677.6 H2afx -2667.35 Cntn2 -6530.98 Vim -4358.5 
Ube2c -10658.2 Cdk1 -2688.8 Map1b -6516.57 Pabpc1 -3934.82 
Cenpf -10597.7 Top2a -2721.8 Tmsb4x -6341.15 Rps26 -3899.48 
Hmgb2 -10170.3 Pbk -2739.31 Rtn1 -5979.21 Knstrn -3829.49 
Cdca8 -10153.5 RP23-45 
G16.5 
-2745.28 Calm2 -5871.55 Ccnb1 -3790.38 
Kif11 -10091.3 Spc24 -2793.88 Tubb2b -5848.25 Cdca3 -3650.89 
Smc2 -10019.2 Rrm2 -2819.05 Nhlh2 -5832.73 Hes1 -3478.53 
Kif23 -9836.1 Hells -2823.58 Nhlh1 -5812.68 Sparcl1 -3219.24 
Spc25 -9816.48 Myod1 -2888.12 Ube2c -5588.54 Lgals1 -3210.86 
Incenp -9795.31 Sox18 -2934.5 Ina -5257.81 Rplp1 -3111.19 
Smc4 -9769.67 Lig1 -2961.18 Cdc20 -5223.26 Pdlim4 -2976.67 
Cdca3 -9768.68 Rassf4 -2973.73 Stmn4 -5202.93 Pdlim3 -2974.85 
Ckap2l -9753 Prmt8 -3074.79 Cenpa -5178.13 Tmsb4x -2903.82 
H2afx -9732.16 Gm17322 -3084.69 St18 -5020.83 Cenpe -2869.64 
Cenpa -9431.5 Lhx1 -3123.36 Gng3 -5010.18 Hpca -2856.89 
Hmmr -9382.73 Rbp4 -3124.41 Tubb5 -4975.68 H2afx -2837.95 
Pbk -9363.79 Hmgb2 -3174.62 Ccnb1 -4936.5 Sowaha -2772.63 
2810417 
H13Rik 
-9345.19 Dek -3294.94 sept4 -4927.75 Rbp4 -2771.45 
Cenpe -9196.21 Pde1c -3331.5 Mllt11 -4904.77 Birc5 -2723.98 
Casc5 -8870.81 Ccnd1 -3354.15 Elavl4 -4885.16 Ccnd1 -2694.68 
Mis18bp1 -8855.66 Smc4 -3385.33 Tagln3 -4817.3 Cenpf -2676.06 
Cdc20 -8853.13 Igfbpl1 -3466.23 Miat -4811.31 RP23-
45G16.5 
-2660.41 
Esco2 -8843.82 Mcm6 -3524.82 Arl6ip1 -4781.09 Tbata -2649.2 
Tacc3 -8806.4 E130114 
P18Rik 
-3545.05 Ckb -4710.43 Ckap2l -2607.67 
        
 
Table 3.3: The top 30 genes at the extremes of the 4 ICs from the analysis of vehicle-treated tumors. 
A list of the top 30 genes expressed at the extremes of the 4 ICs selected from the ICA. Genes are listed 





Gene FDR log2(FC) %Sox2+ Cells %Others 
Sox2 0 1.930036 1 0 
Fabp7 9.3E-184 2.283031 0.374 0.11 
Dbi 2.9E-153 1.049306 0.708 0.45 
Slc1a3 8.7E-133 1.421355 0.327 0.144 
Olig1 1.5E-126 1.360579 0.352 0.066 
Gpr37l1 1.4E-122 1.113887 0.235 0.02 
Ptprz1 2.8E-114 1.154132 0.245 0.026 
Scrg1 2.3E-113 0.932002 0.209 0.016 
Serpine2 2.3E-108 1.420294 0.279 0.046 
Bcan 3.3E-107 1.022319 0.279 0.041 
Cspg5 1.42E-98 1.24908 0.206 0.02 
Ramp1 4.4E-96 0.852691 0.2 0.019 
Ednrb 9.35E-96 1.240174 0.195 0.021 
Olig2 1.66E-94 0.968456 0.316 0.066 
Sparcl1 3.06E-86 1.206161 0.439 0.195 
Neurod1 1.63E-85 -1.37984 0.334 0.542 
Sirt2 4.07E-85 1.018936 0.287 0.149 
Ppap2b 7.78E-85 0.999632 0.224 0.034 
Gjc3 7.56E-81 0.736946 0.139 0.008 
Stmn2 1.38E-80 -1.1098 0.32 0.564 
3110035E14Rik 1.85E-80 1.010172 0.169 0.016 
Timp4 2.85E-79 0.679285 0.146 0.01 
Bcas1 8.29E-78 0.804233 0.422 0.275 
S100a1 1.53E-77 0.831888 0.174 0.019 
Kcnj10 9.28E-77 0.876115 0.168 0.018 
Slc35f1 4.15E-76 0.596622 0.144 0.011 
Plp1 4.45E-76 1.431722 0.211 0.109 
Tril 4.79E-76 0.735137 0.171 0.018 
Cnp 3.26E-75 1.132199 0.184 0.026 
Cst3 2.73E-74 0.785195 0.724 0.526 
     
 
Table 3.4: The set of genes up-regulated in the Sox2+ population compared to all other cells from 
vehicle-treated tumors. A list of the top 30 genes up-regulated in the Sox2+ population as compared to all 
other Sox2- cells in vehicle-treated tumors. Genes are listed with FDR-adjusted p-value, log2(Fold Change), 
the percent of cells expressing the transcript within the Sox2+ population, and the percent of cells expressing 






Classification Gene FDR log2(FC) %Class %Others 
CGNP-Like Serpine2 3.9E-136 -2.8026 0.035 0.885 
CGNP-Like Gpr37l1 5.3E-122 -2.27261 0.015 0.783 
CGNP-Like Ptprz1 1.9E-117 -2.29213 0.026 0.787 
CGNP-Like Fabp7 6.5E-116 -3.85587 0.155 0.918 
CGNP-Like Cacng4 1.9E-110 -2.31234 0.081 0.832 
CGNP-Like Scrg1 2.3E-109 -2.02294 0.008 0.709 
CGNP-Like Lsamp 2.2E-106 -2.01863 0.043 0.758 
CGNP-Like Cspg5 2.4E-105 -2.5258 0.01 0.693 
CGNP-Like Bcan 1E-101 -1.89505 0.068 0.803 
CGNP-Like Ramp1 2.12E-92 -1.8091 0.018 0.652 
Astrocytic Prss23 3.47E-95 1.667073 0.812 0.016 
Astrocytic Hopx 4.3E-90 2.046628 0.875 0.024 
Astrocytic Id4 9.87E-88 1.979821 1 0.039 
Astrocytic Acsbg1 1.04E-80 1.925892 1 0.044 
Astrocytic Nid1 1.29E-77 1.980698 0.906 0.037 
Astrocytic Gpnmb 3.19E-77 1.150858 0.625 0.01 
Astrocytic Rgs5 3.31E-74 2.483813 0.812 0.029 
Astrocytic Npy 1.63E-73 2.164797 0.781 0.026 
Astrocytic Ifitm3 1.62E-71 1.774252 0.812 0.031 
Astrocytic Tnc 3.64E-71 1.914476 0.781 0.027 
AP-Like S1pr1 3.18E-71 1.792318 0.659 0.02 
AP-Like Mlc1 2.67E-70 2.061884 0.854 0.047 
AP-Like Aqp4 5.15E-68 2.504482 0.927 0.06 
AP-Like Pla2g7 5.7E-68 2.319065 0.902 0.057 
AP-Like Agt 1.49E-64 1.974747 0.805 0.042 
AP-Like Slc4a4 6.93E-62 2.801291 0.927 0.079 
AP-Like Aldh1l1 2.14E-57 1.701644 0.707 0.036 
AP-Like Aldoc 2.8E-55 2.450285 0.927 0.088 
AP-Like Slc6a11 7.45E-55 1.797242 0.683 0.038 
AP-Like Clu 1.91E-54 2.484669 0.902 0.091 
Oligodendrocytic Bmp4 9.6E-168 2.768665 0.942 0.001 
Oligodendrocytic Enpp6 4.6E-149 2.303395 0.846 0.001 
Oligodendrocytic Neu4 2.9E-97 1.463828 0.673 0.009 
Oligodendrocytic Lims2 1.73E-92 1.793156 0.731 0.018 
Oligodendrocytic Epcam 7.56E-91 1.375768 0.538 0.001 
Oligodendrocytic Tmem88b 3.18E-90 1.394594 0.615 0.008 
Oligodendrocytic Chn2 3.22E-88 2.406228 0.654 0.013 
Oligodendrocytic Slc1a1 1.32E-84 1.502095 0.846 0.038 
Oligodendrocytic Lgi3 1.12E-82 1.405298 0.615 0.011 
Oligodendrocytic Gpr17 5.16E-73 2.327066 0.904 0.069 
OPC-Like Cspg5 3.6E-104 2.579409 0.916 0.09 
OPC-Like Cspg4 2.87E-81 1.867276 0.597 0.02 
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OPC-Like Serpine2 2.94E-81 2.15234 0.958 0.168 
OPC-Like Cacng4 2.97E-76 2.068577 0.941 0.191 
OPC-Like Cntn1 1.71E-74 2.237482 0.79 0.109 
OPC-Like Pdgfra 1.22E-71 2.231377 0.815 0.133 
OPC-Like Olig1 1.89E-67 2.205983 0.933 0.257 
OPC-Like 3110035E14Rik 1.28E-63 1.422364 0.739 0.077 
OPC-Like Ptprz1 1.58E-63 1.649893 0.849 0.146 
OPC-Like Ascl1 3.11E-55 1.162409 0.345 0 
      
 
Table 3.5: Cluster-specific differential expression profiles from ICA of Sox2+ cells from vehicle-
treated tumors. A partial list of the top 10 genes differentially expressed in Sox2+ cells from the ICA, 
showing distinct astrocytic, oligodendrocytic, AP-like, OPC-like and CGNP-like profiles. Genes are listed 
with FDR-adjusted p-value, log2(Fold Change), the percent of cells expressing the transcript within the 






















IC1 IC2 IC3 IC4 
Gene Loading Gene Loading Gene Loading Gene Loading 
Pcp4 17249 Ckb 12408 Neurod1 17176 Ptprs 11791 
Ntm 16404 Tubb3 11077 Stmn2 15188 Miat 10235 
Snca 15593 Cntn2 11009 Gap43 14408 Xist 9795 
Meg3 15384 Tmsb4x 10178 Cntn2 14174 Nfib 8684 
Car10 14647 Stmn2 10068 Rtn1 13535 Cntn2 7721 
Mapt 14402 Rtn1 9080 Map1b 13289 Reln 7151 
Jph4 13552 Neurod1 9042 Tubb3 12571 Ank3 6987 
Cadm2 13465 Nhlh1 8584 Stmn4 12486 Cacna2d1 6662 
Calb2 13380 Pdzrn3 8529 Celf4 11902 Insm1 6623 
D3Bwg0562e 13167 Gng3 8180 Gpm6a 11706 Gm26924 6596 
Celf4 13114 Nrep 7904 Nrxn1 11436 Nhlh2 6513 
Neurod2 13110 Gap43 7875 Tubb2a 10982 Ankrd11 6306 
Arpp21 13021 Ina 7731 Dpysl3 10951 Gria2 6193 
Atp2b1 12874 Dpysl3 7689 Tmsb4x 10940 Dync1h1 6019 
Cntn1 12758 Stmn4 7424 Sept3 10777 Ppp3ca 5943 
Camk4 12740 Mllt11 7305 Gng3 10621 Clmp 5811 
Pvrl3 12376 BC005764 7290 Mtss1 10211 mt-Rnr1 5719 
Sez6 12343 Sept3 7267 St18 10117 Ccdc88a 5618 
Kcnd2 12125 Tubb2a 7222 Ppp1r14c 10057 Phf20l1 5578 
Gpm6a 12125 Miat 7077 Mapt 9402 Plxnb2 5574 
Prkce 12123 Chrna3 7031 Nrep 9286 Ankrd12 5544 
Grm1 11789 Igfbpl1 6977 Ina 9217 Brsk2 5514 
Spock2 11728 Sept4 6974 Cdk5r1 9206 Sema6a 5513 
Camk2d 11722 Dcx 6930 Elmo1 9069 Elavl3 5507 
Btbd3 11611 Elavl4 6825 Dner 8770 Map2 5482 
Lin7a 11566 Trpc4ap 6761 Rab3a 8618 Podxl2 5467 
Tspan4 11511 Gpm6a 6759 Dcx 8579 Flna 5407 
Ablim1 11507 Elavl3 6726 Trpc4ap 8531 Celsr2 5331 
Ryr2 11399 Chgb 6589 Mllt11 8462 Nktr 5316 
Tenm1 11236 Map1b 6570 Tex14 8414 Mdga1 5057 
        
 
Table 3.6: The top 50 genes at the extremes of the 4 ICs from the analysis of vismodegib-treated and 
control tumors. A list of the top 30 genes enriched in the 4 ICs from ICA analysis of vehicle- and 







Gene FDR log2(FC) %Cluster 0 %Others 
Rpl13a 0 0.437042593 0.977 0.913 
Rps5 0 0.430126209 0.985 0.944 
Rps14 0 0.403282137 0.982 0.94 
Tuba1a 0 -0.741963024 0.858 0.95 
Rtn1 0 -0.781283764 0.518 0.74 
Map1b 0 -0.884520861 0.358 0.653 
Gap43 0 -0.952991478 0.367 0.666 
Tubb3 0 -1.172262378 0.223 0.546 
Stmn2 0 -1.341248288 0.271 0.634 
Cntn2 0 -1.386584341 0.047 0.326 
Neurod1 0 -1.780023473 0.226 0.621 
Gnb2l1 4.1003E-305 0.441826047 0.935 0.853 
Rpl8 1.1748E-302 0.412225533 0.953 0.881 
Rps9 2.0809E-300 0.392851621 0.974 0.915 
Gpm6a 3.6246E-298 -0.926823803 0.19 0.472 
Arl6ip1 5.2794E-295 -0.880699347 0.36 0.604 
Ube2c 6.5584E-293 -1.276097579 0.08 0.323 
Tpx2 2.0958E-289 -1.069658238 0.081 0.339 
Rps3 2.9732E-285 0.382436424 0.969 0.908 
Rplp1 1.2391E-273 0.400456256 0.951 0.855 
Top2a 2.2142E-272 -1.059705631 0.252 0.478 
Stmn4 2.0016E-271 -1.005199309 0.134 0.401 
Nrxn1 2.5658E-266 -0.965380192 0.116 0.376 
Tubb5 5.2453E-263 -0.478753376 0.851 0.933 
Rpl32 5.9322E-263 0.395474175 0.948 0.872 
Celf4 5.8431E-252 -1.013004692 0.128 0.376 
Prc1 1.9184E-250 -1.035594565 0.078 0.308 
Cenpf 1.932E-250 -1.119429622 0.173 0.416 
Rplp2 3.8718E-249 0.4107213 0.916 0.818 
Nusap1 4.0067E-249 -0.939868949 0.052 0.277 
     
 
Table 3.7: The set of genes differentially up-regulated in Cluster 0 in vehicle-treated tumors 
compared to all other vehicle-treated cells. A list of the top 30 genes differentially up-regulated in Cluster 
0 cells of vehicle-treated tumors compared to all other vehicle-treated cells. Genes are listed with FDR-
adjusted p-value, log2(Fold Change), the percent of cells expressing the transcript within Cluster 0, and the 









Top2a 0 2.096832 0.881 0.249 
Cenpf 0 1.893585 0.774 0.18 
Mki67 0 1.844122 0.853 0.21 
Ube2c 0 1.701852 0.586 0.089 
Prc1 0 1.689608 0.594 0.077 
Tpx2 0 1.630632 0.669 0.085 
Cenpe 0 1.563214 0.654 0.135 
Spc25 0 1.482867 0.553 0.056 
Hmgb2 0 1.463203 0.812 0.25 
Nusap1 0 1.452931 0.528 0.052 
Smc4 0 1.431319 0.914 0.452 
Cdca8 0 1.427112 0.629 0.091 
Birc5 0 1.41048 0.626 0.087 
Kif23 0 1.394968 0.511 0.051 
Incenp 0 1.380446 0.624 0.111 
Cenpa 0 1.351657 0.498 0.09 
Hmmr 0 1.341213 0.432 0.034 
Ckap2l 0 1.276544 0.487 0.053 
Ccna2 0 1.263635 0.555 0.072 
Kif11 0 1.263456 0.502 0.056 
Cdc20 0 1.257126 0.431 0.056 
RP23-45G16.5 0 1.253883 0.696 0.189 
Cdk1 0 1.229088 0.509 0.077 
H2afx 0 1.205755 0.618 0.176 
Kif15 0 1.19237 0.491 0.059 
Pbk 0 1.144159 0.5 0.076 
2810417H13Rik 0 1.13713 0.761 0.267 
Tacc3 0 1.135167 0.494 0.072 
Cdca3 0 1.131043 0.492 0.065 
Arhgap11a 0 1.112936 0.412 0.051 
     
 
Table 3.8: Set of genes up-regulated in vismodegib-treated cells of Node AT compared to vehicle-
treated cells of Node BT. A list of the top 30 up-regulated genes from the differential gene expression 
analysis comparing cells from Node AT in vismodegib-treated cells to cells from Node BT from vehicle-
treated cells. Genes are listed with FDR-adjusted p-value, log2(Fold Change), the percent of cells expressing 
the transcript within the vismodegib-treated Node AT cells, and the percent of cells expressing the transcript 





Figure Data Gene Expression Threshold 
(scaled nUMI) 
Fig. 3.2b Vehicle-treated Tumor Col3a1 3 
Fig. 3.2b Vehicle-treated Tumor C1qb 3 
Fig. 3.2b Vehicle-treated Tumor Meg3 4 
Fig. 3.2b Vehicle-treated Tumor Sox10 1 
Fig. 3.2b Vehicle-treated Tumor Aqp4 3 
Fig. 3.2b Vehicle-treated Tumor Pecam1 2 
Fig. 3.3a P7 Cerebellum Col3a1 3 
Fig. 3.3a P7 Cerebellum C1qb 3 
Fig. 3.3a P7 Cerebellum Meg3 4 
Fig. 3.3a P7 Cerebellum Sox10 1 
Fig. 3.3a P7 Cerebellum Aqp4 3 
Fig. 3.3a P7 Cerebellum Pecam1 1 
Fig. 3.3b P7 Cerebellum Pax2 1 
Fig. 3.3b P7 Cerebellum Pax3 1 
Fig. 3.3b P7 Cerebellum Sox2 2 
Fig. 3.3b P7 Cerebellum Ascl1 2 
Fig. 3.3c P7 Cerebellum Ccnd2 3 
Fig. 3.3c P7 Cerebellum Barhl1 2 
Fig. 3.3c P7 Cerebellum Cntn2 1 
Fig. 3.3c P7 Cerebellum Rbfox3 2 
Fig. 3.3c P7 Cerebellum Grin2b 2 
Fig. 3.3c P7 Cerebellum Gli1 1 
Fig. 3.4c Vehicle-treated Tumor (parenchyma only) Ccnd1 2 
Fig. 3.4c Vehicle-treated Tumor (parenchyma only) Ccne2 1 
Fig. 3.4c Vehicle-treated Tumor (parenchyma only) Ccna2 2 
Fig. 3.4c Vehicle-treated Tumor (parenchyma only) Ccnb2 2 
Fig. 3.5a Vehicle-treated Tumor Sox2 1 
Fig. 3.5a Vehicle-treated Tumor SmoM2-EYFP 1 
Fig. 3.5d Vehicle-treated Tumor, Sox2+ Cells Aqp4 1 
Fig. 3.5d Vehicle-treated Tumor, Sox2+ Cells Sox10 1 
Fig. 3.5e Vehicle-treated Tumor, Sox2+ Oligodendrocytes Mbp 1 
Fig. 3.5e Vehicle-treated Tumor, Sox2+ Oligodendrocytes Pdgfra 1 
Fig. 3.5e Vehicle-treated Tumor, Sox2+ Oligodendrocytes Mog 1 
Fig. 3.5e Vehicle-treated Tumor, Sox2+ Oligodendrocytes SmoM2-EYFP 1 
Fig. 3.5f Vehicle-treated Tumor, Sox2+ Astrocytes Olig1 1 
Fig. 3.5f Vehicle-treated Tumor, Sox2+ Astrocytes SmoM2-EYFP 1 
Fig. 3.6a Vehicle & Vismodegib-treated Tumors Col3a1 3 
Fig. 3.6a Vehicle & Vismodegib-treated Tumors C1qb 3 
Fig. 3.6a Vehicle & Vismodegib-treated Tumors Meg3 4 
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Fig. 3.6a Vehicle & Vismodegib-treated Tumors Sox10 1 
Fig. 3.6a Vehicle & Vismodegib-treated Tumors Aqp4 3 
Fig. 3.6a Vehicle & Vismodegib-treated Tumors Pecam1 2 
Fig. 3.6e Vehicle & Vismodegib-treated Tumors SmoM2-EYFP 1 
Fig. 3.7a Vehicle & Vismodegib-+B22treated Tumors Gli1 1 
Fig. 3.7c Vehicle & Vismodegib-treated Tumors Hes1 1 
Fig. 3.7e Vehicle & Vismodegib-treated Tumors Myod1 1 
Fig. 3.8a Vehicle & Vismodegib-treated Tumors Ezh2 1 
Fig. 3.8a Vehicle & Vismodegib-treated Tumors Suz12 1 
Fig. 3.8a Vehicle & Vismodegib-treated Tumors Eed 1 
Fig. 3.8d Vehicle & Vismodegib-treated Tumors, Sox2+ 
Cells 
Fabp7 1 
Fig. 3.8d Vehicle & Vismodegib-treated Tumors, Sox2+ 
Cells 
Hes1 1 
Fig. 3.8e Vehicle & Vismodegib-treated Tumors, Sox2+ 
Cells 
Nes 1 
Fig. 3.8e Vehicle & Vismodegib-treated Tumors, Sox2+ 
Cells 
Vim 3 
Fig. 3.8e Vehicle & Vismodegib-treated Tumors, Sox2+ 
Cells 
Yfp 1 
Fig. A.5 P7 Cerebellum Slc17a1 1 
Fig. A.5 P7 Cerebellum Calb2 1 
Fig. A.5 P7 Cerebellum Gad1 1 
Fig. A.5 P7 Cerebellum Calb1 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Ccnd1 2 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Ccne2 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Ccna2 2 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Ccnb2 2 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Mki67 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Pcna 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Ccnd1 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Ccnd2 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Gli1 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Atoh1 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Barhl1 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Cntn2 1 
Fig. A.7 Vehicle-treated Tumor (parenchyma only) Rbfox3 1 
Fig. A.9 Vehicle & Vismodegib-treated Tumors Ptch1 1 
Fig. A.9 Vehicle & Vismodegib-treated Tumors Hhip 1 
Fig. A.9 Vehicle & Vismodegib-treated Tumors Sfrp1 1 
    
 
Table 3.9. The set of gene expression thresholds used to generate the feature plots. A list of the genes 
represented in the indicated feature plots with the expression threshold in scaled nUMI indicated. 
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Reagent Concentration Source Identifier 
Animal Studies 
C57BL/6 mice N/A The Jackson 
Laboratory 
Stock #000664 
Math1-Cre mice N/A The Jackson 
Laboratory 
Stock #011104 
SmoM2-eYFPloxP/loxP mice N/A The Jackson 
Laboratory 
Stock #005130 
PhamloxP/loxP mice N/A The Jackson 
Laboratory 
Stock #018385 
Gli-luc mice N/A Generously shared by 
Dr. Oren Becher, 
Northwestern 
University and Dr. 




N-Methyl-2-pyrrolidone (NMP) 1:10 Millipore Sigma Catalog #328634 
Polyethylene glycol (PEG) 9:10 Millipore Sigma Catalog #P3015-
250G 
Vismodegib 75 mg/kg or 100 
mg/kg in 
NMP:PEG 
LC Laboratories Catalog #V-4050 





Tail lysis buffer 1X Allele Biotechnology Catalog #ABP-
PP-MT01 
Cre Forward primer: GCG GTC 
TGG CAG TAA AAA CTA TC 
200 µM Invitrogen JAX #oIMR1084 
Cre Reverse primer: GTG AAA 
CAG CAT TGC TGT CAC TT 
200 µM Invitrogen JAX #oIMR1085 
SmoM2-eYFP Forward primer:  
AAG TTC ATC TGC ACC ACC G 
400 µM Invitrogen JAX #oIMR0872 
SmoM2-eYFP Reverse primer: 
TCC TTG AAG AAG ATG GTG 
CG 
400 µM Invitrogen JAX #oIMR1416 
Pham Common primer: CCA AAG 
TCG CTC TGA GTT GTT ATC 
200 µM Invitrogen JAX #13840 
Pham WT Reverse primer: GAG 
CGG GAG AAA TGG ATA TG 
200 µM Invitrogen JAX #13841 
Pham Mutant Reverse primer: TCA 
ATG GGC GGG GGT CGT T 
200 µM Invitrogen JAX #oIMR7320 
Gli-luc Forward primer:  TAT CAT 
GGA TTC TAA AAC GG 
200 µM Invitrogen N/A 
Gli-luc Reverse primer:  CAG CTC 
TTC TTC AAA TCT ATA C 
200 µM Invitrogen N/A 
Apex Taq DNA Polymerase Master 
Mix 
1X Genessee Scientific Catalog #42-138 
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Platinum Blue PCR SuperMix 1X Invitrogen Catalog # 
12580015 
Molecular biology grade water – Corning Inc. 46-000-CM 
Immunofluorescence and Immunohistochemistry 
Paraformaldehyde (PFA) 4% in PBS   
Phosphate Buffered Saline (PBS) 1X   
Antigen Retrieval 1:100 Vector Laboratories Catalog #H-3300 
Donkey serum 2% in 0.3% PBST Millipore Sigma Catalog #D9663 
DAPI 1:2500 Invitrogen Catalog #D1306 
SOX2 1:200 Cell Signaling 
Technology 
Catalog #4900 
HES1 1:200 Cell Signaling 
Technology 
Catalog #11988 
MYOD1 1:100 (Mouse) Novus Catalog #NBP2-
32882-0.1mg 
phospho-RB (Ser807/811) 1:3000 Cell Signaling 
Technology 
Catalog #8516 
GFAP 1:2000 Dako Catalog #Z0334 
NeuN 1:10,000 Millipore Catalog 
#MAB377 
Calbindin 1:400 Cell Signaling 
Technology 
Catalog #2173 








Novolink Polymer Per manufacturer’s 
instructions 
Leica Biosystems Catalog 
#RE7200-CE 




Vector Laboratories Catalog #MP-
7401 




Vector Laboratories Catalog #MP-
7402 
Dissociation 







Hank’s Balanced Salt Solution 
(HBSS) 
1X Gibco Catalog #14175-
095 
D-(+)-Glucose 6g/L Millipore Sigma Catalog #G7021 
Flow Cytometry 








Heat inactivated Fetal Bovine 
Serum (HI-FBS) 




Sodium azide (NaN3) 0.1% in FACS 
wash buffer 
Fisher Scientific Catalog #S2271-
25 




Table 3.10. List of reagents and materials used in Chapter 3 with concentrations, vendor name, and 
catalog number listed where applicable. 
 
FxCycle Violet 1:100 ThermoFisher 
Scientific 
Catalog #F10347 
phospho-RB Alexa Fluor 488 1:50 Cell Signaling 
Technology 
Catalog #4277 
MyoD Allophycocyanin (APC) 1:50 Novus Catalog #NBP2-
34772APC 
GFAP Alexa Fluor 647 1:50 Cell Signaling 
Technology 
Catalog #3657 
Commercial Assays  
Macosko et al., 2015 Drop-seq 
beads 
90-110/μL ChemGenes Lot # 090316 
Nextera XT NA Illumina FC-131-1024 































ONGOING WORK: RNA-PROCESSING THROUGH MAGOH IS NECESSARY TO 
PROMOTE CEREBELLAR GROWTH 
Introduction 
Disruptions in cerebellar proliferation lead to neurodevelopmental disorders such as 
medulloblastoma and microcephaly. Medulloblastoma is the most common malignant pediatric 
brain tumor and is believed to arise from cerebellar granule neuron progenitors (CGNPs) (Gibson 
et al., 2010; Cavalli et al., 2017; Vladoiu et al., 2019). In contrast, mutations in genes that promote 
neural progenitor amplification have been linked to microcephaly. Human genetic screens have 
identified genes necessary for brain growth. For example, loss of function mutations in genes such 
as Aspm have been associated with autosomal recessive microcephaly in human patients (Naveed 
et al., 2018; Okamoto et al., 2018). We have previously found that Aspm is required for normal 
cerebellar growth and that loss of Aspm induces DNA damage and apoptosis during cerebellar 
development and medulloblastoma growth (Williams et al., 2015). 
 A recent mouse genetic screen identified mutations in Magoh, a member of the exon 
junction complex (EJC), which caused microcephaly (Silver et al., 2010). Magoh loss in mice 
caused prolonged mitosis, premature differentiation, and p53-mediated apoptosis, leading to 
hypoplasia and abnormal cerebral architecture (Silver et al., 2010; Silver et al., 2013; Pilaz et al., 
2016). These studies in mice were among the first to suggest that the exon junction complex 
component MAGOH can control brain size and regulate stem cell division (Silver et al., 2010; 
McMahon et al., 2016). Subsequent studies have shown that mutations in the core EJC component 
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Rbm8a (Y14) can also produce microcephaly in mice (Mao et al., 2015; Zou et al., 2015; Mao et 
al., 2016). 
RNA processing genes in the exon junction complex (EJC) regulate brain size during 
development and cancer growth by regulating mRNA splicing, transport, export, and nonsense-
mediated decay (McMahon et al., 2016). The interaction of the core components RBM8A (Y14) 
and MAGOH with eIF4A3 are necessary for the binding of the EJC to mRNA to regulate splicing, 
while auxiliary components of the EJC are more commonly associated with mRNA export 
(UAP56, Aly/Ref and TAP) or mRNA surveillance and nonsense-mediated decay (NMD; MLN51 
and UPF1/2/3B) (Kataoka et al., 2001; Shibuya et al., 2004; Brogna and Wen, 2009; Boehm and 
Gehring, 2016; Woodward et al., 2017). Knockdown of Y14 promoted the alternative splicing of 
BCL-X pre-mRNA into the pro-apoptotic Bcl-xS as opposed to the anti-apoptotic Bcl-xL in 
various cell types (Michelle et al., 2012). Additionally, MAGOH has been implicated in the mRNA 
export of important developmental signaling pathway proteins such as PI3 kinase/AKT signal 
transduction (Quaresma et al., 2013), and in the regulation of MAPK splicing (Ashton-Beaucage 
et al., 2010), further supporting the role for the EJC in development. Differential regulation of 
mRNA by the EJC during development may also be critical for cell cycle progression and cell 
specification (Inaki et al., 2011; Silver et al., 2013; Fukumura et al., 2016; Pilaz et al., 2016; Baralle 
and Giudice, 2017; Ryu et al., 2019). 
Previous studies have speculated that mRNA splicing and NMD regulation may also be 
critical for cancer cell survival (Eswaran et al., 2013). Roles for the exon junction complex have 
been described in multiple cancer types, such as hepatocellular carcinoma, gliomas, lung cancer, 
and breast cancer (Degot et al., 2004; Baguet et al., 2007; Lindeboom et al., 2016; Lin et al., 2018; 
Lin et al., 2019). In breast cancer, expression of MAGOH has been associated with metastatic 
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lymph node 51 (MLN51) and the formation of stress granules (Degot et al., 2004; Baguet et al., 
2007). However, expression of the EJC components promoting NMD varies across cancers 
(Lindeboom et al., 2016), indicating that regulation of proliferation through the EJC may be cell 
type specific. Stratification of tumors by expression of MAGOH showed a favorable prognostic in 
breast cancer with high MAGOH expression (Stricker et al., 2017). Similar tumor stratification by 
eIF4A3 expression demonstrated that high eIF4A3 expression was associated with poor prognosis 
in multiple cancer types (Lin et al., 2018). However, the role of the EJC in the developing 
cerebellum or the cerebellar-derived cancer medulloblastoma is unknown. 
We explored whether MAGOH function was necessary to maintain cerebellar and 
medulloblastoma tumor growth by conditionally and temporally deleting Magoh in cerebellar 
granule neuron progenitors and CGNP-derived medulloblastoma tumor cells in mice through the 
use of the globally-expressing CAG-CreER. We found that conditional deletion of Magoh during 
postnatal cerebellar development led to DNA damage and Caspase-mediated cell death in 
progenitors, but not neighboring mature neurons. DNA damage accumulated in progenitors during 
every phase of the cell cycle and resulted in accumulation of pHH3+ mitotic cells. Magoh deletion 
was characterized by an increase in p53 phosphorylation and CDKN1A (aka p21) activation. 
Although co-deletion of trp53 inhibited phosphorylation of H2A.X, a marker of double-stranded 
breaks (DSBs) in DNA, cells continued to undergo apoptosis. Furthermore, conditional deletion 
of Magoh in medulloblastoma-prone mice expressing a constitutively active form the SHH 
receptor Smo, SmoA1, induced DNA damage and cell death in tumor cells, as in cerebellar 
development. These findings demonstrate that the EJC core component MAGOH is required to 
prevent DNA damage and cell death in proliferating cells during cerebellar development and 




Magoh haploinsufficiency impairs cerebellar growth 
To determine MAGOH expression during brain development, we first used 
immunohistochemical staining to detect the MAGOH protein. MAGOH was expressed throughout 
the brain during early postnatal development, both in progenitor-rich zones such as the external 
granule layer (EGL) of the cerebellum, the subventricular zone (SVZ), and the dentate gyrus (DG) 
of the hippocampus (Fig. 4.1A). We also detected MAGOH in differentiated neurons, including 
the cerebellar granule neurons (CGNs) of the internal granule layer (IGL) of the cerebellum (Fig. 
4.1A). 
To determine the function of Magoh during cerebellar development, we crossed 
MagohloxP/loxP mice with Math1-Cre mice to produce Math1-Cre/MagohloxP/wt (Magohhet) progeny. 
CGNPs are the predominant cell type within the cerebellum that express Math1 from E12.5 in a 
rostro-caudal progression (Machold and Fishell, 2005; Wang et al., 2005). Magohhet mice were 
viable, asymptomatic, and fertile. However, when we examined cerebella from Magohhet mice 
from postnatal day 1 (P1) through P15, we detected disturbances in cerebellar architecture. 
Although the EGL appeared normal at early postnatal ages (Fig. 4.1B, P1), over time the EGL 
thinned in Magohhet cerebella and fewer lobules developed as compared to controls (Fig. 4.1B, P7, 
P15).  
Immunohistochemistry at P1 showed heterogeneous expression of MAGOH in CGNPs 
(Fig. 4.1C), indicating that MAGOH might be developmentally regulated. Proliferation and 
differentiation as determined by PCNA and p27 respectively at early postnatal ages showed no 
differences between Magohhet and control mice (Fig. 4.1C). We were also unable to detect any 
difference in apoptotic rates at P1 as demonstrated by cleaved Caspase-3 (cC3) staining (Fig. 
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4.1C). However, Magohhet mice demonstrated a higher rate of phospho-Histone H3 (pHH3) 
positive CGNPs, indicating a potential stalling of cells in mitosis (Fig. 4.1C). 
The lack of symptoms observed in Magohhet mice allowed us to breed Magoh deletion to 
homozygosity to produce Math1-Cre/MagohloxP/loxP (MagohcKO) mice. MagohcKO mice were 
consistently smaller than their heterozygous littermates, exhibited ataxia early in life, and were 
unable to be weaned. Examination of MagohcKO cerebella revealed severe hypoplasia, 
characterized by a thinned or absent EGL beginning at P1, which resulted in the absence of an IGL 
(Fig. 4.1B). Loss of Magoh caused a depletion of PCNA+ cells in the EGL and p27+ cells in the 
IGL, demonstrating a failure of CGNPs to proliferate and generate differentiating neurons (Fig. 
4.1C). We were unable to detect mitotic cells in Magoh-deficient cerebella, as demonstrated by 
pHH3 staining, or apoptotic cells, as labeled by cC3 (Fig. 4.1C). Due to the severity of the 
phenotype, we were unable to determine the cause of the hypoplasia and thus turned to a 
temporally controlled genetic deletion model. 
Conditional deletion of Magoh depletes CGNPs by inducing DNA damage and apoptosis 
To further characterize the role of MAGOH in cerebellar development, we crossed 
MagohloxP/loxP mice with CAG-CreER mice to produce CAG-CreER/MagohloxP/loxP progeny 
(MagohCreER). CAG-CreER is an inducible Cre model that allows for the temporal and conditional 
activation of Cre in the presence of tamoxifen (Hayashi and McMahon, 2002). We administered 
4-hydroxy-tamoxifen (4OHT) in MagohCreER mice and CAG-CreER- control littermates at P5, 
before the peak of proliferation in the cerebellum, and collected samples 24, 48, and 72 hrs. later. 
Interestingly, 4OHT administration deleted Magoh only in progenitor-rich zones, such as the SVZ, 
the granule layer of the DG, and the EGL of the cerebellum (Fig. 4.2A). 
Examination of histological sections showed that conditional Magoh deletion resulted in a 
thinned EGL 48 and 72 hrs. after 4OHT administration (Fig. 4.2B). Moreover, loss of Magoh in 
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CGNPs resulted in a complete loss of proliferative pRB+ cells in the EGL 72 hrs. after 4OHT 
injections (Fig. 4.2C). Interestingly, at 48 hrs. after 4OHT administration, we observed a trend 
towards an increase in pHH3+ mitotic cells (p-value=0.052; Fig. 4.2D), indicating a potential 
accumulation of cells in M-phase. We also noted that loss of Magoh in CGNPs was also 
accompanied by loss of the EJC member, RBM8A, which is necessary for the binding of the EJC 
to mRNA (Fig. 4.2E) (Kataoka et al., 2001). 
Magoh deletion induces DNA damage and apoptosis in proliferating CGNPs 
To determine why CGNPs were being ablated, we stained for DNA damage by pH2A.X 
and apoptosis by cC3. Magoh-depleted CGNPs expressed pH2A.X 24hrs. after 4OHT 
administration (Fig. 4.3A). DNA damage continued after 48 hrs., and led to apoptotic cell death, 
which persisted more than 72 hrs. after injecting tamoxifen (Fig. 4.3A). Apoptosis can be induced 
by p53 activation in the presence of stress such as DNA damage, and previous studies have 
demonstrated that loss of MAGOH or RBM8A can lead to p53-dependent cell death (Mao et al., 
2016; Pilaz et al., 2016; Lu et al., 2017). To determine if Magoh deletion was activating the 
intrinsic apoptotic pathway through p53, we stained samples for phosphorylated p53. MagohCreER 
cerebella exhibited increased p53 phosphorylation 48 hrs. after 4OHT administration (Fig. 4.3B). 
Correspondingly, p53 phosphorylation coincided with CDKN1A activation in CGNPs (Fig. 4.3B). 
These results indicate that MAGOH is necessary to prevent DNA damage and p53-induced cell 
cycle arrest and apoptosis. 
Loss of Magoh induces DNA damage throughout the cell cycle 
Previous studies have shown that loss of Magoh in cortical progenitors induced DNA 
damage and produced an accumulation of cells in mitosis (Silver et al., 2010). We performed 
fluorescence-activated cell sorting (FACS) analysis on mice treated with 4OHT and collected after 
48 hrs. to determine which phase of the cell cycle was accumulating DNA damage. The 
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distribution of cells across cell cycle phases was not significantly different between MagohCreER 
cerebella compared to control littermates, with the exception of a slight decrease in the percent of 
cells in G1 in MagohCreER cerebella (Fig. 4.4A, C). However, MagohCreER CGNPs demonstrated 
an increasing accumulation of pH2A.X+ cells across all cell cycle phases (Fig. 4.4B, C). These 
results indicate that loss of Magoh induces DNA damage throughout cell cycle progression.  
DNA damage response in Magoh-deleted cells depends on p53 
To determine if p53-induced DNA damage and cell death was driving the MagohCreER 
phenotype, we crossed trp53loxP/loxP mice with MagohCreER mice to produce CAG-
ERCre/MagohloxP/loxP/trp53loxP/loxP (Magoh/p53CreER) mice (Marino et al., 2000). We found that 
conditional deletion of trp53 alongside Magoh prevented the expression of p-p53 and blocked 
CDKN1A activation in the EGL (Fig. 4.5A). Co-deletion of trp53 did not prevent pH2A.X 
expression in CGNPs 48 hrs. after 4OHT administration and CGNPs continued to exhibit cC3+ 
cells by 72 hrs. after injection (Fig. 4.5B), although both pH2A.X and cC3 expression were reduced 
as compared to MagohCreER cerebella. These studies demonstrate that p53 is not the only driver of 
the DNA damage response and apoptosis caused by Magoh loss.  
Magoh is required for SHH-driven medulloblastoma growth 
We next crossed MagohCreER mice with ND2:SmoA1 mice to produce SHH-
medulloblastoma prone CAG-CreER/MagohloxP/loxP/ND2:SmoA1 (MagohSmoA1) mice. 
ND2:SmoA1 mice express a mutated form of the SHH receptor Smoothened (Smo) under the 
NeuroD2 promoter and spontaneously develop SHH-driven tumors around P60 (Hallahan et al., 
2004). We monitored mice and determined tumor growth when mice exhibited symptoms such as 
enlarged head, head tilt, ataxia and/or hunched posture. We administered 4-OHT when mice 
exhibited symptoms and collected after 48 hrs for immunohistochemical analysis (Fig. 4.6A). We 
observed scattered MAGOH- cells in the tumorigenic regions of MagohSmoA1 cerebella while 
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almost all of the cells in SmoA1 cerebella remained MAGOH+ (Fig. 4.6A). We also noted an 
increase in pH2A.X+ and cC3+ cells in 4OHT-injected MagohSmoA1 mice, although this did not 
confer a survival benefit (Fig. 4.6B; data not shown). We hypothesized that the lack of significant 
differences in survival might be caused by the severity of the tumor at the time of 4OHT 
administration. 
To target MagohSmoA1 tumors after formation, we monitored tumor growth by magnetic 
resonance imaging (MRI). We imaged mice every 6 weeks to determine when tumors formed in  
SmoA1 and MagohSmoA1 mice. We administered 4OHT at the onset of tumor formation, when we 
noted obvious structural differences in the cerebellum. We then continually administered 4OHT 
every 48 hrs. and imaged every week before collecting brains for further analysis (Fig. 4.6C). As 
with MagohSmoA1 mice treated with a single dose of 4OHT, we noted MAGOH- cells in MagohSmoA1 
mice treated with 4 injections of 4OHT (Fig. 4.6C). Repeated injections of 4OHT decreased 
proliferating pRB+ cells and induced higher levels of DNA damage and apoptosis in MagohSmoA1 
tumors (Fig. 4.6D, E). Quantification of pH2A.X+, cC3+, and pH2A.X+/cC3+ cells revealed slight 
increases in DNA damage and apoptosis in tumors due to Magoh loss that did not reach statistical 
significance (Fig. 4.6F). However, we noted that repeated 4OHT administration in tumor-prone 
mice induced higher levels of pH2A.X+, cC3+, and pH2A.X+/cC3+ cells, suggesting that early 
detection of tumors and continued 4OHT injections might promote DNA damage and cell death 
in tumors to potentially extend survival. Together, these studies indicate that Magoh is also 
required for the survival of SHH-driven tumors.  
 
Discussion 
We explored the function of MAGOH in cerebellar development and medulloblastoma 
tumor growth through genetic and molecular studies. We found that MAGOH is required to 
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prevent DNA damage and apoptosis in proliferating cells, particularly CGNPs and the CGNP-
derived tumor, medulloblastoma. Conditional deletion of Magoh in Math1+ progenitors during 
cerebellar development caused hypoplasia marked by abnormal foliation and a loss of CGNs. 
Conditional deletion of Magoh during the peak of postnatal neurogenesis in the cerebellum 
induced p53 phosphorylation and CDKN1A activation, which caused accumulation of pH2A.X+ 
cells throughout the cell cycle. Co-deletion of trp53 attenuated, but did not prevent, the DNA 
damage and apoptotic response in CGNPs. Moreover, deletion of Magoh in SmoA1-driven 
medulloblastomas was sufficient to induce DNA damage and apoptosis, as in CGNPs. 
Previous studies have demonstrated that MAGOH is required to prevent DNA damage and 
cell death in cortical progenitors, and that loss of Magoh is sufficient to induce microcephaly 
(Silver et al., 2010; Mao et al., 2016; Pilaz et al., 2016). Our studies show that MAGOH is also 
required for the survival of cerebellar progenitors. Interestingly, the co-deletion of trp53 in cortical 
progenitors was sufficient to prevent microcephaly caused by loss of EJC core component 
members, especially Magoh (Mao et al., 2016). However, we have shown that co-deletion of trp53 
in cerebellar progenitors attenuates DNA damage and apoptosis but is unable to prevent the 
hypoplastic phenotype observed in mice with Magoh deletion. These observations coincide with 
the variety of rescue phenotypes observed in other core EJC component members with trp53 co-
deletion (Mao et al., 2016). 
Alterations in proteasome regulation and ribosome biogenesis may contribute to the 
phenotype observed in proliferating cells, as defects in these cellular processes have been linked 
to human neurodevelopmental diseases (Tafforeau et al., 2013; Armistead and Triggs-Raine, 
2014). Human eIFA3 has previously been shown to interact with NOM1, which is necessary for 
ribosomal RNA biogenesis, to regulate pre-mRNA processing (Alexandrov et al., 2011). Loss of 
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EJC core component members have also been shown to alter ribosomal transcripts (Mao et al., 
2016). Moreover, the core EJC component member, RBM8A (aka Y14) has been shown to 
regulate the alternative splicing of Bcl-x into the anti-apoptotic Bcl-xL and the pro-apoptotic Bcl-
xS (Michelle et al., 2012), suggesting an alternative mechanism of inducing cell death in cells 
lacking proper EJC function. Differential gene expression analysis of Magoh-deleted CGNPs 
through bulk RNA-sequencing or single-cell RNA-sequencing may indicate the predominant 
mechanism underlying the role of MAGOH during cerebellar development. 
Expression of EJC component members has been linked to other cancers, such as breast 
cancer and gliomas (Degot et al., 2004; Lindeboom et al., 2016; Lin et al., 2018). We show that in 
CGNP-derived medulloblastomas, MAGOH expression promotes tumor cell survival. While loss 
of Magoh after the onset of tumor formation was unable to provide a survival benefit in mice with 
medulloblastomas, early detection of tumors and continued deletion of Magoh through 4OHT 
administration induced high levels of DNA damage and apoptosis. Understanding the mechanisms 
underlying MAGOH-mediated survival may provide new therapeutic targets for medulloblastoma. 
Together, our findings suggest that MAGOH is required for the maintenance of proliferating cells 
during cerebellar development and medulloblastoma tumor growth. 
 
Methods 
A detailed list of reagents and materials used can be found in Table 4.1. 
Mouse models 
MagohloxP/loxP mice harboring loxP sites flanking exon 2 of the Magoh gene were 
generously shared by Dr. Debra L. Silver (Mcmahon et al., 2014). MagohloxP/loxP mice were bred 
with the Math1-Cre line generously gifted by Dr. David Rowitch and Dr. Robert Wechsler-Reya, 
to produce Math1-Cre/MagohloxP/wt (Magohhet) and Math1-Cre/MagohloxP/loxP (MagohcKO) 
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progeny. MagohloxP/loxP mice were also bred with CAG-CreER mice purchased from Jackson 
Laboratories (Hayashi and McMahon, 2002) to produce CAG-CreER/MagohloxP/loxP (MagohCreER) 
progeny. Trp53loxP/loxP mice (Marino et al., 2000) were bred with MagohCreER mice to produce 
CAG-CreER/MagohloxP/loxP/trp53loxP/loxP (Magoh/p53CreER) mice. Where indicated, MagohCreER, 
Magoh/p53CreER and MagohloxP/loxP control littermates were intraperitoneally (I.P.) injected twice 
with 4-hydroxy-tamoxifen (4OHT) dissolved in sunflower seed oil, 12 hours apart, and collected 
at the indicated time points. 
NeuroD2:SmoA1 mice were purchased from Jackson Laboratories (Hallahan et al., 2004) 
and bred with CAG-CreER/MagohloxP/loxP mice to generate CAG-CreER/MagohloxP/loxP/NeuroD2: 
SmoA1 (MagohSmoA1) and control MagohloxP/loxP/NeuroD2:SmoA1 (SmoA1) littermates. 
MagohSmoA1 and SmoA1 mice were I.P. injected with 4OHT twice, 12 hours apart, and collected 
after 48 hrs., or continually injected every 48 hrs. before collecting at the indicated time point. 
Mice were monitored daily for changes in body weight and symptoms such as ataxia, tremor, and 
seizures. Animals were euthanized and brains harvested if body weight dropped more than 20% 
over 24 hours and/or they developed severe neurological symptoms according to approved 
protocols. All mice were maintained on a C57BL/6 background and in accordance with established 
NIH practices established by the Guide for the Care and Use of Laboratory Animals and approved 
under the University of North Carolina (UNC) Institutional Animal Care and Use Committee. 
Immunostaining cerebellar sections and quantification 
Mouse brains were harvested, processed, and immunostained as previously described 
(Crowther et al., 2016; Lang et al., 2016) using antibodies listed in supplementary materials and 
methods. Briefly, mice were anesthetized with isoflurane before harvesting brain tissue, which 
were drop-fixed with 4% paraformaldehyde in PBS for 48 hrs. at 4oC, and processed using 
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increased concentrations of ethanol before embedding in paraffin. Immunostained sections were 
counterstained with 200 ng/mL 4’6-diami-dino-2-phenylindole (DAPI/ #D1306, Thermo Fisher 
Scientific) in 1x PBS for 20 minutes. Stained slides were digitally acquired using an Aperio 
ScanScope XT (Aperio). To quantify pHH3, p-p53, CDKN1A/p21, pH2A.X, and cC3, the region 
of the EGL was manually annotated on each section and then subjected to automated cell counting 
using Tissue Studio (Definiens) for fluorescent slides. P-values were determined by two-tailed 
Student’s t-tests with R version 3.6.0. 
Flow cytometry analysis 
For flow cytometry analysis, mice were IP injected with 4OHT and injected with 40 mg/kg 
5-ethnynyl-2’-deoxyuridine (EdU) in 25 µl of HBSS after 48 hrs. After 2 hrs., mice were 
anesthetized with isoflurane and euthanized by decapitation. Cerebellar tissue was dissected and 
dissociated using the Papain Dissociation System (Worthington Biochemical) as previously 
described (Lang et al., 2016). Briefly, cerebella were incubated in papain at 37oC for 15 min, 
triturated, and underwent centrifugation, resuspension, and the formation of a density gradient with 
ovomucoid inhibitor. Cells were resuspended in HBSS with 6g/L glucose and then fixed with the 
Fix & Perm Cell Fixation & Cell Permeabilization Kit (ThermoFisher Scientific). Cells were 
stained for FxCycle Violet, pH2A.X, and/or pHH3 using the antibodies listed in the Supplementary 
Materials and Methods section. Samples were run on the Becton Dickinson LSR Fortressa and 






Figure 4.1. Magoh loss in CGNPs inhibits cerebellar growth. (A) Immunohistochemical staining of 
MAGOH in a representative sagittal section of a P7 mouse brain. (B) Representative histological sagittal 
sections of control mice, mice haploinsufficient for Magoh, and mice with homozygous deletion of 
Magoh at the indicated ages. The EGL and IGL are labeled where indicated. Scale bars measure 200 µm 
for P1, 500 µm for P7, 1 mm for P15, and 100 µm in insets. (C) Immunohistochemical staining for 
MAGOH, PCNA and p27, pHH3, and cC3 as indicated in cerebellar sagittal sections of control, Magohhet, 





Figure 4.2. Deletion of Magoh at the peak of postnatal neurogenesis inhibits cerebellar growth. (A) 
Immunohistochemical staining of MAGOH in representative sagittal sections in control mice and 
MagohCreER mice injected with 4OHT and collected after 48 hrs. Scale bars measure 2 mm for whole 
brain, 500 µm for specified brain regions, and 100 µm in insets. (B) Histological sagittal sections of 
cerebella from control and MagohCreER mice injected with 4OHT at P5 and collected at the indicated ages 
and timepoints. The EGL and IGL are annotated where indicated. (C) Immunohistochemical staining for 
p-RB in control and MagohCreER mice injected with 4OHT and collected after 72 hours. (D) 
Immunohistochemical staining for pHH3 in control and MagohCreER mice injected with 4OHT and 
collected after 36 or 48 hrs. (D’) Quantification of the percent pHH3-positive cells in the EGL of the 
indicated genotypes (n=3). (E) Immunohistochemical staining of MAGOH and RBM8A (aka Y14) in 
representative cerebellar sections of control and MagohCreER mice injected with 4OHT and collected after 
48 hrs. Scale bars measure 500 µm and 100 µm in insets. Horizontal bars represent means and error bars 




Figure 4.3. Loss of Magoh induces DNA damage and apoptosis through activation of p53 and 
CDKN1A. (A) Immunohistochemical staining of pH2A.X and cC3 in control mice and MagohCreER mice 
injected with 4OHT and collected 24, 48, or 72 hrs. later. (A’) Quantification of the percent pH2A.X, 
cC3, or pH2A.X/cC3 dual-positive cells in the EGL of the indicated genotypes (n=6). (B) 
Immunohistochemical staining of p-p54 and CDKN1A in representative cerebellar sections of control and 
MagohCreER mice injected with 4OHT and collected after 48 hrs. (B’) Quantification of the percent p-p53 
or CDKN1A positive cells in the EGL of the indicated genotypes from (B) (n=4). Scale bars measure 500 
µm and 100 µm in insets. Horizontal bars represent means and error bars indicate SEM. Statistical 





Figure 4.4. Magoh loss induces DNA damage across cell cycle phases. (A) Representative gates for 
FACS data from control and MagohCreER distinguishing cell cycle phases by DNA content, EdU 
fluorescence intensity, and p-HH3 fluorescence intensity as indicated. (B) Thresholds for pH2A.X 
positivity at the indicated cell cycle phase for all replicates of control and MagohCreER mice injected with 
4OHT and collected after 48 hrs. (C) Quantification of the percent of cells in the indicated cell cycle 
phase of MagohCreER mice injected with 4OHT and collected after 48 hrs. as compared to control mice and 
quantification of the percent pH2A.X-positive cells in the indicated cell cycle phase of samples (n=3). 
Horizontal bars represent means and error bars indicate SEM. Statistical significance determined by two-





Figure 4.5. Co-deletion of trp53 partially rescues the MagohCreER phenotype. (A) 
Immunohistochemical staining of p-p53 and CDKN1A for control, MagohCreER, and Magoh/p53CreER mice 
injected with 4OHT and collected after 48 hrs. (A’) Quantification of the percent p-p53 or CDKN1A 
positive cells in the EGL of the indicated genotype as in (A) (n=4 per genotype). (B) 
Immunohistochemical staining for pH2A.X and cC3 in control mice, MagohCreER mice treated with 4OHT 
for 48 hrs., and Magoh/p53CreER mice treated with 4OHT for 48 and 72 hrs. (B’) Quantification of the 
percent pH2A.X, cC3, or pH2A.X/cC3 dual-positive cells in the EGL of the indicated genotypes from (B) 
(n=6 per genotype). Scale bars measure 500 µm and 100 µm in insets. Horizontal bars represent means 






Figure 4.6. Conditional deletion of Magoh in medulloblastoma-prone SmoA1 mice inhibits tumor 
growth. (A) Representative sagittal sections of tumors from SmoA1 or MagohSmoA1 mice injected with 
4OHT and collected after 48 hrs. stained for H&E or MAGOH. (B) Immunohistochemical staining of 
pH2A.X and cC3 in SmoA1 or MagohSmoA1 mice as in (A). (C) Representative sagittal sections of tumors 
from SmoA1 or MagohSmoA1 mice injected with 4 doses of 4OHT and stained for H&E or MAGOH. (D) 
Immunohistochemical staining of p-RB in SmoA1 or MagohSmoA1 mice as in (C). (E) 
Immunohistochemical staining of pH2A.X and cC3 in SmoA1 or MagohSmoA1 mice as in (C). (F) 
Quantification of the percent pH2A.X, cC3, or pH2A.X/cC3 dual-positive cells in the tumors of the 
indicated genotypes from (B, E) (n=6 per genotype). Scale bars measure 500 µm and 100 µm in insets. 
Horizontal bars represent means and error bars indicate SEM. Statistical significance determined by two-




Reagent Concentration Source Identifier 
Animal Studies 
C57BL/6 mice N/A The Jackson 
Laboratory 
Stock #000664 
MagohloxP/loxP mice N/A Donated by Dr. 
Debra L. Silver’s lab 
MGI #1330312 
Math1-Cre mice N/A The Jackson 
Laboratory 
Stock #011104 
CAG-CreER mice N/A The Jackson 
Laboratory 
Stock #004682 
Trp53loxP/loxP mice N/A The Jackson 
Laboratory 
Stock #008462 
NeuroD2:SmoA1 mice N/A The Jackson 
Laboratory 
Stock #008831 




4-hydroxy-tamoxifen (4OHT) 6.25 mg/kg in 
25 µl of 
sunflower seed 
oil 
Millipore Sigma Catalog #H7904-
25MG 
5-ethnynyl-2’-deoxyuridine (EdU) 40 mg/kg in 25 
µl of HBSS 
Life Technologies Catalog #A10044 
PCR 
Tail lysis buffer 1X Allele Biotechnology Catalog #ABP-PP-
MT01 
Cre Forward Primer: GCG GTC 
TGG CAG TAA AAA CTA TC 
200 µM Invitrogen JAX #oIMR1084 
Cre Reverse Primer: GTG AAA 
CAG CAT TGC TGT CAC TT 
200 µM Invitrogen JAX #oIMR1085 
Magoh Forward Primer: GGC 
CCC TTT AGG CTC ATA CAT 
TTT A 
200 µM Invitrogen (Silver et al., 2010) 
Magoh Reverse Primer: ATC AAT 
AAT TCT CTT TAA CTC TTC 
CAT CAC ACT 
200 µM Invitrogen (Silver et al., 2010) 
Trp53 Forward Primer:  AAG 
GGG TAT GAG GGA CAA GG 
200 µM Invitrogen JAX #oIMR8543 
 
Trp53 Reverse Primer: GAA GAC 
AGA AAA GGG AGG G 
200 µM Invitrogen JAX #oIMR8544 
SmoA1 Forward Primer: TAG 
CTC TTT TCT GAA GTC CG 
200 µM Invitrogen (Hallahan et al., 
2004) 
SmoA1 Reverse Primer: TTC CCG 
CAC TAA CCT AAT GG 
200 µM Invitrogen (Hallahan et al., 
2004) 
Apex Taq DNA Polymerase 
Master Mix 
1X Genessee Scientific Catalog #42-138 











Heat inactivated FBS 100% for 
dissociation 
10% in media 
Gibco Catalog #10437028 
Hank’s Balanced Salt Solution 1X Gibco Catalog #14175-095 
D-(+)-Glucose 6g/L (33 mM) Millipore Sigma Catalog #G7021 
Immunofluorescence and Western Blot 
Antigen Retrieval 1:100 Vector Laboratories Catalog #H-3300 
Phosphate Buffered Saline (PBS) 1X Corning Inc. Supplier #46-013-CM 
Tween 20 0.3% in PBS Sigma-Aldrich Catalog #P9416 
Donkey serum 2% in 0.3% 
PBST 
Millipore Sigma Catalog #D9663 
Tris Buffered Saline with Tween 
(TBST) 
1X Cell Signaling 
Technology 
Catalog #9997 
Bovine Serum Albumin (BSA) 1% Fisher Scientific Catalog #BP9700-100 
4-20% Mini-PROTEAN® TGXTM 
Precast Protein Gels 
N/A Bio Rad Catalog #4561094 
DAPI 1:2500 for IF Invitrogen Catalog #D1306 
cleaved Caspase-3 (Asp175) 1:200 for IHC Cell Signaling 
Technology 
Catalog #9661 
Phospho-Histone H2A.X (Ser139)  1:200 for IHC Cell Signaling 
Technology 
Catalog #2577 
PCNA 1:2000 for IF Abcam Catalog #ab92552 
CDKN1B/p27 1:1000 Cell Signaling 
Technology 
Catalog #3686 
phospho-RB (Ser807/811) 1:3000 for IF 




phospho-Histone H3 (Ser10) 
(6G3) 
1:100 for IHC Cell Signaling 
Technology 
Catalog #9706 
CDKN1A/p21 1:500 for WB 
1:2000 for IHC 
Abcam Catalog #ab109199 
Goat anti-rabbit Alexa Fluor 488 1:400 for IF ThermoFisher 
Scientific 
Catalog #A-11034 
Goat anti-mouse Alexa Fluor 555 1:400 for IF ThermoFisher 
Scientific 
Catalog #A-21424 
Novolink Polymer Per 
manufacturer’s 
instructions 
Leica Biosystems Catalog #RE7200-CE 





Vector Laboratories Catalog #MP-7401 









Table 4.1. List of reagents and materials used in Chapter 4 with concentrations, vendor name, and 
catalog number listed where applicable. 
Flow Cytometry 








Heat inactivated FBS 5% in FACS 
wash buffer 
Gibco Catalog #10437028 
Sodium azide (NaN3) 0.1% in FACS 
wash buffer 
Fisher Scientific Catalog #S2271-25 
FxCycle Violet 1:100 ThermoFisher 
Scientific 
Catalog #F10347 
Phospho-Histone H2A.X (Ser139) 
(20E3) Alexa Fluor 647 Conjugate 
1:50 Cell Signaling 
Technology 
Catalog #9720 
Click-iT™ EdU Cell Proliferation 











CHAPTER 5: DISCUSSION 
Precise regulation of proliferation during development is required to prevent 
neurodevelopmental disease. While most neural development occurs during embryonic 
development, the cerebellum largely develops postnatally. Sonic hedgehog (SHH) signaling has 
long been known to promote growth during cerebellar neurogenesis while WNT signaling has long 
been considered to be vital for cortical and midbrain development. We have found that WNT 
signaling can oppose SHH during cerebellar development and that GSK-3 is vital to promote 
proliferation and migration of cerebellar granule neuron progenitors (CGNPs) as demonstrated in 
Chapter 2. In Chapter 3, we have shown how cell diversity in CGNP-derived, SHH-driven 
medulloblastoma tumor cells can produce heterogeneous responses to a SHH-pathway inhibitor, 
vismodegib. Finally, in ongoing work outlined in Chapter 4, we have found that the RNA 
processing protein, MAGOH, is necessary to prevent premature cell death during CGNP expansion 
and in medulloblastoma growth. Together, these studies demonstrate the complexity of 
mechanisms underlying cell growth in the cerebellum during postnatal neurogenesis and add to 
our current understanding of cerebellar development and medulloblastoma tumor growth. 
GSK-3 regulates SHH-driven growth in the cerebellum and medulloblastoma 
While SHH has been known as a mitogenic factor for CGNPs for many years, the role of 
WNT signaling in the cerebellum has not been well-defined. Previous studies have suggested that 
WNT signaling through CTNNB might oppose cerebellar development and tumor growth (Lorenz 
et al., 2011; Pöschl et al., 2013; Pöschl et al., 2014) but the endogenous role of GSK-3 and the 
WNT signaling pathway in CGNPs had not been fully explored. We have found that the 
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suppression of WNT signaling through GSK-3 is required for modulation of cerebellar and 
medulloblastoma tumor growth, as loss of both GSK-3 isoforms, Gsk-3α and Gsk-3β, decreased 
proliferation and increased cell cycle exit without inducing cell death. GSK-3 is required to 
promote CGNP and tumor cell proliferation by suppressing CTNNB and CDKN1A signaling, and 
regulates CGNP migration through a CTNNB-independent mechanism. Deletion of CTNNB in 
the cerebellum induced a mild hyperproliferative phenotype at the peak of postnatal cerebellar 
neurogenesis, which resolved over time, indicating an endogenous suppression of WNT signaling 
during cerebellar development. Moreover, pharmacological inhibition of GSK-3 in vitro blocked 
proliferation in cultured CGNPs and medulloblastoma tumor cells. Together, these findings 
demonstrate a physiological role for GSK-3-mediated suppression of WNT/CDKN1A signaling 
in the developing cerebellum and medulloblastoma. 
Future Directions 
GSK-3 modulates SHH-driven growth 
We found that deletion of Gsk-3α/β in Math1+ progenitors caused severe cerebellar 
hypoplasia early in postnatal development. SHH signaling is a hallmark of cerebellar development 
and is necessary for proper cerebellar growth and foliation. SHH is secreted by nearby Purkinje 
neurons to promote CGNP proliferation and has largely been regarded as the main signal driving 
CGNP proliferation. Our findings suggest that loss of Gsk-3 is sufficient to disrupt SHH-driven 
growth in CGNPs and medulloblastomas. Detection of SHH transcription factors Gli1/2/3 through 
in situ hybridization and qRT-PCR may demonstrate whether WNT activation directly affects 
SHH signaling. 
Additional experiments using single-cell analyses such as FACS or Drop-seq may also 
provide novel information regarding the transcriptional changes caused by Gsk-3 loss. Although 
we were able to detect transcriptomic changes in Gsk-3-deleted cerebella by microarray analysis, 
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the changes we detected were an average of the gene expression changes across the cerebellum 
and may include transcripts from other cellular populations. By pulse-labeling Gsk-3 deleted and 
control cerebella with BrdU and EdU, dissociating cells, and staining for GSK-3α/β, DNA content, 
and proliferation markers for FACS analysis as in Fig. 2.7H and I, we may be able to determine 
the CGNP-specific effects of Gsk-3 deletion on cell cycle progression. For example, if GSK-3 is 
required for the G1/S transition in CGNPs, we would expect to see an accumulation of cells in G1 
and a depletion of cells in S, G2, and M in cells lacking GSK-3α/β. We would also expect to detect 
fewer p-RB+, BrdU+, and EdU+ cells as in our immunohistochemical analyses (Fig. 2.1F, G; Fig. 
2.2). These studies would determine whether specific cell cycle phases are affected by Gsk-3 
deletion and whether GSK-3 plays a role in controlling cell cycle progression. 
Alternatively, single-cell RNA-sequencing by Drop-seq would provide an unbiased 
platform to analyze cell-specific differences in Gsk-3 deleted cerebella, as in Chapter 3. As in our 
microarray analysis, cerebella from P2 cerebella may be dissociated from Gsk-3DKO mice and 
control littermates and subjected to Drop-Seq. Transcriptomic analysis through clustering, t-SNE 
visualization, and differential gene expression analysis could segregate the cell-autonomous 
effects of Gsk-3 deletion in CGNPs from non-cell-autonomous effects of CGNP-specific Gsk-3 
deletion in other cerebellar cell populations. As in our microarray analysis, we would expect to 
detect upregulation of WNT signaling and cell cycle arrest genes in CGNP-like cells. We may also 
expect upregulation of WNT transcription factors in GFAP+ cells such as Bergmann glia, as 
evidenced by morphological changes we detected in Fig. A.1. These studies would provide an 
unbiased, exploratory view into the transcriptomic changes induced by Gsk-3 loss in Math1+ 
progenitors and determine whether Math1-specific Gsk-3 deletion induces gene expression 
changes in neighboring cells. 
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GSK-3 regulates migration during cerebellar development 
We determined that severe cerebellar hypoplasia caused by CGNP-specific deletion of 
Gsk-3α/β was caused by deficient proliferation and increased cell cycle exit. Co-deletion of the 
WNT effector, Ctnnb, rescued CGNP proliferation, resulting in a reestablishment of CGNs in the 
cerebellum. Interestingly, while Ctnnb co-deletion promoted proliferation, CGNPs were unable to 
migrate across the Purkinje cell layer into the cerebellum to form the internal granule layer (IGL) 
and instead remained in disorganized regions across the molecular layer (Figure 2.5 D-F). We 
found mild abnormalities in Purkinje cells and Bergmann glia in Gsk-3/CtnnbTKO mice, which may 
explain some of the migratory defects we observed (Figure 2.5 G). However, since Gsk-3/Ctnnb 
co-deletion was specifically targeted to Math1-expressing cells, which in the cerebellum are 
limited to CGNPs (Ben-Arie et al., 1997; Machold and Fishell, 2005), we believe the migratory 
defects are cell-autonomous effects caused by the loss of Gsk-3. Additionally, Ctnnb deletion alone 
produced no deficits in CGNP migration (Figure 2.5A), suggesting that migration is mediated 
through a CTNNB-independent mechanism of GSK-3. 
As in the cerebellum, deletion of Gsk-3 in cortical neurons produced migratory defects, 
potentially through decreased phosphorylation of doublecortin (DCX) and CRMP-2 (Morgan-
Smith et al., 2014). Differential gene expression analysis comparing Gsk-3DKO cerebella to Math1-
Cre+ controls may identify genes that are necessary for CGNP migration. To further investigate 
GSK-3-mediated migration in cerebellar progenitors, we may compare transcriptional profiles 
from Gsk-3DKO, Gsk-3/CtnnbTKO and CtnnbcKO cerebella through microarray analysis or RNA-
sequencing of bulk cerebellar tissue. Comparison of these three genotypes may reveal migration 
genes downregulated by Gsk-3 deletion that are CTNNB-independent. Immunohistochemical 
detection of the protein targets of downregulated genes would show whether they are expressed 
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migrating CGNPs. Furthermore, genetic deletion or inhibition of the identified genes in CGNPs 
would confirm whether these proteins are necessary for CGNP migration and would demonstrate 
the role of GSK-3 in regulating CGNP migration during cerebellar growth. 
WNT pathway suppression by GSK-3 may be necessary in Purkinje neurons and Bergmann glia 
Additionally, while our studies demonstrate an endogenous function of GSK-3 in CGNP 
development, the role of WNT signaling within other cell types in the cerebellum remains largely 
unexplored. We found that deletion of Gsk-3 induced a corresponding increase in the WNT 
transcription factor TCF7 in Bergmann glia and that Gsk-3/Ctnnb loss caused morphological 
abnormalities in Bergmann glia and Purkinje neurons (Fig. 2.5G, Fig. A.1). Loss of WNT receptors 
Lrp5/6 in Nestin+ progenitors caused dysregulated cerebellar lamination and foliation caused by 
disruption of Purkinje cell organization (Huang et al., 2016). Loss of Ctnnb in GFAP+ cells in the 
cerebellum caused similar defects in cerebellar organization caused by defects in CGNP migration 
and Purkinje cell localization (Wen et al., 2013; Huang et al., 2016). Additionally, a prior study 
deleted adenomatous polyposis coli (APC), the binding partner of GSK-3, in GFAP+ cells and 
found that Apc loss resulted in degeneration of radial glial processes and Purkinje cells, resulting 
in microglial activation (Wang et al., 2011). Unfortunately, genetic targeting of Purkinje neurons 
through Nestin-Cre and glial cells through GFAP-Cre may lead to off-target effects in CGNPs, as 
both Nestin+ and GFAP+ stem cells can give rise to committed Math1+ neural progenitors in the 
cerebellum (Yamaguchi et al., 2000; Mignone et al., 2004; Silbereis et al., 2010; Li et al., 2013). 
Taken together, these studies suggest a role for WNT signaling in cerebellar Purkinje neurons and 
Bergmann glia, which may be further explored. 
To investigate the role of GSK-3 and WNT signaling in these cell types, Gsk-3α and Gsk-
3β or Ctnnb may be selectively and conditionally deleted in Purkinje neurons by Pcp2-Cre. 
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Therefore, Pcp2-Cre, which should only be expressed in Purkinje neurons, would discern between 
Purkinje-specific and CGNP-specific effects of WNT activation or loss. Activation of the WNT 
signaling pathway in Purkinje neurons through Gsk-3 deletion may also indicate whether WNT 
directly opposes the SHH pathway, as Purkinje neurons produce and secrete SHH in the 
cerebellum to promote CGNP proliferation (Dahmane and Ruiz i Altaba, 1999; Wechsler-Reya 
and Scott, 1999). If WNT activation negatively influences the production and/or secretion of SHH, 
loss of GSK-3 function in Purkinje cells may also induce cerebellar hypoplasia caused by lack of 
CGNP proliferation. However, if WNT activation is independent of SHH signaling in Purkinje 
neurons, we may only observe defects in Purkinje cell localization, morphology, or function 
without affecting the number of CGNPs during development. Disruptions in Purkinje cell 
morphology and function may be characterized by quantifying the number of Calbindin+ Purkinje 
neurons, performing sholl analysis to determine complexity of dendritic arborizations, 
electrophysiological recordings to characterize firing properties, and/or behavioral assays such as 
a rotarod test to determine if mice exhibit ataxic phenotypes. These studies may determine whether 
Purkinje neurons, like CGNPs, require suppression of the WNT pathway during cerebellar growth. 
GSK-3 modulates SHH-driven medulloblastoma tumor growth 
Our studies have shown that SHH-driven medulloblastoma tumor cells, like CGNPs, 
require GSK-3 to suppress WNT/CDKN1A signaling during growth. Further studies should be 
carried out to ascertain the effectiveness of GSK-3 inhibition as a potential therapy for 
medulloblastoma. In studies detailed in Chapter 2 and demonstrated in Figure 2.3 and Figure 2.7, 
we have shown the efficacy of the GSK-3 inhibitor, CHIR-98014, in blocking proliferation in 
cultured CGNPs and medulloblastoma tumor cells. In preliminary studies, we have also shown 
that oral administration of CHIR-98014 at various doses does not impair weight gain in mice when 
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administered after P12 (Figure 5.1). However, it remains to be seen whether CHIR-98014 can 
effectively cross the blood brain barrier (BBB) to block tumor growth. Mass spectrometry imaging 
(MSI) by infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI), which 
we have used in Chapter 3 to probe the spread of vismodegib in the brain, may be used to indicate 
whether CHIR-98014 is able to effectively penetrate the brain, particularly the cerebellum and 
cerebellar-derived tumors. 
If CHIR-98014 can cross the BBB, further studies should be carried out to determine if 
GSK-3 inhibition through CHIR-98014 can inhibit tumor growth in vivo. Survival rates, tumor 
area, and tumor cell proliferation should be assayed to determine if CHIR-98014 can effectively 
block SHH-driven medulloblastoma growth in tumor-prone mice. Additionally, the effect of GSK-
3 inhibition on metabolism, gut function, and nervous system function should also be probed to 
prevent systemic off-target effects, particularly given the role of GSK-3 and WNT signaling in 
other tissue types(Ring et al., 2003; Tejeda-Muñoz and Robles-Flores, 2015). If CHIR-98014 
either does not cross the BBB or proves ineffective in blocking tumor growth, other GSK-3 
inhibitors may be explored. We previously tested other GSK-3 inhibitors in CGNP cultures, which 
provided modest reductions in proliferation (Figure A.2). Additionally, other GSK-3 inhibitors 
have been predicted to or have been shown to be BBB-permeable (Koh et al., 2007; Kramer et al., 
2012; Georgievska et al., 2013), and can be similarly tested in vitro in CGNPs and tumor cells and 
in vivo in wild-type and tumor-prone mice. These studies would determine if GSK-3 inhibition 
could block SHH-driven medulloblastoma growth in vivo and may provide a new targeted therapy 
for SHH-subgroup medulloblastomas. 
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Cellular heterogeneity in medulloblastomas causes treatment failure in response to 
vismodegib 
Medulloblastoma, one of the most common malignant pediatric brain tumors, has been 
classified into broad molecular subgroups which reflect the bulk transcriptomic identities of 
tumors (Northcott et al., 2011; Taylor et al., 2012). However, recent studies using transcriptomic 
analyses and clinical data have revealed heterogeneity even within these broad molecular 
subgroups (Cavalli et al., 2017). Additionally, the advent of single-cell transcriptomics analysis 
has allowed researchers to further probe heterogeneity within tumors, demonstrating that cellular 
diversity in tumors may contribute to treatment failure in response to targeted therapies (Patel et 
al., 2014; Macosko et al., 2015; Tirosh et al., 2016; Venteicher et al., 2017; Filbin et al., 2018). 
We have shown that a single oncogenic stressor, which constitutively activates the SHH 
signaling pathway in CGNPs produces tumors with diverse cell types. Subpopulations of our tumor 
cells exhibit different cell fate trajectories which largely exist as a continuum of proliferation to 
differentiation states. We have found that treatment with a SHH pathway inhibitor, vismodegib, 
produces differential responses in subpopulations of tumor cells. Vismodegib-sensitive cells were 
marked by expression of HES1, a transcription factor in the NOTCH signaling pathway, which 
has previously been shown to be important for cerebellar development (Solecki et al., 2001; 
Ingram et al., 2008). Conversely, vismodegib-resistant cells were marked by expression of 
MYOD1, a myocyte differentiation transcription factor, which has previously been shown to have 
an opposing role as a tumor suppressor in medulloblastoma (Dey et al., 2013). Although we have 
demonstrated cellular heterogeneity in SHH-driven medulloblastomas with differential response 
to vismodegib, more studies must be carried out to understand the mechanisms underlying 
vismodegib sensitivity or resistance. These studies may provide novel targets for the treatment of 




Hes1 and MyoD1 mark cells with differential responses to vismodegib 
Through single-cell RNA-sequencing by Drop-Seq, we found that medulloblastomas 
induced by constitutively active SHH signaling through SmoM2 contained diverse cell types 
characterized by differential gene expression patterns. Tumors were inherently comprised of 
stromal cells, including glial cells, endothelial cells, and neurons, and CGNP-like tumor cells in 
varying differentiation states. We also demonstrated that the SHH-pathway inhibitor, vismodegib, 
induced differential responses in cells within the tumors. Namely, cells expressing Hes1 appeared 
to be vismodegib-sensitive and cells expressing MyoD1 appeared to be vismodegib-resistant. 
Although we have identified putative cell types within SHH-driven medulloblastomas with 
differential responses to a targeted therapy, further studies should be conducted to characterize 
mechanisms of vismodegib-sensitivity and resistance. 
Our data suggest that Hes1 expression may be mediated through SHH signaling and thus 
may be sensitive to SHH pathway inhibition through vismodegib. NOTCH pathway inhibition 
should therefore target a subset of SHH medulloblastoma tumor cells and show limited efficacy, 
as with vismodegib treatment. However, MyoD1 expression appears to be independent of SHH 
signaling, since MYOD1-expressing cells are largely unaffected by vismodegib treatment and 
continue to proliferate. Identification of MYOD1+ cells through a fluorescent marker, subsequent 
isolation of live MYOD1+ cells through FACS, and implantation of the isolated cells into 
immunodeficient mice would indicate whether MyoD1-expressing cells are able to recapitulate the 
tumorigenic phenotype. Furthermore, since MYOD1 is a transcription factor, chromatin 
immunoprecipitation with sequencing (ChIP-seq) could identify the subset of genes MYOD1 
directly regulates within the tumor. These studies would determine the potential for MYOD1+ cells 
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to support tumor formation and identify genes that may promote growth even in the presence of 
SHH pathway inhibition. 
Cells expressing PRC2 members appear to be vismodegib resistant 
Epigenetic regulation of gene expression through the polycomb repressive complex 2 
(PRC2) may be necessary to promote tumor growth. PRC2 catalyzes the methylation of histone 
H3K27 to repress gene transcription and H3K27 mutations have been identified as a hallmark of 
pediatric gliomas (Chan and Morey, 2019; Harutyunyan et al., 2019; Laugesen et al., 2019; Silveira 
et al., 2019). We have shown that a subset of medulloblastoma cells express the core PRC2 
members Ezh2, Eed, and Suz12 and appear to be vismodegib resistant. To identify the 
transcriptional targets of the PRC2 in medulloblastoma, ChIP-seq may be used. Enrichment of the 
repressive H3K27me3 mark across genes or at transcription start sites may identify genes that 
oppose tumor growth. Additionally, the genetic or pharmacologic inhibition of PRC2 activity 
through Ezh2, Eed or Suz12 may clarify the role of the PRC2 during cerebellar development and 
SHH-driven medulloblastoma. 
If the PRC2 members are necessary for medulloblastoma growth, deletion of any of the 
PRC2 members or a combination of the members may block tumorigenesis or slow growth. 
Multiplexing genomic studies of PRC2 deletion with molecular approaches, such as bulk RNA-
seq, Drop-Seq, FACS, and/or IHC for specific markers can further specify the role of the PRC2 in 
medulloblastoma. Additionally, inhibition of PRC2 function, such as through inhibition of EZH2, 
may also help to elucidate the requirement of the PRC2 in medulloblastoma. Prior studies have 
identified an EZH2 inhibitor that may block tumor growth in diffuse intrinsic pontine gliomas 
(DIPG) (Mohammad et al., 2017). If successful, combination of a PRC2 inhibitor with vismodegib 
may prevent recurrent tumors. Together, these studies would determine if PRC2 function is 
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necessary to maintain tumor growth and may provide new therapeutic targets for 
medulloblastomas. 
Sox2+ cells may label a stem cell-like population in medulloblastomas 
A long-standing hypothesis in the cancer field has been that cancer stem cells may 
repopulate tumors and cause recurrence (Dirks, 2008; Hambardzumyan et al., 2008a; 
Hambardzumyan et al., 2008b). We identified classic stem cell markers in our heterogeneous 
population of SHH-driven medulloblastoma tumor cells, including Sox2, Gfap, Olig1, Oli2, Blbp7 
(Fabp7), and Pdgfra (Vanner et al., 2014). However, even within this population of Sox2+ cells, 
we identified diverse gene expression patterns and differential responses to vismodegib. 
Interestingly, some Sox2+ cells expressed Hes1 and appeared to be vismodegib sensitive, while 
other Sox2+ cells remained after vismodegib treatment. Gene expression profiling of Sox2+ cells 
may identify differences regulating growth. Previous studies have shown that Sox2+ tumor cells 
have tumor-initiating potential (Vanner et al., 2014) but did not distinguish between diverse Sox2+ 
cells, which we have determined to be either glial-like or stem cell-like. By stratifying Sox2+ cells 
based on their expression patterns, and transplanting different Sox2+ populations into 
immunodeficient mice or assaying their growth in vitro, it may be possible to determine the 
specific transcriptional programs necessary for tumor growth. These studies would determine the 
tumorigenic potential of Sox2+ cells in medulloblastoma. 
MAGOH is required to prevent cell death in CGNPs and CGNP-derived tumor cells 
Regulation of growth during brain development requires the function of the exon junction 
complex (EJC), a key regulator of mRNA processing (McMahon et al., 2016; Woodward et al., 
2017). Previous studies have shown that loss of function of any of the core EJC component 
members, RBM8A, eIFA3, or MAGOH, in cortical progenitors leads to microcephaly caused by 
p53-mediated DNA damage and cell death (Silver et al., 2010; Mao et al., 2015; Zou et al., 2015; 
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Mao et al., 2016; Pilaz et al., 2016). Moreover, studies have shown that the EJC is required for the 
regulation of mRNA splicing, transport, export, and nonsense-mediated decay (NMD) (Michelle 
et al., 2012; McMahon et al., 2016) to promote brain growth. However, the role of the EJC, and 
particularly the core component, MAGOH, remains unexplored in cerebellar postnatal 
neurogenesis and in the cerebellar cancer, medulloblastoma. 
We have shown that MAGOH is required for the maintenance of proliferating cells during 
postnatal development as loss of Magoh in CGNPs early in development caused severe cerebellar 
hypoplasia. Temporally-controlled deletion of Magoh during postnatal neurogenesis induced DNA 
damage and apoptosis, which accumulated during cell cycle progression. DNA damage and 
apoptosis was partially caused by activation of p53 and CDKN1A signaling, since co-deletion of 
trp53 in Magoh-deleted cells attenuated the number of pH2A.X+ and cC3+ cells. Furthermore, we 
showed that Magoh deletion induced DNA damage and apoptosis in a model of SHH-driven 
medulloblastoma, suggesting that medulloblastoma tumor cells, like CGNPs, require the function 
of MAGOH. Together, these studies are among the first to show a physiological role for MAGOH 
and the EJC during cerebellar development and medulloblastoma tumor growth. 
Future Directions 
Magoh is required for postnatal cerebellar neurogenesis 
We have shown that deletion of Magoh in CGNPs is sufficient to induce p53-mediated 
DNA damage and apoptosis. However, the exact mechanisms underlying cellular stress in 
response to loss of MAGOH function are unknown. In Chapter 3, we have used single-cell RNA-
sequencing through Drop-seq to interrogate heterogeneity in cellular responses to a targeted 
therapy, vismodegib. Similarly, we have observed heterogeneous responses in cells to MAGOH 
deletion, in which only a subset of CGNPs lose Magoh with the administration of 4OHT and 
undergo DNA damage and cell death. Use of scRNA-seq techniques like Drop-seq (Macosko et 
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al., 2015) would allow for the identification of cells with Magoh deletion and the further analysis 
of differential gene expression in response to Magoh loss. Previous studies have demonstrated that 
the EJC is required for the specification of cell fate and amplification (Ashton-Beaucage et al., 
2010; Inaki et al., 2011; Quaresma et al., 2013; Zou et al., 2015), and loss of Magoh may lead to 
gene expression changes incompatible with CGNP and CGN survival. Differential gene expression 
analysis of Magoh-deleted cells as compared to Magoh+ cells could uncover the transcripts 
regulated by MAGOH and the EJC. 
The EJC is also responsible for nonsense-mediated decay (NMD) in cells, a mechanism 
through which mRNA transcripts with premature termination codons undergo destruction (Boehm 
and Gehring, 2016; Woodward et al., 2017). NMD is largely mediated by auxiliary components 
of the EJC, UPF1, UPF2, and UPF3B (Popp and Maquat, 2018). Phosphorylation of UPF1 occurs 
during NMD to promote destruction of mRNA targets and has previously been shown to regulate 
cell fate and differentiation in cortical progenitors (Lou et al., 2014). Identifying the targets of 
NMD mediated by SHH-driven growth in CGNPs may shed light on how the EJC regulates 
cerebellar growth. RNA immunoprecipitation with sequencing (RIP-Seq) targeted to p-UPF1 
would identify mRNA transcripts undergoing NMD (Kurosaki et al., 2014; Kurosaki et al., 2018) 
during cerebellar development. Inhibition of SHH signaling, which blocks CGNP proliferation, 
would indicate which mRNA transcripts must be degraded to promote SHH-driven growth. By 
combining data from RIP-Seq with scRNA-seq data from experiments described above, a more 
comprehensive list can be compiled of the genes regulated by MAGOH that are necessary for 





Trp53 co-deletion partially rescues hypoplasia caused by Magoh loss 
We have shown that co-deletion of trp53 attenuates the hypoplastic phenotype caused by 
deletion of Magoh. However, trp53 co-deletion was unable to completely block the induction of 
DNA damage and apoptosis, despite blocking CDKN1A signaling. These results indicate that 
trp53 is not the sole effector of the Magoh-deletion phenotype. Previous studies have suggested 
that the EJC regulates ribosome biogenesis, which may be p53-independent (Alexandrov et al., 
2011; Tafforeau et al., 2013; Mao et al., 2016). Proteomic analysis of pre-rRNA processing 
proteins may determine whether MAGOH is required for ribosomal processing.  
Moreover, the EJC has been shown to regulate mRNA splicing of anti-apoptotic and pro-
apoptotic genes (Michelle et al., 2012), which could induce apoptotic cell death even in the absence 
of p53 signaling. Both Bcl-x and Mcl produce splicing variants with opposing roles in apoptosis 
(Bae et al., 2000; Bingle et al., 2000; Shkreta et al., 2011). qRT-PCR of anti- and pro-apoptotic 
splicing variants of Bcl-x and Mcl in Magoh-deleted cells as compared to Magoh-intact cells 
would determine whether disruption of EJC-regulated alternative splicing causes apoptotic cell 
death. Finally, comparison of gene expression profiles and NMD targets through Drop-Seq and/or 
RIP-seq from MagohCreER and Magoh/p53CreER mice would identify p53-specific and p53-
independent transcriptional activation. Together, these studies would determine the role of p53 
signaling as a consequence of MAGOH regulation during CGNP proliferation. 
MAGOH is required for medulloblastoma tumor cell growth 
We have found that loss of Magoh during medulloblastoma tumor growth causes DNA 
damage and apoptosis as in CGNPs. However, Magoh deletion did not extend survival of tumor-
bearing SmoA1 mice. We have noted that Magoh deletion in both CGNPs and SmoA1 tumor cells 
appears to be heterogenous and staggered, with cells undergoing DNA damage and apoptosis at 
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different rates. Understanding the mechanisms underlying MAGOH-mediated maintenance of 
proliferating cells may uncover new therapeutic targets for medulloblastomas. As described above, 
differential gene expression analysis through Drop-Seq, analysis of NMD targets through RIP-
Seq, and examination of apoptotic variants through qRT-PCR may identify genes and proteins 
required for tumor cell growth. Furthermore, genetic deletion of Magoh in other medulloblastoma 
subgroups would determine if the EJC is similarly required for cerebellar tumors activated by other 
oncogenic stressors. If Magoh loss disrupts tumor cell growth in other subgroups, inhibiting 
Magoh or its downstream targets may effectively extend survival in tumor-bearing mice and may 
eventually be used to treat medulloblastomas in patients. Together, these studies would determine 
the role of MAGOH in medulloblastoma tumor growth and may provide new therapeutic targets 






Figure 5.1. Maximal tolerated dose (MTD) study in WT mice treated with increasing doses of 
CHIR-98014. Graph demonstrates differences in weight calculated by subtracting weight on a given day 
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Figure A.1. Morphological abnormalities in Bergmann glia and Purkinje neurons in Gsk-3DKO 
cerebella. (A) Representative sagittal sections of cerebella from control and Gsk-3DKO mice at P2 and P3 
stained for the Purkinje cell marker, Calbindin, and the Bergmann glial marker, FABP7. (B) 
Immunohistochemical staining for TCF7 and FABP7 in sagittal cerebellar sections from Gsk-3DKO and 




Figure A.2: GSK-3 inhibitors decrease proliferation in cultured CGNPs. (A) DAPI, EdU-stained, and 
p-RB and p-HH3 immunofluoresence images of cultured CGNPs treated with vehicle, SHH, or SHH with 
the indicated doses of the GSK-3 inhibitors LY2090314, AZD1080, or LiCl. CGNPs were pulse-labeled 
with EdU 1hr. before fixation. (B) Quantification of replicate cultures from A with the proportion of 
positive cells expressed as fold change relative to SHH controls (n=12 per condition). Error bars represent 
SEM. Dots represent replicate samples. (C) Adjusted p-values for comparisons of vehicle-treated and 
SHH-treated controls to CGNPs with the indicated doses of LY209, AZD1080, or LiCl. Significance is 
denoted by colored boxes indicated in the legend, as determined by ANOVA with Tukey HSD post-hoc 




Figure A.3: Gsk-3 deletion does not induce apoptosis in medulloblastoma-prone mice. (A) 
Representative sagittal sections of M-Smo control and M-Smo/Gsk-3DKO mice subjected to cC3 
immunohistochemistry. Black arrowheads highlight cC3+ cells. Scale bars measure 2 mm for low 
magnification images and 50 μm for higher magnification images. The regions of the higher magnification 




Figure A.4: CHIR98 decreases cyclin D2 levels in cultured medulloblastoma cells. (A) 
Representative western blot image comparing cyclin D2 and actin protein expression of medulloblastoma 
cells treated in vitro with vehicle, 1 μM CHIR98, or 1 μM LY209. (B) Quantification of replicate cultures 
from (A) with luminescence normalized to actin and expressed as fold change relative to control tumor 
cells (vehicle: n=8; CHIR98: n=3; LY209: n=4). Error bars indicate SEM. Dots represent replicate mice. 
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Figure A.5. Identification of distinct neuronal cell types in P7 WT cerebella and medulloblastoma. 
Subclassification of neuronal cell types by the expression of indicated marker genes, plotted on (A) the P7 





Figure A.6. ICA reveals a gradient of differentiation states in vehicle-treated tumors. (A) t-SNE 
projection of CGNP-like cells from vehicle treated tumors, with cells placed according to Euclidean 
distance from each other in 5-dimensional, with each IC color-coded from yellow to blue. Cell cycle 
phase mapped onto the vehicle ICA t-SNE as in (A) showing localization of (B) G1/S, (C) S, (D) G2, (E), 




Figure A.7. Differential expression of proliferation and differentiation markers across vehicle-
treated tumor cells.  Feature plots of indicated marker genes on the ICA-directed t-SNE projection of 
CGNP-like cells. (A) Mki67, (B) Pcna, (C) Ccnd1 and (D) Ccnd2, (E) Gli1, (F) Atoh1 (aka Math1) (G) 





Figure A.8. Vismodegib treatment produces differential responses in medulloblastoma tumor cells. 
(A) Fractional population of each cluster in tumors from vehicle-treated and vismodegib-treated mice, 
normalized to total number of cells per mouse, formatted as in Fig. 3.6G. (B) IHC for NeuN and 
Calbindin, comparing neuronal populations in vehicle-treated tumors to tumors in mice treated for 3 days 
or 2 weeks with vismodegib, normalized to the number of Purkinje cells within the section. In the 
adjacent quantification, each dot represents the ratio of NeuN+ cells/Calbindin+ cells in a specific 
replicate. (C) IHC for cC3, comparing apoptotic cells in vehicle-treated tumors to tumors in mice treated 
with vismodegib for 3 days. The adjacent quantification shows the percent cC3+ cells within each tumor, 
with each dot representing a specific replicate. Scale bars = 2 mm, except in insets where scale bars = 100 




Figure A.9. SHH activation persists in a subset of vismodegib-treated tumor cells. Feature plots of 
indicated SHH markers on the PCA-directed tSNE projection of vehicle-treated and vismodegib-treated 




Figure A.10. HES1 and MYOD1 mark tumor cells with differential responses to vismodegib. (A) 
Medulloblastomas in sagittal hindbrain sections stained for HES1 and pRB from representative P15 M-
Smo mice, treated with 3 daily doses of vehicle or vismodegib or 2 weeks of vismodegib. In the adjacent 
quantification, each dot represents the percent of cells expressing the indicated marker for a specific 
replicate. (B) IHC for MYOD1 and pRB in tumors from representative M-Smo mice treated with either 3 
days of vehicle or vismodegib, or 2 weeks of vismodegib. The adjacent quantification represents the 
percent of cells expressing each marker, with each dot representing a specific replicate. Scale bars = 2 




Figure A.11. HES1 and MYOD1 are heterogeneously expressed in human medulloblastomas. RNA 
seq data on Hes1 and Myod1 expression in human medulloblastoma samples, as presented in Cavalli et al. 




Figure A.12. Correlation plots reveal differential SHH pathway activation after vismodegib 
treatment. (A) Correlation plot after imputation of data, showing expression of Gli1 on the X-axis and 
Ptch1 on the Y-axis, in vehicle- and vismodegib-treated tumors graphed separately. Each dot represents 
an individual cell and are color-coded according to Node denotation. (B) Correlation plot after imputation 
of data, showing expression of Sufu on the X-axis and Gli1 on the Y-axis, in vehicle and vismodegib-
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